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SUMMARY 
Breast cancer (BC) is the most frequently diagnosed cancer in women in the US 
and Europe, affecting one in eight women. Despite improvements in 
radiotherapy, cytotoxic, hormonal, and targeted therapies, BC remains the 
second leading cause of cancer deaths in women, exceeded only by lung cancer. 
Metastatic relapse is a main cause of this high mortality, and occurs up to long 
periods of time after the removal of the primary tumor. Understanding the 
mechanisms that control metastasis is therefore pivotal for the design of 
improved and safe breast cancer treatment regimen. 
Hypoxia is a characteristic feature of most solid tumors, including BC, and 
is a strong stimulus of tumor cell invasion and metastasis. Hypoxia signaling 
regulates nearly every single step of the metastatic cascade, including epithelial-
to-mesenchymal transition (EMT), intravasation, survival in the circulation, 
formation of the pre-metastatic niche, and growth from micro- to macro-
metastatic lesions. Furthermore, hypoxic tumors display lower sensitivity to 
treatment, leading to poor prognosis. The hypoxia-inducible transcription factors 
(HIFs) mediate a variety of cellular adaptations to hypoxia. Prolyl-hydroxylases 
(PHD1-3) are oxygen sensors that regulate HIF levels in normoxia by targeting it 
for proteasomal degradation. Despite the crucial role of PHD2 as an oxygen 
sensor, its role in tumor growth and metastasis in general and of BC in particular, 
remains largely debated. Studies from our and other research teams on PHD2 in 
cancer yielded interesting results, highlighting different possible roles of PHD2 
that may be cell-type dependent. On the one hand, the host lab demonstrated 
that haplodeficiency of PHD2 selectively in endothelial cells (ECs) reduced 
metastasis without affecting tumor growth, by normalizing the abnormal tumor 
vessels and reducing tumor cell intravasation, suggesting that PHD2 could be an 
anti-BC drug target. Using transplantable tumor models, others reported that 
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silencing of PHD2 in cancer cells either increased or decreased tumor growth 
with different underlying mechanisms. Dissection of the role of PHD2 in 
conditions that allow the evaluation of cell-intrinsic effects as well as the impact 
of bidirectional tumor / stroma cross-talk, remains strongly warranted. This is 
particularly relevant in light of pharmacological PHD2 blockade, which would 
target PHD2 in all cells inside the tumor. Furthermore, the studies mentioned 
above only used transplantable tumor models. The role of PHD2 in breast cancer 
using a clinically more relevant spontaneously arising BC model thus remains 
undefined.  
In this study, we utilized the spontaneously arising PyMT-oncogene driven 
breast cancer model and intercrossed this transgenic line with mice with 
heterozygous gene deficiency of PHD2 (PHD2+/- mice; named PyMT+/- mice upon 
intercross with the the PyMT line). Tumor growth was unaffected, but metastasis 
and intravasation were reduced in PyMT+/- mice as compared to control mice 
(PyMT mice intercrossed with PHD2 wild type mice; named PyMT+/+ mice). 
Applying genetic strategies in vivo and in vitro, we show that this reduction in 
metastasis and intravasation can be ascribed to two independent mechanisms. 
First, we show that global “genetic targeting” of PHD2 in the entire tumor in 
PyMT+/- mice induces tumor vessel normalization (a.o. tighter endothelial lining, 
improved pericyte coverage, better perfused), similar to selective PHD2 
haplodeficiency in ECs in xenograft models. Secondly, reduction in metastasis 
was also attributable to reduced activation of cancer-associated fibroblasts 
(CAFs). As compared to PyMT+/+ tumors, PyMT+/- tumors contained fewer 
activated CAFs, which deposited less cross-linked collagen matrix and 
contracted the collagen matrix less. These processes are known to induce 
cancer cell invasion. We showed that reduced CAF activation was independent 
of PHD2 level in fibroblasts, but reliant on the level of PHD2 in cancer cells. 
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PHD2 haplodeficiency in cancer cells lowered the release of TGF-β1 and 
diminished the differentiation of normal fibroblasts to activated CAFs.  
Taken together, these results provide evidence that PHD2 is a potential 
therapeutical target; the inhibition of which can offer substantial anti-metastatic 
benefit. Additionally, improved vessel function in spontaneously developing tumor 
model by PHD2 haplodeficiency could increase chemotherapy delivery and thus 
provide an advantage during surgical tumor resection.  
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SAMENVATTING 
Borstkanker is de meest voorkomende vorm van kanker bij vrouwen in de 
Verenigde Staten en Europa. Het treft er één op acht vrouwen. Ondanks de 
vooruitgang in radiotherapie, cytotoxische, hormoon -en doelgerichte therapieën, 
blijft borstkanker de op één na grootste doodsoorzaak bij vrouwen, na 
longkanker. Dit is te wijten aan de grote kans op herval vaak jaren na de 
behandeling van de primaire tumor. Daarom is het belangrijk om de 
mechanismen te begrijpen achter metastase, om veilige en meer doeltreffende 
behandelingen tegen kanker te ontwikkelen. 
Hypoxie (zuurstoftekort) is een fenomeen dat voorkomt in de meeste 
vaste tumoren, waaronder ook bij borstkanker. Het beïnvloedt elke stap in het 
metastaseproces, van de epitheliale naar mesenchymale transitie (EMT), het 
binnendringen in de bloedvaten (intravasatie), het overleven in de bloedstroom, 
de vorming van de pre-metastatische niche, tot de groei van micro-metastatische 
noduli tot macrometastasen. Bovendien vermindert hypoxie in tumoren de 
gevoeligheid aan therapieën, wat leidt tot een slechtere prognose. De hypoxie-
geïnduceerde factoren (HIFs) mediëren verschillende cellulaire aanpassingen 
aan hypoxie. Prolyl hydroxylasen (PHD1-3) zijn zuurstofsensors die de 
hoeveelheid HIFs reguleren bij een normaal zuurstofniveau (normoxie) door het 
stimuleren van hun proteolytische degradatie. Ondanks de cruciale rol van PHD2 
als zuurstofsensor, blijft haar rol in tumorgroei en metastase, in het bijzonder bij 
borstkanker, omstreden. Studies van anderen alsook onze groep onthulden 
interessante resultaten die erop wijzen dat PHD2 verschillende rollen kan 
hebben, die vermoedelijk afhankelijk zijn van het celtype. Enerzijds toonde onze 
groep aan dat endotheelcel (EC)-specifieke haplodeficiëntie van PHD2 
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metastasen afremt zonder effect op tumorgroei, door tumorbloedvaten te 
normaliseren en zo intravasatie te verminderen. Deze resultaten geven aan dat 
PHD2 een mogelijk doelwit is in de strijd tegen borstkankermetastase. Andere 
groepen toonden in transplanteerbare tumormodellen aan dat het onderdrukken 
van PHD2 in tumorcellen de tumorgroei zowel kan afremmen als stimuleren, met 
verschillende achterliggende mechanismen. Bijgevolg is het belangrijk om de rol 
van PHD2 in kanker te ontwarren in een model dat zowel tumorcel-intrinsieke 
effecten als effecten van tumor / stroma interacties toelaat. Dit is vooral 
belangrijk omdat elke farmacologische PHD2-inhibitie alle cellen binnen de tumor 
zou treffen. Bovendien gebruikten de bovenvermelde studies enkel 
transplanteerbare tumormodellen. De rol van PHD2 in een klinisch meer relevant 
spontaan ontwikkelend borstkankermodel blijft dus nog steeds niet gedefinieerd.   
In deze studie gebruikten we het spontaan ontwikkelende 
borstkankermodel dat geïnduceerd wordt door het PyMT-oncogen. Muizen 
transgeen voor dit oncogen werden gekruist met muizen met heterozygote PHD2 
gen deficiëntie (PHD2+/- muizen; na inkruisen met de PyMT transgene lijn 
PyMT+/- muizen genoemd). Er was geen effect op tumorgroei, maar het aantal 
metastasen en de intravasatie waren aanzienlijk verminderd in PyMT+/- muizen, 
vergeleken met controle muizen (PyMT lijn ingekruist met PHD2 wild type 
muizen; verder PyMT+/+ muizen genoemd). Gebruikmakend van genetische 
strategieën zowel in vivo als in vitro, toonden we aan dat deze vermindering het 
resultaat is van twee onafhankelijke mechanismen. Eerst toonden we aan dat de 
genetische onderdrukking van PHD2 in de hele tumor in PyMT+/- muizen 
tumorbloedvaten normaliseert, gelijkaardig aan endotheelcel-specifieke PHD2-
onderdrukking in xenograft modellen. Ten tweede bleek de afremming van het 
metastaseproces mede te danken aan een verminderde activatie van kanker 
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geassocieerde fibroblasten (CAFs). Deze produceerden minder extracellulaire 
matrix en trekken de collageenmatrix minder samen. Dit zijn processen waarvan 
het geweten is dat ze metastasering stimuleren. We toonden aan dat de activatie 
van CAFs niet afhankelijk is van de hoeveelheid PHD2 in fibroblasten, maar wel 
van de hoeveelheid PHD2 in tumorcellen. PHD2 haplodeficiënte tumorcellen 
scheidden minder TGF-β1 wat de activatie van normale fibroblasten tot CAFs 
vermindert.  
Tezamen tonen deze resultaten aan dat PHD2 een doelwit is dat bij 
inhibitie een aanzienlijk anti-metastatisch effect kan hebben. In dit spontane 
tumormodel leidt PHD2-haplodeficiëntie tot verbeterde bloedvatfunctie waardoor 
de chemotherapie efficiënter tot de tumor gebracht kan worden, hetgeen 
voordelig is voor een hieropvolgende operatieve verwijdering van de tumor. 
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CHAPTER I 
INTRODUCTION 
 
1. CANCER BIOLOGY 
Cancer, estimated to affect on in three people during the course of their life, is 
the most common life-threatening disease. Normal cells strictly comply with the 
signals that instruct them to grow, divide and die in an orderly manner. In 
contrast, cancer cells are characterized by uncontrollable cell proliferation and 
the ability to deregulate instructing cues, eventually becoming masters of their 
own fate. Highly proliferative cancer cells are capable of evading growth 
suppressors, resisting cell death and enabling replicative immortality. They break 
tissue homeostasis and form tumor masses that invade adjacent tissue and 
eventually metastasize (Hanahan and Weinberg, 2000; Hanahan and Weinberg, 
2011). The incurable nature of cancer is related to its metastatic dissemination. It 
has been estimated that 90% of all cancer-related deaths are caused by 
metastasis (Spano et al., 2012). Despite major therapeutic advances, breast 
cancer mortality remains the leading cause of women’s mortality (Ferlay et al., 
2015).  
 Cancer arises from normal cells through genetic and cellular alterations, 
which enable cancer cells to become tumorigenic and eventually malignant. 
Chronic proliferative capacity of cancer cells requires a sustained supply of 
nutrients and oxygen. To face the new metabolic needs, cancer cells promptly re-
shape the tissue environment over the course of cancer progression. It is now 
well appreciated that heterogeneity of tumors is not only dependent on aberrant 
mutations in cancer cells, but also the diverse nature of their microenvironment. 
Most tumors are composed of cancer cells co-existing with a variety of stromal 
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cells: endothelial cells, pericytes, immune cells, adipocytes and cancer-
associated fibroblasts (CAFs), embedded in the complex extracellular matrix 
(ECM) network. Along with cancer cell invasive properties, the diversity of the 
microenvironment (its composition, stromal cell proportion and activation states) 
determines the invasive and metastatic capacities of the tumor (Quail and Joyce, 
2013). The contribution of some types of cells of the tumor microenvironment in 
the metastatic process will be discussed in more detail in section 3. 
 
2. METASTATIC CASCADE 
Metastasis is a complex, multistep biological process consisting of the following 
stages: Epithelial-to-Mesenchymal Transition (EMT), invasion, intravasation, 
survival in the circulation, organ-specific extravasation, colonization and 
eventually outgrowth from micro- to macro-metastasis (Figure 1).  
FIGURE 1: THE METASTATIC CASCADE.  
Schematic representation of the different steps of the metastatic cascade. Cancer cells at the 
primary tumor site acquire invasive phenotype (through EMT) and are capable of escaping from 
the primary site alone or aided by stromal cells, after which they intravasate. In the circulation, 
platelets and components of the coagulation system support cancer cell survival. Cancer cells, 
escorted to the metastatic site, adhere to endothelial cells and extravasate. At the metastatic sites 
several pre-conditioned stromal cells may help to direct metastatic dissemination by creating a 
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niche that is permissive for cancer cell colonization, and then grow from the micro-metastases to 
macro-metastases. EMT, epithelial to mesenchymal transition; TAM, tumor associated 
macrophages. Adapted from (De Bock et al., 2011). 
 
Successful metastasis requires bidirectional communication between cancer 
cells and the microenvironment at each of these steps (De Bock et al., 2011; 
Quail and Joyce, 2013). Moreover, hypoxia signalling plays a pivotal role in most 
of these steps.  
 
2.1.  LOCAL INVASION OF THE PRIMARY TUMOR 
Cancer cell migration and invasion are critical parameters of metastatic spread. 
During this process cancer cells undergo extensive molecular and cellular 
adaptations that regulate cancer cell cytoskeletal dynamics and the turnover of 
cell-cell and cell-matrix adhesive junctions. Similar to the other steps of the 
metastatic cascade, reciprocal reprogramming of both cancer cells and adjacent 
tissue is critical, and not only enables invasion, but also determines diverse 
modes of dissemination (Friedl and Alexander, 2011; Yilmaz and Christofori, 
2010). 
In order to invade the surrounding tissue and disseminate to distant 
organs cancer cells must undergo epithelial-to-mesenchymal transition (EMT), an 
essential process also during normal embryonic development (Kalluri and 
Weinberg, 2009). At the cellular level, EMT involves the dissolution of adherens 
and tight junctions and loss of cell polarity, resulting in dissociation of individual 
cells from the epithelial layer of origin. This process is a consequence of 
molecular adaptation of cells in response to microenvironmental stimuli (i.e. 
hypoxia, epidermal growth factor (EGF), hepatocyte growth factor (HGF), 
fibroblast growth factors (FGFs) and transforming growth factor (TGF)-β1, 
insulin-like growth factors (IGFs), platelet-derived growth factor (PDGF)). Several 
of these cytokines induces expression of key EMT-associated transcription 
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factors (Snail-1, Snail-2, Zeb-1, Zeb-2, Twist; known repressors of E-cadherin 
gene expression). In addition, some of them regulate mitogen-activated protein 
kinase (MAPK), phosphoinositide 3-kinase (PI3K) and Wnt / β-catenin 
signalling’s that are crucial in inducing and maintaining EMT (Tiwari et al., 2012). 
At the molecular level, cells undergoing EMT lose their epithelial markers, such 
as tight junction proteins, claudins and occludins, the adherence junction proteins 
(E-cadherin) and cytokeratins, and concomitantly upregulate several 
mesenchymal markers (N-cadherin, vimentin, fibronectin, matrix 
metalloproteinases, integrins αv and β1) (Figure 2). These molecular changes 
facilitate a transition from polarized epithelial cells to motile mesenchymal-like 
cells.  
 
FIGURE 2: INVASIVE SWITCH: EPITHELIAL-TO-MESENCHYMAL TRANSTION (EMT). 
Schematic representation of the EMT process. During EMT, cells lose their cell-cell and cell-ECM 
contacts and re-arrange their cytoskeleton. These cellular changes are the consequences of a 
transition from polarized epithelial cells (characterized by expression of epithelial-like markers, in 
yellow) to motile and invasive mesenchymal-like cells (identified by mesenchymal markers, in 
green). This molecular and cellular switch enables cancer cells to migrate, locally invade and 
metastasize. Adapted from (Kalluri and Weinberg, 2009). 
 
Depending on the tumor type, multiple types of cell migration / invasion can be 
found to different degrees and in variable mixes. They can disseminate as 
individual cells or invade in solid cell strands, sheets or cluster (called ‘collective 
migration’). While leukemias, lymphomas and most solid stormal tumors such as 
sarcomas disseminate as single cells, epithelial tumors (i.e. breast carcinoma, 
squamous cell carcinoma) use the collective migration strategy (Friedl and Wolf, 
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2003). Interestingly, however, recent findings highlighted, that the porosity and 
confinement of the ECM determines the invasion mode of mesenchymal tumor 
cells (fibrosarcoma and melanoma). Whereas fibrillar and highly porous ECM 
allows single cell dissemination, ECM of increased density induces cell-cell 
interaction, leader-follower cell behaviour and collective cell invasion, which 
relies on proteolytic degradation of the matrix (Haeger et al., 2014). These 
findings suggest that cancer cells acquire different invasive modes depending on 
ECM density; further confirming that tumor microenvironmental heterogeneity 
dictates molecular and phenotypic adaptations of cancer cells.   
Furthermore, metastatic cancer cells, in contrast to non-metastatic ones, 
are able to attach to and move along collagen fibers (Wang et al., 2002). Many of 
these fibers are embedded in the blood vessels (Condeelis and Segall, 2003), 
and thus they can serve as highways for cancer cell dissemination. The invasion 
of cancer cells, as they move through the tumor, can be enhanced or promoted 
by stromal cells, such as tumor-associated macropahages (TAMs) and CAFs. 
Indeed, intravital microscopy revealed that breast cancer cells invade alongside 
TAMs (Roussos et al., 2011). This interaction occurs through a paracrine loop, in 
which cancer cells secrete colony-stimulating factor-1 (CSF-1) to recruit TAMs, 
resulting in their activation and secretion of ligands, such as EGF that in turn 
stimulates cancer cell motility (Figure 3) (Wyckoff et al., 2004; Wyckoff et al., 
2007). Macrophages are higly plastic cell that can alter their polarization state to 
accommodate different physiological condtions. Clasically activated “M1” 
macrophages produce type I proinflammatory cytokines, participate in antigen 
presentation and have an anti-tumorigenic activity. Alternatively activate “M2” 
macrophages produce type II cytokines, promote anti-inflammatory responses 
and have pro-tumorgenic functions (Quail and Joyce, 2013). CAFs also 
contribute to a wide spectrum of secreted factors, including chemokines 
(CXCL12, CCL2, CCL5, CCL7, CXCL8 and CXCL14), cytokines (SDF-1, IL-6, 
TGF-β1) and growth factors (HGF, EGF, FGF), which stimulate the invasion of 
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cancer cells. Moreover, they increase angiogenesis and contribute to the 
recruitment of immune cells to the tumor (Cirri and Chiarugi, 2011). In addition to 
their paracrine signaling, CAFs exert a direct physical impact on the tumor 
microenvironment by modulating the ECM. CAFs not only secrete components of 
the ECM, but also remodel it via the secretion of proteases (matrix 
metalloproteases (MMPs), urokinase type plasminogen activator (uPA)) and 
crosslinking enzymes (lysyl oxidase (LOX), lysyl oxidase-like 2 (LOXL2)), and by 
direct matrix contraction (Calvo et al., 2013; Cirri and Chiarugi, 2011; Kasashima 
et al., 2014). Altogether, this promotes ECM stiffness and consequently 
increases intratumoral mechanical stress. These microenvironmental changes 
directly affect the malignant phenotypes and metastatic behavior of cancer cells 
(Kumar and Weaver, 2009). 
 
 
FIGURE 3: INTERACTION BETWEEN CANCER AND STROMAL CELLS - EFFECT ON INVASION AND 
INTRAVASATION. 
A, CAFs and vascular cells, such as pericytes and ECs, secrete SDF-1 to promote the invasion of 
cancer cells expressing CXCR4. While cancer cells secrete CSF-1 and promote proliferation of 
TAMs, CSF1R+ TAMs promote the invasion and intravasation of EGFR-expressing cancer cells 
by secreting EGF (Wyckoff et al., 2004). B, TAMs promote cancer cell intravasation through 
paracrine signalling, proteolytic degradation of basement membrane and dissociation of 
endothelial tight junctions. SDF-1, stromal derived factor-1; EGF epidermal growth factor; EGFR, 
EGF receptor; CSF-1 colony stimulating factor-1; CSF1R, CSF-1 receptor. Adapted from (Joyce 
and Pollard, 2009). 
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Acquiring an invasive tumor cell phenotype is a critical first step of the metastatic 
cascade, allowing cancer cells to egress from the primary tumor to blood or 
lymphatic vessels.  
 
2.2. CANCER CELL INTRAVASATION  
For successful intravasation directional migration of cancer cells towards blood 
vessels is required, followed by invasion through the vessel wall. This is 
accomplished through an adhesive interaction between cancer cells and the 
basement membrane (BM) of ECs and through integrin-mediated communication 
and proteolytic degradation of the BM (Spano et al., 2012). Most studies indicate 
that cancer cells actively invade and intravasate. However, it is also recognized 
that endothelial barrier impairment is equally important in this process (Carmeliet 
and Jain, 2011b; Zervantonakis et al., 2012). An impaired endothelium, with 
fenestrations in its lining, can enable passive cancer cell dissemination from the 
primary tumor to the circulation (Zervantonakis et al., 2012), as discussed in 
more detail in section 3.1. 
Stromal cells can also assist cancer cell intravasation. Either by facilitating 
cancer cell motility and invasion within the primary tumor towards blood vessels 
(see section 2.1) or by direct physical disruption of vessels (Figure 3). 
Interactions between perivascular TAMs and cancer cells appear to be critical for 
intravasation (Wyckoff et al., 2007), suggesting that perivascular TAMs facilitate 
the breaching of the vascular barrier by proteolytic degradation (Figure 3B). 
Moreover, macrophages can also increase the permeability of the EC barrier by 
secreting tumor necrosis factor-α (TNF-α) (Zervantonakis et al., 2012) and locally 
promoting the intravasation of cancer cells. 
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2.3. CANCER CELL SURVIVAL IN THE CIRCULATION 
Around 4 million cancer cells can be shed into the circulation every day from a 
gram of primary tumor (Butler and Gullino, 1975; Wong and Hynes, 2006), yet 
less than 0.01% of these will result in metastases (Joyce and Pollard, 2009). 
Epithelial cells require a direct interaction with proximal cells or ECM for their 
survival, thus, in non-adherent conditions cells undergo a form of programmed 
cell death, known as anoikis (Frisch and Francis, 1994). Circulating cancer cells 
develop resistance to anoikis by several molecular mechanisms, such as 
upregulation of caveolin-1 (Halim et al., 2012) or by constitutive activation of 
downstream pro-survival signals: PI3K, Ras-Erk, NF-κB and Rho GTPase 
(Guadamillas et al., 2011), among others. It has also been reported that 
preconditioning of cancer cells in hypoxia contributed to anoikis resistance by 
suppressing α5 integrin (Rohwer et al., 2008) or Bim and Bmf as well as 
increased expression of EGFR-MAPK-extracellular signal-regulated kinase (Erk) 
pathway (Whelan et al., 2010).   
Not only anoikis will limit the success rate of the metastatic process, but also 
the hostile microenvironment of the circulation. In the blood, cancer cells are 
confronted with many challenges, such as hemodynamic shear forces, 
turbulences, surveillance from and attack by immune cells, especially natural 
killer (NK) T cells (Gupta and Massague, 2006). To increase their chances for 
survival, cancer cells use platelets as a shield (Nash et al., 2002), either by 
binding coagulation factors on the platelets and forming an embolus aggregate 
that protects the cancer cell from NK cell-mediated lysis (Nieswandt et al., 1999; 
Palumbo et al., 2007), or through an independent mechanism related to 
circulating pro-thrombin (Palumbo et al., 2007). Not surprising, high platelet 
count is associated with decreased survival in multiple cancers (Jurasz et al., 
2004). Moreover, platelets and fibrin may also promote clotting of cancer cells in 
small capillaries, facilitating adhesion to the endothelium and metastasis in 
 35 
distant organs (Konstantopoulos and Thomas, 2009). Besides platelets, 
circulating cancer cells can also co-travel with stromal cells such as CAFs, which 
not only increase cancer cell survival in the circulation but also provides a growth 
advantage at the metastatic site (Duda et al., 2010). 
 
2.4. CANCER CELL EXTRAVASATION IN DISTANT ORGANS 
In order to home in on a distant tissue, circulating cancer cells must first adhere 
to ECs. Whereas passive entrapment might partially contribute to the metastatic 
seeding, active adhesion and invasion through the capillary vessel wall is 
necessary for establishing metastases. The process of extravasation is 
dependent on the type of organ-specific vascular barriers (Figure 4).  
FIGURE 4: ORGAN-SPECIFIC VASCULAR BARRIERS FOR BC EXTRAVASATION. 
Circulating breast cancer cells can infiltrate a distant organ they are able to survive in non-
adherent conditions and breach the vessel wall at distant sites. Each of the organs, specific for 
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BC metastasis (brain, lung and bones), contains distinct vascular barriers for disseminating 
cancer cells. In the brain, the blood-brain barrier with its tightly interconnected endothelial cells 
and pericytes, glial cells, and a thick BM is a less-penetrable barrier for extravasation than bone 
marrow sinusoids with a fenestrated endothelium and lacking BM. Also, lung capillary network is 
well structured, consisting of a tight monolayer of EC, covered by homogenous BM and pericytes 
make it more challenging for cancer cells to infiltrate. BC, breast cancer; BM, basement 
membrane; ECs, endothelial cells. Adapted from (Nguyen et al., 2009). 
 
 
Apart from the importance of structural features of capillary walls in organ-
specific extravasation (see Figure 4), unique interactions between endothelial 
surface molecules and cancer cells are required for successful infiltration in 
distant organs. Indeed, in vitro studies of adhesion of different human prostate 
cancer cell lines to ECs of different origins showed that these prostate cancer 
cells preferentially adhere to ECs originating from the bone marrow (Lehr and 
Pienta, 1998; Scott et al., 2001). This is coherent with the pattern of metastatic 
dissemination of prostate tumors.  
Hypoxia signalling can promote successful cancer cell extravasation by 
upregulating the expression of several adhesion molecules (E-selectin, vascular 
cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1), 
integrins) and carbohydrate ligands for selectins. Thus it enhances cancer cell 
adhesion to ECs (Koike et al., 2004). Moreover, hypoxia signaling in the primary 
tumor also increases the secretion of angiogenic factors (VEGF, TGF-β1, 
placenta growth factor (PlGF), and TNF-α) into the circulation, that can 
permeabilize and destabilize the vessels at the metastatic site by inducing local 
release of ANG-2 and proteases MMP-3 and MMP-9 (Hiratsuka et al., 2011; 
Huang et al., 2009). Additionally, TGF-β1 secreted by the primary BC tumor 
increases ANGPTL4-secretion by disseminating cancer cells. ANGPTL4 
facilitates the disruption of EC cell-cell junctions in the lungs, allowing trans-
endothelial passage and subsequent infiltration into the lung parenchyma of 
cancer cells (Padua et al., 2008). Both TGF-β1 and ANGPTL4 are upregulated 
by hypoxia signaling (Falanga et al., 1991; Le Jan et al., 2003). Importantly, the 
role of ANGPTL4 in tumor formation remains controversial. While in this (Padua 
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et al., 2008) and in other (Nakayama et al., 2010; Zhu et al., 2011) studies 
ANGPTL4 has been reported to have an oncogenic and pro-metastatic function, 
others suggest tumor- or angiogenesis-suppressive functions (Galaup et al., 
2006; Ito et al., 2003; Li et al., 2004; Okochi-Takada et al., 2014).  
 
2.5. CANCER CELL COLONIZATION IN DISTANT ORGANS 
Metastatic colonization is a final event required for cancer cells to form 
metastases in distant organs. Extravasated cancer cells will follow one of three 
alternative paths: cell death, dormancy (the cancer cell will be able to survive in 
the distant organ by entering a quiescence state), or colony formation (cancer 
cells will proliferate and drive tumor growth by counterbalancing cell death) 
(Chambers et al., 2002). These fates are determined by the interaction of cancer 
cells with components of the target metastatic organ, such as stromal cells and 
the ECM. In most cases, the inability to proliferate in the new microenvironment 
of the target organ is the limiting factor for metastasis formation, as shown in 
melanoma and BC (Luzzi et al., 1998; Morris et al., 1994; Naumov et al., 2002).  
Stephen Paget already recognized in 1889 that cancer cells (‘the seed’) 
will only grow when they find a compatible, hospitable tissue (‘the soil’) (Paget, 
1889). Primary tumors can modify ‘the soil’ in distant organs for successful 
engraftment of cancer cell by secreting several factors (VEGF, PlGF, TGF-β1) 
that contribute to the development of a pre-metastatic niche (Figure 5).  
In response to these factors inflammatory S100 chemokines and serum 
amyloid A3 (SAA3) are upregulated in the pre-metastatic sites, promoting the 
infiltration of bone marrow-derived haematopoietic cells (BMDCs) (Hiratsuka et 
al., 2006; Hiratsuka et al., 2008; Kaplan et al., 2005). BMDCs in turn secrete a 
plethora of factors (TNFα, MMP2 and MMP9, and TGF-β1) that either increase 
vascular permeability, remodel the ECM of the target organ, promote cancer cell 
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proliferation or recruit other host cells (Hiratsuka et al., 2002; Kim et al., 2009). 
Moreover, activated fibroblasts, possibly also originating from mesenchymal stem 
cells (MSCs), secrete fibronectin and LOX to modify the local ECM (Erler et al., 
2009) (Figure 5A). Besides MSCs, endothelial progenitor cells are recruited to 
the early metastatic niche to mediate angiogenesis, enabling the switch from 
micro- to macro-metastasis (Gao et al., 2008; Kaplan et al., 2005) (Figure 5C).  
 
 
FIGURE 5: METASTATIC COLONIZATION. 
This figure illustrates different steps of successful colonization: A, pre-metastatic niche - growth 
factors secreted by the primary tumor, including VEGF, PlGF and TGF-β, inflammatory S100 
chemokines and SAA3 are upregulated in pre-metastatic sites leading to clustering of bone 
marrow-derived haematopoietic progenitor cells (HPCs) or activation of local fibroblasts that 
modulate the local ECM. SDF1, secreted by platelets is also chemotactic for CXCR4-positive 
HPCs and metastatic tumour cells (MTCs). HPCs secrete a variety of pre-metastatic factors 
including TNF-α, MMP9 and TGF-β. Activated fibroblasts secrete fibronectin, an important 
adhesion protein in the niche, and LOX, modifying the local extracellular matrix; B, 
micrometastasis – MTCs that successfully infiltrate the pre-metastatic niche of target organs will 
form micrometastases; C, macrometastasis – to supply the nutrients and oxygen, EPCs are 
recruited to the metastatic niche. Moreover, angiogenic tip cells provide tumor-promoting factors 
to facilitate switch from dormancy to proliferation. BMDCs, bone marrow-derived hematopoietic 
cells; CXCR4, C-X-C chemokine receptor 4, ECM, extracellular matrix; EPCs, endothelial 
progenitors cells; HPCs, bone marrow-derived hematopoietic cells; LOX, lysyl oxidase; MMP9, 
matrix metalloproteinase 9; MTCs, metastatic cancer cells; PlGF, placental growth factor; SAA3, 
serum amyloid A3; SDF1, stromal-derived growth factor 1; TGF-β, transforming growth factor-β; 
A 
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TNF-α, tumor necrosis factor-α (VEGF, vascular endothelial growth factor A. Adapted from 
(Psaila and Lyden, 2009). 
 
Hypoxia signaling can also positively regulate this step of the metastatic 
cascade. Hypoxia-regulated LOX is an important mediator of bone marrow cell 
recruitment to form the pre-metastatic niche (Erler et al., 2009). Hypoxia also 
induces the expression of SDF-1 and CXCR-4 (Jin et al., 2012), a signaling axis 
that has been reported to contribute to BC dissemination (Nguyen et al., 2009).  
 Cancer cells that are capable of infiltrating the target organ can remain 
dormant as micrometastases for a variable amount of time (up to decades). This 
trait of cancer cells is responsible for the untraceable nature of many 
malignancies. Cancer cells are dormant either because they entered a quiescent 
state (cellular dormancy) or because cancer cell proliferation is balanced by cell 
death, for example due to the lack of proper nutrient and oxygen supply by blood 
vessels (angiogenic dormancy) (Aguirre-Ghiso, 2007; Hedley and Chambers, 
2009). These dormant cells are difficult to detect, but it is even more challenging 
to target them with the current therapeutic strategies (Naumov et al., 2003; 
Townson et al., 2009). The pre-metastatic niche and cancer stem cells, a 
population of cancer cells that have ability to rise to all distinct cancer cell types, 
significantly contribute to metastatic colonization (Giancotti, 2013; Malanchi et al., 
2012), and could explain why certain patients relapse after a short time. The 
mechanism of metastatic outgrowth in late-relapsing patients has, however, not 
been completely elucidated. Indeed, a recent study of Ghajar et al. aimed to 
provide the underpinnings of it. They showed that dormancy of metastatic BC 
cells can be regulated by EC thrombospondin-1, but its suppressive function is 
overruled when angiogenesis is initiated in the metastatic organ. Sprouting 
vessels not only support, but accelerate metastatic growth of BC cells by 
secreting tumor-promoting factors (TGF-β1 and periostin (POSTN)) from the 
leading tip cell of the angiogenic sprouts (Ghajar et al., 2013). While this provides 
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additional evidence for the importance of surrounding stroma in the process of 
metastatic outgrowth, it does not explain the underlying mechanism regulating 
the reactivation of dormant cancer cells.  
 
3. THE ROLE OF STROMAL CELLS IN TUMOR PROGRESSION AND METASTASIS 
Although tumorigenesis has typically been viewed as a cancer cell – autonomous 
process, the contribution of stromal cells to tumor progression and metastasis 
has now been acknowledged (Joyce and Pollard, 2009; Quail and Joyce, 2013). 
The stroma consists of a diverse population of cells (ECs, smooth muscle cells, 
fibroblasts, immune cells) that provide structural and physiological support to the 
tissue. Stromal cells co-evolve with cancer cells during tumor progression and 
also contribute to cancer cell heterogeneity, for example by paracrine interaction. 
They undergo both morphological and functional transitions to create a favorable 
microenvironment for cancer cell growth and dissemination (Egeblad et al., 2008; 
Josson et al., 2010; Sung et al., 2008; Wallace et al., 2011; Weinberg, 2008). In 
this section I will discuss the role of some of the stromal components in 
tumorigenesis and metastasis relevant for this project: vascular cells and CAFs.  
 
3.1. VASCULAR ENDOTHELIAL CELLS - ANGIOGENESIS 
Tumor cell proliferation is highly dependent on oxygen and nutrient supply. At the 
early stages, when the tumor is still small, diffusion of oxygen (limited to a 
distance of 20-200 µm, depending on tissue constraints (Carmeliet and Jain, 
2000; Pries and Secomb, 2014)) and other solutes (with higher maximal diffusion 
distance) (Pries and Secomb, 2014) suffices. However, it is generally accepted 
that tumors are not able to grow beyond the size of 1-2 mm in diameter without 
an adequate blood supply. The initiation of angiogenesis, or the ‘angiogenic 
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switch’, has to occur to ensure exponential tumor growth (Bergers and Benjamin, 
2003). It is also recognized that the ‘angiogenic switch’ is a rate-limiting event in 
carcinogenesis (Hanahan and Weinberg, 2000; Rogers et al., 2014).  
Blood vessels in the tumor can develop from pre-existing capillaries or 
post-capillary venules by sprouting angiogenesis, intussusception (splitting of 
pre-existing vessel), vasculogenesis (recruitment of BMDCs and EPCs that 
differentiate into ECs), vessel co-option (cancer cells hijack an existing vessel) or 
vascular mimicry (in which cancer cells can line a vessel) (Carmeliet and Jain, 
2011a). While neovascularization is the most commonly described type of 
angiogenesis in a variety of tumors, astrocytomas acquire their blood supply 
without initiating sprouting angiogenesis but by vessel co-option (Bergers and 
Benjamin, 2003). 
 Sprouting angiogenesis is initiated when cells are deprived of oxygen. In 
avascular areas, adaptive responses are initiated, mainly mediated by the 
hypoxia inducible factor-1 (HIF1) (Fraisl et al., 2009). HIF1 activates the 
transcription of a plethora of genes, including vascular endothelial growth factor 
(VEGF). VEGF is a key growth factor driving sprouting angiogenesis, both in 
physiological and pathological conditions. The importance of VEGF in 
angiogenesis has been demonstrated by genetic studies. Both haplodeficiency 
and overexpression of VEGF resulted in embryonic lethality between embryonic 
day 11 and 12 due to severe vascular defects (Carmeliet et al., 1996; Ferrara et 
al., 1996; Miquerol et al., 2000). The VEGF family consists of five members: 
VEGF-A (or simply VEGF), VEGF-B, VEGF-C, VEGF-D and PlGF (Olsson et al., 
2006). These secreted, dimeric glycoproteins of approximately 40kDa ligands 
can bind three receptor tyrosine kinases (RTKs), VEGF receptor-1, -2, and -3 
(VEGFR1-3). Binding of VEGF leads to the formation of VEGFR homodimers 
and heterodimers and subsequent signal transduction. The different VEGF 
isoforms have overlapping yet distinctive binding properties for each of their 
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tyrosine kinase receptors. These different properties contribute to the functional 
diversity of VEGF isoforms. VEGF-A, the key growth factor regulating 
angiogenesis, induces its angiogenic signal by binding to VEGFR-2 (also known 
as fetal liver kinase-1 (FLK-1) in mouse and as kinase insert domain receptor 
(KDR) in human). Activation of VEGFR-2 induces direct effects on ECs by 
promoting their proliferation, survival, vessel sprouting and permeability (Moens 
et al., 2014). 
 During sprouting angiogenesis, tip cells sprout from an existing vessel, 
leading the way and navigating towards the angiogenic signal. Stalk cells, trailing 
behind the tip cells, proliferate and extend the vascular lumen as sprouts 
elongate. Tip and stalk cell differentiation is tightly controlled by a feedback 
system of VEGF and Notch, as well as other genetic signals (De Smet et al., 
2009). Recent studies from the host lab show that besides growth factors, the 
key glycolytic regulator 6-phosphofructo-2-kinase / fructose-2,6-bisphosphatase 
3 (PFKFB3) regulates angiogenesis by controlling the balance between tip and 
stalk cell (De Bock et al., 2013). Phalanx cells are quiescent ECs, lining vessels 
once the vascular unit is established. They form a streamlined monolayer of ECs, 
covered by pericytes and homogenous BM (De Smet et al., 2009).  
In healthy organs, blood vessels are composed of a monolayer of phalanx 
ECs with a smooth surface with cobblestone-morphology, interconnected by 
junctional molecules (VE-cadherin and claudins). They are covered by pericytes 
that, together with phalanx ECs, produce a BM to form a stable vascular unit 
(Figure 6A). In tumors however, homeostatic vessel morphogenesis is often 
deregulated, resulting in vessels that are abnormal in structure and shape. 
Abnormal tumor blood vessels are tortuous and misshapen with a highly 
dysfunctional, leaky and porous EC layer. Unlike normal blood vessels, they 
have defective BM and pericyte coverage (Carmeliet and Jain, 2011b) (Figure 
6B). This abnormal structure of tumor blood vessels facilitates cancer cell 
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intravasation and further dissemination. The aberration of tumor blood vessels is 
a result of non-productive angiogenesis. Rapidly growing tumors are in constant 
need for oxygen and nutrients. Cancer cells try to overcome this shortage by 
upregulating angiogenic factors, such as vascular endothelial growth factors 
(VEGF), angiopoietin-2 (ANG-2), and interleukin-2 (IL-2), to attract more blood 
vessels. However, because of this excessive production, these angiogenic 
factors start to act as abnormalization factors, leading eventually to aggravated 
vessel disorganization, increasing intratumoral hypoxia and interstitial fluid 
pressure (factors positively regulating cancer cell dissemination) (Carmeliet and 
Jain, 2011b). Thereby, these factors fuel non-productive angiogenesis in an 
endless self-reinforcing loop (Figure 6B, upper right panel). 
 
 
FIGURE 6: TUMOR BLOOD VESSELS ARE STRUCTURALLY AND FUNCTIONALLY ABNORMAL. 
Schematic representation of structural parameters of healthy (A) and tumor (B) blood vessels. A, 
In healthy tissue, blood vessels develop a well-organized network of arteries and veins to support 
the need for oxygen and nutrients (upper part panel A), with a normal vessel wall and 
endothelium (lower part of panel A). B, In a rapidly growing tumor, both the vasculature (upper 
part of panel B), as well as the vessel wall and endothelium (lower part of panel B) are abnormal 
in shape and structure, resulting in increased hypoxia (represented by blue shading) and IFP. 
BM, basement membrane; ECs, endothelial cells; IFP, interstitial fluid pressure. Adapted from 
(Carmeliet and Jain, 2011b). 
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In addition to its crucial role as a regulator of sprouting angiogenesis, VEGF 
plays a critical role in promoting the permeability of tumor blood vessels, thereby 
further facilitating the intravasation of cancer cells (Dvorak et al., 1999). 
Moreover, hypoxia-induced ANG-2 destabilizes tumor blood vessels (reduces the 
coverage of ECs by pericytes) by antagonizing the activity of anigopoetin-1 
(ANG-1) (Falcon et al., 2009). 
Because of the fundamental role of angiogenesis in cancer, blocking 
molecules involved in angiogenesis appeared to be an attractive strategy for 
cancer therapies 
 
3.1.1. ANTI-ANGIOGENIC THERAPY: SUCCESSES AND LIMITATION 
Since the concept of targeting angiogenesis to starve tumors to death was 
introduced, more than 40 years ago (Folkman, 1971), ten anti-angiogenic drugs 
targeting VEGF or its receptors are approved for cancer therapy, with many more 
in clinical trails (Jain, 2014). Among these, the pioneers in angiogenesis 
inhibitors are: a ligand-trapping humanized monoclonal antibody against VEGF-A 
– bevacizumab (Avastin, Genentech / Roche), and two kinase inhibitors – 
sorafenib (Nexavar, Bayer) and sunitinib (Sutent, Pfizer) – that target tyrosine 
kinases (among others VEGFR-2).   
 Despite the encouraging intial results in pre-clinical models and clinical 
trials, anti-angiogenic therapy by itself failed to meet the expectations. These 
initial benefits, in the order of weeks to months (at best), are only transitory, 
because of either intrinsic resistance of tumors to these agents prior to treatment 
or the development of resistance after an initial response (Bergers and Hanahan, 
2008; Jain, 2014). In the latter case, the evasion of anti-angiogenic therapy is 
mediated by the development of alternative mechanisms to sustain tumor growth. 
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In part, the following adaptive can be involved: (i) activation and / or upregulation 
of alternative pro-angiogenic signaling pathways; (ii) activation of 
vasculogenesis; (iii) increased pericyte coverage of the tumor vessels, which 
confers resistance to therapy; (iv) increased invasion of cancer cells that allows 
them to access the blood supply of normal tissue without the necessity of 
neovascularization (Bergers and Hanahan, 2008).  
 Moreover, VEGF inhibition as a single therapy has been suggested to 
promote a switch of the cancer cells to a more invasive and more metastatic 
phenotype, possibly contributing to the limitations of patients’ survival (Kerbel, 
2008). Indeed, the results from pre-clinical studies on several tumor models 
confirmed that inhibition of angiogenesis as a monotherapy promotes tumor 
progression to malignancy, with heightened local invasion and increased 
metastatic capacity (Ebos et al., 2009; Paez-Ribes et al., 2009).  
On the contrary to these ‘vessel pruning’ strategies, recent preclinical and 
initial clinical results revealed that ‘normalization of the vascular abnormalities’ in 
cancer is emerging as a complementary therapeutic approach to standardized 
cancer therapies (Carmeliet and Jain, 2011b; Jain, 2014). 
 
3.1.2. VESSEL NORMALIZATION AS A NEW THERAPEUTHIC APPROACH TO BLOCK 
METASTASIS 
In tumors, the production of angiogenic factors is excessive and leads to the 
development of functionally and structurally abnormal vessels. The strategy of 
tumor vessel normalization aims to restore the equilibrium of pro- and anti-
angiogenic factors that are skewed in the tumor microenvironment.  This would 
revert the utterly abnormal structure and function of the tumor vessels towards a 
more normal state (Goel et al., 2011). These changes would not only contribute 
to the development of less hypoxic tumors with lower invasive and metastatic 
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properties, but could also contribute to an improved chemoresponse by 
improving drug delivery.  
The importance of vessel normalization has been recognized in 2001. The 
idea stemmed from the observation that monotherapy of bevacizumab had 
divergent outcomes compared to combined bevacizumab and chemotherapy on 
overall survival in patients (Jain, 2001). While monotherapy with an anti-VEGF 
monoclonal antibody failed to prolong the overall survival of patients, combined 
treatment with chemotherapy conferred a survival benefit (Jain, 2001; Jain, 
2014). This beneficial effect was mediated by transient ‘normalization’ of the 
abnormal vasculature of tumors as a result of anti-angiogenic treatment that 
temporally improved tumor perfusion and reduced intratumoral hypoxia (known to 
promote resistance to chemotheraphy and radiotherapy). Thus, therapies that 
were administered during the window of time when tumor vessels were 
normalized might have achieved better efficacy (Jain, 2001; Jain, 2014).   
Since 2001, several preclinical studies using direct and indirect anti-
angiogenic agents supported the tumor vessel normalization hypothesis (Izumi et 
al., 2002; Tong et al., 2004; Winkler et al., 2004; Yuan et al., 1996). Moreover, a 
number of additional targets, present either in cancer cells or in stromal cells, 
have been implicated in facilitating or hindering vessel normalization (Jain, 2014). 
Among these, studies from our lab showed that genetic blockade of PHD2 in ECs 
promotes tumor vessel normalization (Mazzone et al., 2009). Moreover, we 
uncovered unanticipated activities of chloroquine (FDA-approved antimalarial 
drug) as a tumor vessel normalizing agent (Maes et al., 2014). 
Altogether, these studies support the notion that tumor vessel 
‘normalization’, rather than vessel ‘pruning’, presents a promising strategy to 
diminish cancel cell invasive and metastatic capacity, whilst improving drug-
delivery and chemotherapy-response, thus promising a prolonged overall 
survival. 
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3.2. CANCER-ASSOCIATED FIBROBLASTS 
CAFs are the most prominent cell type within the tumor stroma of many tumors, 
especially in breast, prostate and pancreatic carcinomas (Kalluri and Zeisberg, 
2006; Pietras and Ostman, 2010). In fact, the fibroblast population in pancreatic 
cancers may comprise more than 90% of the overall tumor mass (Karagiannis et 
al., 2012).  
The transformation of local fibroblasts is pathologically important in the 
progression of cancer. CAFs are a form of perpetually activated fibroblasts. They 
proliferate faster and deposit higher amounts of ECM components than resting 
fibroblasts in benign tissue (Kalluri and Zeisberg, 2006). While in the early phase 
of carcinogenesis fibroblasts can have tumor suppressing activities, the 
phenotype of activated fibroblasts (CAFs) switches to a tumor promoting state as 
the tumor progresses (Proia and Kuperwasser, 2005). CAFs have an important 
role in tumorigenesis and in malignant progression. They facilitate proliferation, 
invasion and motility of malignant cells, and eventually contribute to metastasis 
(Cirri and Chiarugi, 2011). Their pro-tumorigenic and pro-metastatic activities are 
related to several mechanisms (Figure 7).  
First, CAFs facilitate tumor cell invasion through protease- and force-
dependent matrix remodeling (Calvo et al., 2013; Gaggioli et al., 2007). They 
stimulate angiogenesis and provide building blocks (amino acids, nucleotides) 
and metabolites (glutamine, pyruvate, lactate) for cancer cell metabolism, 
promoting tumor growth, invasion and metastasis (Liu et al., 2011). CAFs and 
hypoxia are both crucial for tumor progression, however little is known about how 
hypoxia affects the recruitment and activation of CAFs. It has recently been 
indicated that the recruitment of fibrocytes (possible CAF precursors) / 
myofibroblasts to sites of pathological fibrosis may be driven by hypoxia (Giaccia 
and Schipani, 2010).  Although it is unknown whether tumor hypoxia does indeed 
play a role in the recruitment of CAF precursors to the tumor, tumor hypoxia may 
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control the differentiation of CAFs from precursor cells through mechanisms 
involving TGF-β1 and endothelin-1 (ET-1) (Bellini and Mattoli, 2007). Overall, 
hypoxia might enhance most of the pro-tumorigenic activities of CAFs. 
 
FIGURE 7: PLEIOTROPIC ACTIVITIES OF CAFS. 
Within the tumor microenvironment CAFs communicate with several cell types: resident epithelial 
cells, cancer cells, ECs, pericytes, and inflammatory cells through either direct interaction or 
secretion of growth factors and chemokines. CAFs remodel the ECM of the tumor 
microenvironment by depositing collagen and expressing tenascin C, thus altering matrix 
structure. Moreover, CAFs are capable of proteolytically remodelling the ECM by secreting MMPs 
and contracting the matrix. These modifications eventually lead to the formation of tracks within 
the matrix that facilitate cancer cell migration and invasion. By secreting chemokines (MCP1, IL-
1), CAFs mediate inflammatory responses and VEGF secreted by CAFs promotes angiogenesis. 
By releasing TGF-β and HGF they promote the transformation of normal epithelial cells and 
stimulate cancer cell invasion and proliferation. Adapted from (Kalluri and Zeisberg, 2006). 
 
Secondly, CAFs produce ECM components that provide critical cues for growth, 
survival, motility of the cancer cells, and angiogenesis. It is generally believed 
that, in tumors, activated fibroblasts are the main cellular source of ECM. Recent 
studies show that matrix stiffness promotes BC progression via mechano-
reciprocal induction of tumor cell contractility (Levental et al., 2009). The matrix 
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microenvironment is also important for tumor invasion and metastasis as tumor 
cells migrate along collagen fibers (Friedl and Gilmour, 2009). Reticular collagen 
surrounding mammary glands restrain invasion, while alignment of dense 
collagen fibers perpendicular to the tumor boundary promotes migration 
(Provenzano et al., 2008). Notably, increased mammographic density due to the 
stromal matrix is one of the greatest risk factors for developing BC (Boyd et al., 
2002), and the presence of a tumor-associated collagen signature-3 (TACS-3) is 
an independent prognostic indicator regardless of tumor grade and size, 
estrogen or progesterone receptor status, node status or tumor subtype (Conklin 
et al., 2011). In fact, TACS-3 is characterized by bundles of straightly aligned 
collagen fibers that are oriented perpendicular to the tumor boundary, and 
regions containing TACS-3 correspond to sites of focal invasion into the stroma 
(Provenzano et al., 2006).  
Hypoxia and HIFs have been linked to fibrosis in various tissues during 
pathological conditions and they act as strong stimuli for tumor matrix production 
and remodeling (Giaccia and Schipani, 2010). Hypoxia activates collagen 
synthesis in periarterial smooth muscle cells and in fibroblasts, stimulates the 
production of syndecan-4, galectin-1 and fibronectin. TGF-β1, the activity of 
which is increased in hypoxic areas (Higgins et al., 2008), promotes 
desmoplastic reactions in BC cells. Moreover, hypoxia modulates cell adhesion 
via integrin-dependent and -independent mechanisms (Jean et al., 2011), which 
are closely associated with ECM synthesis and remodeling (Geiger et al., 2001). 
It enhances integrin β1-expression in fibroblasts, leading to focal adhesion kinase 
(FAK) activation. Hypoxia also augments the expression of some selectin 
ligands, thereby facilitating endothelial cell adhesion to E-selectin on the surface 
of cancer cells (Jean et al., 2011). Lysyl oxidase (LOX), which enhances cell-to-
matrix adhesion and the migration of tumor cells on modified collagen fibers, is 
increased in hypoxic human BC cells (Erler et al., 2006). However, hypoxia also 
influences ECM degradation through the production of matrix metalloproteinases 
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(MMPs) (Munoz-Najar et al., 2006). As a functional consequence, hypoxia 
mediated ECM synthesis and remodeling contributes to cancer invasion and 
metastasis. 
Third, CAFs can foster metastasis in distant target organs. A particular 
challenge in the treatment of BC is early metastatic dissemination followed by 
long periods of cellular dormancy. The mechanisms responsible for maintaining 
survival and triggering outgrowth of dormant tumor cells remain largely unknown. 
One possible mechanism that may regulate tumor dormancy is the interaction of 
tumor cells with their microenvironment. It has been postulated more than a 
century ago by Paget that metastases will develop only when the tumor cell (the 
‘seed’) and the microenvironment of a given tissue (the ‘soil’) are compatible 
(Goss and Chambers, 2010). Recent studies showed that adhesive interactions 
with ECM components, as well ECM remodeling (increased collagen I 
deposition) suffice to induce the switch from dormancy to proliferative tumor 
growth via integrin β1 signaling and cytoskeleton reorganization (Barkan et al., 
2010). Moreover, metastatic cells can be accompanied by CAFs from the primary 
tumor (Duda et al., 2010) that create a nutritive microenvironment at the distant 
metastatic site, thereby increasing the number of metastases. Furthermore, 
CAFs and MSCs promote tumor growth, invasion, and metastasis via cytokine 
signaling (Karnoub et al., 2007; Orimo et al., 2005). Overall, CAFs are present in 
human BC and promote tumorigenesis, invasion, survival in the circulation, 
formation of the pre-metastatic niche and metastasis. Hypoxia signaling might 
also stimulate several of these processes, as indicated above. 
Recent studies also demonstrated, however, tumor-inhibitory effects of 
CAFs in certain tumor types (pancreatic cancer) suggesting that CAFs exhibit 
phenotypic plasticity (Augsten, 2014; Ozdemir et al., 2014). CAFs are also being 
increasingly recognized as attractive therapeutic targets (Micke and Ostman, 
 51 
2005; Takebe Naoko, 2013), and particulary in breast cancer, they also induce 
resistance to therapy (Mao et al., 2012; Ostman, 2012).  
 
4. HYPOXIA SIGNALING 
Hypoxia is a common feature of solid tumors, resulting from aberrant vessel 
function and rapid cancer cell proliferation. Cancer cells are able to survive under 
conditions of low oxygen by mounting adaptive responses to maintain metabolic, 
bio-energetic and redox demands (Majmundar et al., 2010). Several clinical and 
preclinical studies have demonstrated that intratumoral hypoxia is associated 
with poor prognosis, metastasis and resistance to cancer therapies (Fyles et al., 
2002; Hockel et al., 1996a; Hockel et al., 1996b; Jubb et al., 2010). The ability of 
cells to adapt to hypoxia relies on the upregulation of hypoxia-inducible factors 
(HIFs) and nuclear factor-κB (NF-κB), among others (Cummins and Taylor, 
2005; Taylor, 2008).  
 
4.1. HYPOXIA INDUCIBLE FACTORS – FUNCTION, EXPRESSION AND REGULATION 
HIFs play a central role in the cellular responses to hypoxia (Semenza, 2007). 
HIFs are transcription factors that induce the expression of hundreds of genes 
that regulate cell survival and apoptosis, erythropoiesis, angiogenesis, vascular 
tone, iron homeostasis, pH regulation, as well as adaptive changes in cellular 
metabolism (Semenza, 2007). HIFs are composed of an oxygen-regulated HIFα 
and a constitutive HIF-β subunit (also known as the aryl hydrocarbon nuclear 
translocator, ARNT). In normoxia, the HIFα subunit is continuously synthesized 
and degraded, whereas in hypoxia, its degradation is inhibited and it 
accumulates. Upon translocation to the nucleus, HIFα dimerizes with HIFβ 
through their helix-loop-helix (HLH) and PER-ARNT-SIM (PAS) domains (Figure 
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8).  HIF heterodimers recognize and bind to hypoxia response elements (HREs; 
that have consensus sequence 5’-TACGTGCT-3’) in target genes, and recruit co-
activator proteins p300-CREBBP (CREB-binding protein), leading to increased 
transcription (Majmundar et al., 2010). 
There are three isoforms of HIFα in mammals: HIF1α, HIF2α (also known 
as endothelial PAS domain-containing protein-1, EPAS-1), and HIF3α (or 
inhibitory PAS domain protein, IPAS), of which HIF1α and HIF2α are the best 
characterized (Kaelin and Ratcliffe, 2008). HIF3α lacks the C-terminal 
transactivation domain and is believed to be a negative regulator of hypoxia-
regulated gene expression, most likely by binding competitively to HIFβ subunits, 
when they are limiting (Heikkila et al., 2011). HIF1α is expressed ubiquitously in 
all cells, while HIF2α and HIF3α are expressed only in certain tissues. HIF2α 
expression and transcriptional activity is restricted to vascular ECs, lung type II 
pneumocytes, kidney epithelial cells and the liver parenchyma. While HIF3α has 
been shown to be only expressed in cerebellar Purkinje cells, the corneal 
epithelium of the eye and in the thymus (Bertout et al., 2008). 
While HIFs are the key regulator of cellular responses to hypoxia, there 
are other enzymes that are responsible for sensing the oxygen level and 
subsequently regulating HIFα activity, the oxygen sensors prolyl hydroxylase 
domain proteins (PHDs) (discussed in section 4.2). In normoxic conditions, HIFα 
subunits are hydroxylated by PHDs at the conserved proline residues Pro-402 
and Pro-564 within the so-called oxygen-dependent degradation domains 
(ODDs). Hydroxylated HIFα subunits are recognized by the von Hippel-Lindau 
tumor suppressor (VHL), targeting it for polyubiquitination and degradation by the 
proteasome (Figure 8) (Ivan et al., 2001; Jaakkola et al., 2001; Mahon et al., 
2001; Maxwell et al., 1999).  
PHDs require oxygen and α-ketoglutarate (α-KG) as substrates, and 
ascorbic acid and ferrous iron (Fe2+) as co-factors for hydroxylation (Bruick and 
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McKnight, 2001; Epstein et al., 2001; Wong et al., 2013). In addition to PHDs, the 
HIFα subunit is regulated by another oxygen-dependent hydroxylase, factor 
inhibiting HIF (FIH). FIH hydroxylates asparagine Asn-803 on the HIFα subunit 
and thereby reduces its affinity for p300/CREBBP co-factors, resulting in reduced 
transcriptional activity of HIF (Mahon et al., 2001; McNeill et al., 2002). 
 
FIGURE 8: HIF ACTIVITY REGULATION IN NORMOXIA AND HYPOXIA. 
In normoxic conditions, when the oxygen supply is abundant, prolyl hydroxylase domain-
containing proteins (PHDs) and factor inhibiting HIF (FIH) hydroxylate proline or asparagine 
residues, respectively, on the HIFα subunit. The von Hippel-Lindau (VHL) protein complex 
recognizes hydroxylated proline residues, leading to proteosomal degradation of HIFα. 
Hydroxylation of asparagine residues represses transcriptional activity of HIF by blocking the 
interaction of HIFα and its co-activator p300. Insufficient oxygen supply leads to inactivation of 
PHDs and FIH. As a consequence, HIFα is stabilized and dimerizes with HIFβ to promote the 
transcription of a plethora of genes involved in adaptive responses to hypoxia. bHLH-PAS, basic 
heli-loop-helix-PAS protein domain; CODD, C-terminal oxygen degradation domain; FIH, factor 
inhibiting HIF; HIF, hypoxia-inducible factor; NODD, N-terminal oxygen degradation domain; 
PHDs, prolyl hydroxylase domain-containing proteins; VHL, von Hippel-Lindau protein;  Adapted 
from (Fraisl et al., 2009). 
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4.2. OXYGEN SENSORS – PHDS AND FIH 
To date, the family of oxygen sensors consists of: prolyl hydroxylase domain-
containing protein 1 (PHD1), also known as HIF prolyl hydroxylase 3 (HPH-3) or 
egg-laying defective nine homologue 2 (EGLN2); prolyl hydroxylase domain-
containing protein 2 (PHD2), also known as HPH-2 or EGLN1; prolyl hydroxylase 
domain-containing protein 3 (PHD3), also known as HPH-1 or EGLN3); and 
factor inhibiting HIF (FIH, also known as HIF1AN).  
These oxygen sensing enzymes are α-KG–dependent dioxygenases that 
use oxygen as a substrate, and ferrous iron as a co-factor to catalyze 
hydroxylation. Interestingly, these enzymes have relatively low affinity for oxygen, 
with Km values (the concentration of oxygen required for half-maximal catalytic 
rate) in the range 100-250 µM for PHDs (with the highest KM reported for PHD2) 
(Ehrismann et al., 2007; Hirsila et al., 2003; Koivunen et al., 2006) and 90 µM for 
FIH (Koivunen et al., 2004). These oxygen levels required for half-maximal 
catalytic activities of PHDs and FIH are higher than the oxygen level in the tissue 
(Vaupel et al., 1991), and impaired diffusion in cancer likely creates even lower 
values. This discrepancy is the reason why these dioxygenases are highly 
sensitive to small changes in oxygen levels, thus acting as oxygen sensors. 
The activity of PHD hydroxylases can also be regulated by metabolic 
intermediates. While α-KG is required for the enzymatic activity of PHDs, several 
tricarboxylic acid (TCA) cycle metabolites (fumarate, isocitrate and succinate) 
competitively inhibit PHDs (Hewitson et al., 2007; MacKenzie et al., 2007; Selak 
et al., 2005). Accumulation of these metabolites can result from genetic 
mutations in the metabolic enzymes succinate dehydrogenase and fumarate 
hydratase. In tumors, this leads to the inhibition of PHDs, HIF activation and 
promotion of tumorigenesis (Kaelin, 2011). Mutations in isocitrate dehydrogenase 
(IDH)-1 and IDH-2, common in human glioblastomas, gliomas and leukemias and 
other types of tumors, also reduce PHD activity by decreasing the cytosolic levels 
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of α-KG. Subsequent work provided a more in depth explanation suggesting that 
mutant IDH-1/IDH-2 decreases α-KG by preferentially producing the 
oncometabolite (R)-enantiomer of 2-hydroxyglutarate ((R)-2-HG). Structural 
similarity of (R)-2-HG to α-KG results in competitive inhibition of PHDs (Dang et 
al., 2009; Prensner and Chinnaiyan, 2011). On the contrary, a recent study 
reported that (R)-2-HG increases, not decreases, the activity of PHD1 and PHD2, 
lowered HIF signaling and surprisingly promoted cancer cell proliferation 
(Koivunen et al., 2012). These divergent, yet intriguing, results warrant further 
studies on the contextual molecular mechanism of (R)-2-HG activities.  
Reactive oxygen species (ROS) have been shown to be a negative 
regulator of PHD activity by oxidizing ferrous iron to ferric iron, in a dose and 
time-dependent manner (Wong et al., 2013). Apart from ascorbic acid that 
reduces iron to its ferrous state (Schofield and Ratcliffe, 2004), other reducing 
agents, such as glutathione, could suffice to maintain a redox status of iron 
(Wong et al., 2013). 
 
4.2.1. HIF-INDEPENDENT ACTIVITIES OF PHDS 
In addition to their crucial role as regulators of HIF stability and activity, PHDs 
also regulate other downstream targets either by hydroxylation or by direct 
interaction.   
 One of the signalling pathways regulated by PHDs is the nuclear factor κ-
light chain enhancer of activated B cells (NF-κB). The NF-κB pathway is involved 
in many cellular functions, including proliferation, cellular immune responses and 
cell survival (Perkins, 2007). It has been shown in several models that PHD1 and 
PHD3 inhibit IκB kinase (IKK), and consequently decrease NF-κB signalling 
(Cummins et al., 2006; Fu and Taubman, 2010; Fu and Taubman, 2013; Xue et 
al., 2010). PHD2 is also a negative regulator of the NF-κB pathway during 
arteriogenesis (Takeda et al., 2011) and vasculogenesis (Chan et al., 2009). A 
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recent study identified that PHD3, but not PHD1 or PHD2, interacts with and 
inhibits K63-linked ubiquitination of IKK subunit gamma (IKKγ). This interaction 
was independent of its hydroxylation activity (Fu and Taubman, 2013). However, 
it is not clear whether negative regulation of NF-κB signalling by other PHDs 
occurs via hydroxylation or in a hydroxylation-independent manner (Figure 9).  
FIGURE 9: NF-κB activity is negatively regulated by PHDS. 
Inflammatory stimuli and growth factor signaling cause phosphorylation of inhibitor of κB kinase 
(IKK)β, leading to complex formation with IKKα and IKKγ, resulting in the subsequent activation 
and phosphorylation of the inhibitor of transcription factor NF-κB (IκBα). Phosphorylated IκBα is 
then degraded by the proteasome, releasing the transcription factor NF-κB (consisting of p50 and 
p65 subunits), which translocates to the nucleus to activate proinflammatory genes via interaction 
with NF-κB-responsive elements (NRE). Prolyl hydroxylase domain enzymes PHD1, PHD2, and 
PHD3 were suggested to negatively regulate the IKK complex, possibly through hydroxylation, 
although the exact mechanism remains to be shown. PHD3 directly interacts with IKKβ in a 
hydroxylase-independent manner. This negative regulation of IKKβ by PHD3 may involve both 
steric hindrance and/or hydroxylation, whereas for PHD1 and PHD2, a hydroxylase-dependent 
negative regulatory mechanism cannot be excluded. Adapted from (Wong et al., 2013). 
  
 
The regulation of cyclin D1 by PHD1 and PHD2 is also HIF-independent. In a 
cancer context, both PHD1 and PHD2 act as tumor promoters by upregulating 
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cyclin D1 in estrogen-dependent BC and pancreatic tumors, respectively (Su et 
al., 2012; Zhang et al., 2009).  
 Several independent studies also reported that PHD2 regulates TGF-β1 
levels, though the regulation seems to be cell type-dependent. Wottawa et al. 
reported that silencing of PHD2 in the invasive MDA-MB-231 BC cell line resulted 
in decreased TGF-β1 processing by pro-protein convertase furin, impairing the 
secretion of the mature form of TGF-β1. TGF-β1 is an important regulator of 
tumor progression. By silencing PHD2, TGF-β1 secretion was decreased, 
impairing MDA-MB-231 BC progression in vivo (Wottawa et al., 2012). In line 
with these findings, TGF-β1 signalling was also decreased in PHD2-deficient 
keratinocytes resulting in increased keratinocyte proliferation and re-
epithelialization, thereby promoting faster wound healing (Kalucka et al., 2013). 
On the contrary, PHD2 silencing in LM8 osteosarcoma, 3L-D122 Lewis lung 
carcinoma and B16BL6 melanoma increases TGF-β signalling. This is regulated 
on the transcriptional level as also transcript levels of TGF-β isoforms and their 
receptors were increased in PHD2-silenced cancer cells (Klotzsche-von Ameln et 
al., 2011). TGF-β signalling can also be regulated by PHD2 indirectly by other 
proteins. Indeed, PHD2 has been shown to regulate phosphodiesterase 4D, a 
key enzyme controlling the cytosolic cAMP levels. cAMP is an important second 
messenger, regulating many biological processes. Increased cAMP levels 
prevent TGF-β-induced Smad-specific gene transactivation, and antagonize the 
inductive effects of TGF-β on the expression of collagen, connective tissue 
growth factor, tissue inhibitor of matrix metalloproteinase-1, and plasminogen 
activator inhibitor type I, four prototypical TGF-β-responsive genes (Schiller et al., 
2010). PHD2 has been found to upregulate cAMP levels in cardiomyocytes (Huo 
et al., 2012).  
Moreover, PHD3 is also an important regulator of the DNA damage repair 
pathway during hypoxia (Xie et al., 2012). PHD3 associates with and 
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hydroxylates HCLK2, a component of the ATR/CHK1 pathway that mediates 
DNA damage repair and also induces apoptosis. Hydroxylation of HCLK2 is 
necessary for its binding to ATR, and activation of the ATR/CHK1 pathway. 
Inhibition of PHD3 or loss of its hydroxylase activity during hypoxia reduces DNA 
damage-induced apoptosis in cancer. In line with this, PHD3-deficiency in vivo 
desensitizes the mice to ionizing radiation and decreases thymic apoptosis (Xie 
et al., 2012). These results may provide underpinnings of the genetic instability of 
tumors, as PHD3 is downregulated by hypermethylation in various tumors (Place 
et al., 2011).  On the contrary, another study reported that PHD2 and PHD3 
induction during hypoxia by HIF protects glioblastoma cells from HIF-mediated 
cell death (Henze et al., 2010). In hypoxic conditions PHD3 is most robustly 
upregulated as compared to other PHDs (Henze et al., 2010). It is also induced 
through growth factor deprivation in neuronal cells (Henze et al., 2014). In 
glioblastoma, hypoxia co-operates with other growth-inhibiting factors to robustly 
increase PHD3 expression. In this context, PHD3 acts as a tumor suppressor; it 
regulates EGFR internalization to suppress tumor growth. PHD3 controls EGFR 
activity independent of its hydroxylase activity by acting as a scaffold protein that 
interacts with the endocytic adaptor and facilitates the internalization of EGFR. 
Loss of PHD3 in cancer cells results in impaired endocytosis of EGFR and 
hyperphosphorylation, leading to increased EGFR signaling and enhanced cell 
proliferation and survival (Garvalov et al., 2014; Henze et al., 2014). 
Another study added another level of complexity to how PHD3 can 
indirectly regulate HIF activity. Cancer cells are usually highly glycolytic and they 
express high levels of pyruvate kinase muscle isoform 2 (PK-M2). Pyruvate 
kinase is a glycolytic enzyme that regulates the final step of glycolysis by 
converting phosphoenolpyruvate to pyruvate. Besides its glycolytic activity, PK-
M2 can also increase the transcriptional activity of HIF1α. Binding of PK-M2 to 
HIF1α is facilitated by PHD3 through hydroxylation and direct binding to PK-M2 
(Luo et al., 2011). Thus, depending on the oxygen level PHD3 can function as a 
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direct negative (in normoxia) or an indirect positive regulator of HIF1α (in hypoxia 
∼ 1% O2), by hydroxylating HIF1α or PK-M2, respectively. The interaction 
between PHD3 and PK-M2 also inhibits its enzymatic activity in glycolysis (Chen 
et al., 2011). Additionally, PHD2 can also inhibit HIF1α transcriptional activity in 
hypoxic conditions, independent of HIFα hydroxylation, by forming a complex 
with inhibitor of growth protein-4 (ING-4). ING-4 is a tumor suppressor that 
mediates the ability of HIF to induce adaptive transcriptional responses (Ozer 
and Bruick, 2005). Binding of PHD2 to ING-4 inhibits it from activating HIF (Ozer 
et al., 2005). Overall, these and several other studies show a broad range of 
functions of PHDs, underlining their important biological functions. 
 
4.2.2. BIOLOGICAL ROLES OF PHDS: HIF-DEPENDENT AND HIF-INDEPENDENT 
PHDs have near-ubiquitous tissue expression, with PHD2 being the most 
abundant isoform in all cells of the body, except for the testis where PHD1 has 
the highest expression, and heart, where PHD3 is most highly expressed (Wong 
et al., 2013). Also FIH is expressed in a broad range of tissues (Zhang et al., 
2010). Given its cellular abundance and lowest relative affinity to oxygen (see 
above), PHD2 has been considered to have a dominant role in oxygen sensing. 
Indeed, despite the presence of all PHDs, HIF1α activity is almost exclusively 
regulated by PHD2 at normoxia (Berra et al., 2003).  
The crucial role of PHD2 is underlined by genetic studies, where systemic 
PHD2, but not PHD1 or PHD3, homozygous knockout mice die during embryonic 
development (E12.5 – E14.5) due to placental and cardiac defects (Takeda et al., 
2006). PHD1 and PHD3 knockout mice develop normally and develop organ 
specific phenotypes, while the FIH knockout mice are viable, but have lower body 
mass due to enhanced metabolism, outlined in table 1. 
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Table 1. Summary of phenotypes in PHDs and FIH knockout mice.  
Gene Genotype Phenotype Reference 
PHD1 -/- 
Hypoxia tolerance of skeletal muscle and 
liver due to reprogramming to anaerobic 
metabolism 
(Aragones et al., 
2008; Schneider et 
al., 2010) 
Decreased Cyclin D1 level resulting in 
hypoproliferation of lactating mammary 
glands and inhibition of estrogen-dependent 
BC tumorigenesis 
(Zhang et al., 2009) 
PHD2*  
-/-  
(prenatal) 
Embryonic lethality (E12.5-E14.5) due to 
cardiac and placental defects (Takeda et al., 2006) 
-/-  
(postnatal) 
Increased angiogenesis (Takeda et al., 2007) 
Polycythemia and congestive heart failure (Minamishima et al., 2008) 
-/- 
(in 
cardiomyocytes) 
No phenotype in cardiac filament structure 
and function, but increased cardiac capillary 
area and smaller myocardial infract area 
and necrosis after ligation (dependent on 
HIF1α - mediated switch to glycolytic 
metabolism) 
(Holscher et al., 
2011) 
Hypomorph Hif-
p4h-2gt/gt mouse 
 
These mice express decreased amounts of 
Hif-p4h-2 mRNA: 8% in the heart, 15% in 
skeletal muscle, 34-47% in the kidney, 
spleen, lung, and bladder, 60% in the brain 
and 85% in the liver No effect on: 
polycthemia, dilated cardiomyopathy, and 
angiogenesis but reduced myocardial infarct 
size by HIF1α and HIF2α - mediated 
cardioprotection resulting from the induction 
of many genes involved in glucose 
metabolim, cardiac function and blood 
pressure. 
(Hyvarinen et al., 
2010) 
-/- 
(in HSCs) 
Hematopoietic progenitors are outcompeted 
under severe stress condtions.  (Singh et al., 2013) 
+/- 
(systmeic and 
myeloid-spcific) 
Improved arteriogenesis, expansion of 
tissue-resident M2-like macrophages (NF-
κB-dependent), improved limb perfusion 
and decreased necrosis in ischemia 
(Takeda et al., 2011) 
PHD3 -/- Hypofunctional sympathoadrenal system and reduced blood pressure (Bishop et al., 2008) 
PHD1
PHD3 
-/- 
-/- 
Viable and fertile with smaller litters and 
modest erythrocytosis (Takeda et al., 2008) 
PHD2 
 PHD3 
-/-;-/- 
(postnatal) 
Premature lethality caused by hepatic 
steatosis and dilated cardiomyopathy 
(Minamishima et al., 
2009) 
FIH -/- 
Viable, but lower body mass, enhanced 
metabolism, and increased insulin 
sensitiivity 
(Zhang et al., 2010) 
BC, breast cancer; FIH, factor inhibiting HIF; HIF, hypoxia indicible factor; HSC, hematopoietic stem 
cells; PHD, prolyl hydroxylase domain-containing proteins. * Cell type-dependent phenotypes of PHD2 
in tumor are listed in Table 2.  
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Moreover, conditional PHD2 knockout mice revealed additional functions of 
PHD2 in adult organisms both in physiological and pathological conditions (also 
summarized in table 1). 
 
4.2.3. CELL TYPE-DEPENDENT ROLES OF PHD2 IN TUMORS 
Mounting evidence from recent studies support the notion that PHD2 has cell 
type-dependent activities in tumors. Not only the histotype of the tumor 
determines the effect of PHD2 on tumorigenesis and metastasis, the stromal cell 
compartment also contributes to these responses. In the following sections I will 
outline the cell type-dependent roles of PHD2 in tumorigenesis and metastasis, 
also summarized in table 2. 
 
4.2.4. THE ROLE OF PHD2 IN CANCER CELLS 
Several previous studies have investigated the role of PHD2 in cancer cells. It is 
becoming evident that PHD2 in cancer cells can display both an anti- and pro-
tumorigenic effect depending on the cellular context (Bordoli et al., 2010; Chan et 
al., 2009; Couvelard et al., 2008; Klotzsche-von Ameln et al., 2011; Wottawa et 
al., 2012).  
In a few studies, loss of PHD2 tumor-suppressing function was associated 
with increased levels of pro-angiogenic factors; VEGF and IL-8 in MCF-7 breast 
carcinoma xenografts (Bordoli et al., 2010) or angiogenin and IL-8 in HCT116 
colorectal cancer xenografts (Chan et al., 2009). Upregulation of pro-angiogenic 
factors increased tumor angiogenesis or vasculogenesis, respectively, and 
fostered tumor growth in PHD-silenced cancer cells (Bordoli et al., 2010). In the 
context of PHD2 as a tumor suppressor, overexpression of PHD2 in several 
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pancreatic cancer lines reduced tumor growth through cyclin D1, angiogenesis 
and invasion (Su et al., 2012).  
 On the other hand, PHD2 can also display tumor-promoting activities. 
Silencing of PHD2 in LM8 osteosarcoma, Lewis lung carcinoma, and B16BL6 
melanoma reduced tumor growth in a TGF-β- dependent manner (Klotzsche-von 
Ameln et al., 2011). Similarly, decreased TGF-β- secretion in MDA-MB-231 
breast carcinoma reduced tumor xenograft growth upon PHD2 silencing 
(Wottawa et al., 2012).  
Given that metastasis is the primary cause of death of most breast cancer 
patients, it is surprising that the role of PHD2 in regulating this process has been 
only minimally studied, and not at all in a clinically more relevant spontaneously 
arising tumor model. Only when using a transplantable xenograft model, a single 
recent study identified EGLN1 (PHD2) as one of the proteins that are 
upregulated in metastatic breast cancer cells (Naba et al., 2014). Silencing of 
PHD2 in the highly metastatic human mammary carcinoma xenograft, MDA-MB-
231-LM2, implanted in the mammary fat pad of severely immunocompromised 
NOD/SCID/IL2Rγ-null mice, did not affect cancer cell invasion, but inhibited the 
spontaneous and experimental formation of pulmonary metastases (Naba et al., 
2014). This suggests that PHD2 did not regulate the early (intravasation), but 
rather the late (extravasation, lodging, metastatic outgrowth) steps of metastasis 
in this experimental model (Naba et al., 2014). However, the underlying cellular 
mechanism and any possible involvement of stromal cells were not elucidated in 
this study. 
Despite clear evidence from xenograft models, listed above, there are 
more human tumor types that overexpress PHD2 compared to their normal 
histological counterpart than tumor types that decreases the expression of this 
gene, suggesting that PHD2 rather acts as an oncogene than a tumor-
suppressor (Klotzsche-von Ameln et al., 2011).   
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Table 2. Cell type-dependent functions of PHD2 in tumors. 
PHD2-inhibited 
cell type 
Tumor 
growth 
Meta
stasis Mechanism Reference 
tumor cells 
human MCF-7 
breast cancer 
cells 
↑ ? 
- increased secretion of amphiregulin 
(HIF2-dependent), VEGF and IL-8  
- increased angiogenesis 
(Bordoli et al., 
2010) 
human AsPC-1, 
HPAF-II, MIA 
PaCa-2 and 
PANC-1 
pancreatic 
cancer cells 
↑  ? 
- downregulation of cyclin D1 
- HIF-independent 
(Su et al., 
2012) 
human HCT116 
colon cancer 
cells 
↑ ? 
- increased secretion of angiogenin and 
IL-8 
- NF-κB-dependent but HIF-independent 
- increased tumor vascularization 
(Chan et al., 
2009) 
murine LM8 
osteosarcoma, 
B16 melanoma 
and LLC lung 
cancer cells 
↓ ? 
- upregulation of MT1-MMP1 and MMP-2 
- increased TGF-β activity 
- cytostatic effect of TGFβ 
- HIF1-independent 
(Klotzsche-
von Ameln et 
al., 2011) 
human MDA-
MB-231 breast 
cancer 
↓ ? - impaired processing of TGF-β1 by furin - impaired secretion of TGF-β1 
(Wottawa et 
al., 2012) 
Human MDA-
MB-231-LM2 
(metastatic line) 
= ↓ 
- decreased metastasis is likely due to 
impaired extravasation, seeding, 
survival, and grow in the target organ 
(Naba et al., 
2014) 
stromal cells 
ECs (murine) = ↓ 
- vessel normalization 
- reduced metastasis and intravasation 
- improved response to chemotherapy  
- protection from chemotherapy-induced 
side effects 
- HIF2-dependent 
(Leite de 
Oliveira et al., 
2012; 
Mazzone et 
al., 2009) 
myeloid and T-
cells (murine) ↓ ? 
- increased cell death (necrosis)  
- reduced cytokine secretion 
- partially HIF1-dependent 
(Mamlouk et 
al., 2014) 
LLC, Lewis lung carcinoma; ECs, endothelial cells; MMP, matrix metalloproteinase; MT1-MMP1, 
membrane type 1 matrix metalloproteinase 1. 
4.2.5. THE ROLE OF PHD2 IN STROMAL CELLS 
PHD2 is expressed in all cells in the body. Thus it is not surprising that it also 
exerts effects on tumor progression and metastasis when targeted in specific cell 
populations.  Up to now, only a few studies reported the effect of PHD2 blockade 
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in the tumor stroma. Mazzone et al. revealed that PHD2 haplodeficiency in ECs 
does not affect primary tumor growth in several transplantable tumor models but 
reduces intravasation and pulmonary metastasis. They discovered that reduction 
in metastasis was due to normalization of abnormal tumor vessels in a HIF2α 
dependent manner. PHD2 haplodeficiency in ECs does not affect tumor vessel 
density or architecture, but improved endothelial cell lining and pericyte-
coverage, leading to improved vessel function and decreased intratumoral 
hypoxia. Reduced hypoxia diminished the invasive phenotype of cancer cells, 
improved vessel structure and restrained cancer cell intravasation (Mazzone et 
al., 2009). To follow up on the clinical implication of these findings, they further 
investigated whether PHD2 haplodeficiency in ECs combined with standard 
chemotherapy would be beneficial. Indeed, PHD2 haplodeficiency in ECs not 
only improved the delivery of chemotherapeutics and the chemoresponse, it 
protected the mice from side effects of these chemotherapeutics by 
counteracting oxidative damage in the heart and kidney (Leite de Oliveira et al., 
2012).  
 In another study, analysis of PHD2 deficiency in both myeloid cells and T-
lymphocytes reduced primary tumor growth (LLC xenografts), but the effect on 
metastasis has not been investigated (Mamlouk et al., 2014). The reduced tumor 
volume was a result of a decreased secretion of pro-tumoral and anti-tumoral 
cytokines that caused an imbalance between enhanced cell death and improved 
cancer cell proliferation (Mamlouk et al., 2014). 
 
Taken together, these results highlight that the treatment of cancer 
patients with a PHD2 pharmacological blocker might result in complex and 
divergent responses. Therefore, it is important to investigate the consequences 
of PHD2 blockade in both tumor and stromal cells to provide a unifying view on 
its effect on primary tumor growth and metastasis. 
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CHAPTER II 
  RATIONALE AND AIMS 
Prolyl-hydroxylase 2 (PHD2) is an oxygen-sensing enzyme that regulates HIFα 
levels in normoxia by targeting HIFα via hydroxylation for proteasomal 
degradation. We focused on PHD2 because this oxygen sensor has a critical role 
in health and disease, and because hypoxia signaling influences metastasis. 
Even though the role of PHD2 in tumor progression has been previously studied 
by silencing PHD2 in cancer cells in transplantable tumor models, the following 
three medically important questions have not been addressed in these studies.  
First, although metastasis kills >90% of cancer patients, the 
consequences of blocking PHD2, selectively in cancer or stromal cells, on 
metastasis have not been dissected in a spontaneously arising tumor model, 
which more closely mimics human cancer.  
Second, it is unknown whether PHD2 regulates the behavior of CAFs, 
even though emerging evidence indicates that these stromal cells have important 
effects on tumor progression and metastasis.  
Third, given that certain studies reported that PHD2 silencing in cancer 
cells stimulated tumor progression in transplanted tumor models (Bordoli et al., 
2010; Chan et al., 2009), it is unknown if concomitant PHD2 inhibition in both 
malignant and stromal cells (mimicking treatment with a pharmacological blocker) 
promotes or impairs metastasis, when initiated before but certainly also after 
onset of tumor growth in a spontaneous tumor model.  
In this study, we utilized the spontaneously arising Polyoma virus middle T 
antigen (PyMT)-oncogene driven breast cancer model to address these 
outstanding questions.  
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CHAPTER III 
 METHODOLOGY AND MATERIALS 
 
1. MICE 
Animal procedures were approved by the Institutional Animal Care and Research 
Advisory Committee (K.U. Leuven) and were performed in accordance with the 
institutional and national guidelines and regulations. 
MMTV-PYMT SPONTANEOUS BC MODEL: MMTV-PyMT mice were obtained from 
The Jackson Laboratory (Guy et al., 1992). Mammary tumors in PyMT mice arise 
spontaneously in virgin animals due to mammary epithelium directed expression 
of the PyMT antigen by the mouse mammary tumor virus (MMTV)-long terminal 
repeat (LTR) promoter (Lin et al., 2003). PyMT exerts its tumorigenic effects by 
changes in signalling of the Src, Ras, and PI3K pathways (Dankort and Muller, 
2000). Importantly, these signalling pathways are also activated by ErbB-2/Neu, 
a receptor tyrosine kinase that is commonly overexpressed in human breast 
cancers (Reese and Slamon, 1997). Extensive histological characterization of 
tumor progression in the PyMT model has also demonstrated reliable 
recapitulation of the morphological changes that occur during human breast 
cancer progression (Lin et al., 2003). Additionally, changes in gene expression 
concurrent with tumor progression in the PyMT model correlates with changes in 
gene expression observed in human breast cancer disease (Qiu et al., 2004). 
The PyMT model also provides an added advantage in the high rate of 
pulmonary metastasis that allows for the investigation of metastatic disease. 
 68 
PHD2 GLOBAL AND CONDITIONAL KNOCKOUT MICE: The generation of PHD2+/- and 
PHD2lox/lox mice was described previously (Mazzone et al., 2009). Tie2-Cre mice 
(Kisanuki et al., 2001), or VE-cadherin (PAC)-CreERT2 mice (Benedito et al., 
2012) were intercrossed with PHD2lox/lox mice and with MMTV-PyMT mice to 
obtain mice spontaneously developing metastatic mammary gland tumors with 
wild type PHD2 expression in endothelial cells (PyMTTie2-WT or PyMTVE-cadh-WT 
mice, respectively) or with haplodeficiency of the PHD2 gene specifically in 
endothelial cells (PyMTTie2-HE or PyMTVE-cadh-HE mice, respectively). 
PDGFRα:CreERT2 mice (Rivers et al., 2008) were intercrossed with PHD2lox/lox 
mice and with the MMTV-PyMT mice to obtain mice spontaneously developing 
metastatic mammary gland tumors with either wild type PHD2 expression in 
fibroblasts (PyMTCAF-WT mice) or with haplodeficiency of the PHD2 gene 
specifically in fibroblasts (PyMTCAF-HE mice). MMTV-Cre mice were from The 
Jackson Laboratory (Wagner et al., 1997) and were intercrossed with PHD2lox/lox 
mice and with the MMTV-PyMT mice to obtain mice spontaneously developing 
metastatic mammary gland tumors with wild type PHD2 expression in the tumor 
cells (PyMTTC-WT mice) or with haplodeficiency of the PHD2 gene specifically in 
tumor cells (PyMTTC-HE mice), respectively. Cell specific deletion of PHD2 was 
validated by qRT-PCR and immunoblotting. mT/mG reporter mice were from The 
Jackson Laboratory (Muzumdar et al., 2007) and were intercrossed with MMTV-
PyMT mice to obtain mice harboring mTomato+ tumor cells (PyMTmT/mG). All the 
transgenic mice used in this study were backcrossed to FVB genetic background 
and their brief characterization is listed in table 1. Wild type FVB mice were 
obtained from the KU Leuven animal facility.  
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Table 1. List of the mouse lines and their characterization 
Mouse line Abbreviation Specification Backgr
ound 
Reference 
PHD2ko:MMT
V-PyMT 
PHD2+/+:MMTV-
PyMT(PyMT+/+); 
PHD2+/-:MMTV-PyMT 
(PyMT+/-) 
Global PHD2 haplodeficiency 
in all cell of tumor, cancer 
cells and stromal cells 
FVB 
 
(Lin et al., 
2003; 
Mazzone et 
al., 2009) 
Tie2-
Cre:PHD2cko: 
MMTV-PyMT  
PHD2+/+:Tie2-Cre: 
MMTV-PyMT 
(PyMTTie2-WT); 
PHD2+/lox:Tie2-Cre: 
MMTV-PyMT 
(PyMTTie2-HE) 
PHD2 haplodeficiency in ECs 
and Tie2-expressing bone 
marrow derived cells, while 
the rest of the tumor stroma 
and cancer cells are wild 
type. 
FVB 
 
(Lin et al., 
2003; 
Mazzone et 
al., 2009) 
VE-cadherin 
(PAC)-
CreERT2:PHD2
cko: MMTV-
PyMT 
PHD2+/+:VE-cadherin 
(PAC)-CreERT2: 
MMTV-PyMT 
(PyMTCdh5-WT); 
PHD2+/lox:VE-
cadherin (PAC)-
CreERT2: MMTV-PyMT 
(PyMTCdh5-HE) 
PHD2 haplodeficiency in 
ECs, the rest of tumor stroma 
and cancer cells are wild 
type. 
FVB 
 
(Benedito 
et al., 
2012; Lin 
et al., 
2003; 
Mazzone et 
al., 2009) 
PDGFRα-
CreERT2:PHD2
cko: 
MMTV-PyMT 
PHD2+/+:PDGFRα-
CreERT2:MMTV-PyMT 
(PyMTCAF-WT); 
PHD2+/lox:PDGFRα-
CreERT2:MMTV-PyMT 
(PyMTCAF-HE) 
PHD2 haplodeficiency in 
PDGFRα-expressing cells, 
among which are CAFs, the 
rest of tumor stroma and 
cancer cells are wild type. 
FVB 
 
(Leite de 
Oliveira et 
al., 2012; 
Lin et al., 
2003; 
Mazzone et 
al., 2009) 
MMTV-
Cre:PHD2cko: 
MMTV-PyMT 
PHD2+/+:MMTV-
Cre:MMTV-PyMT 
(PyMTTC-WT); 
PHD2+/lox:MMTV-
Cre:MMTV-PyMT 
(PyMTTC-HE) 
PHD2 haplodeficiency in 
cancer cells, CAFs are wild 
type. 
FVB 
 
(Lin et al., 
2003; 
Mazzone et 
al., 2009; 
Wagner et 
al., 1997) 
R26-
CreERT2:PHD2
cko: MMTV-
PyMT 
PHD2+/+:R26-CreERT2: 
MMTV-PyMT 
(PyMTR26-WT); 
PHD2+/lox:R26-
CreERT2:MMTV-PyMT 
(PyMTR26-HE) ; 
PHD2lox/lox:R26-
CreERT2:MMTV-PyMT 
(PyMTR26-HO) 
Inducible global PHD2 
haplodeficiency in all cell of 
tumor, cancer cells and 
stromal cells. In this study 
deletion of PHD2 was 
indeuced at 7 weeks of tumor 
progression. 
FVB 
 
(Leite de 
Oliveira et 
al., 2012; 
Lin et al., 
2003; 
Mazzone et 
al., 2009) 
MMTV-
PyMT:mT/mG 
 
MMTV-PyMT:mT/mG 
(PyMTmT/mG) 
The mT/mG line is a double-
fluorescent Cre reporter 
mouse that expresses 
membrane-targeted tandem 
dimer Tomato (mT) prior to 
Cre-mediated excision and 
membrane-targeted green 
FVB 
 
(Muzumdar 
et al., 
2007). 
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fluorescent protein GFP (mG) 
after excision. For our 
experiments, PyMTmT/mG mice 
were not intercrossed with 
Cre-expressing mice and thus 
did not switch on the 
expression of GFP, but 
expressed Tomato reporter. 
GENOTYPING: Mice were genotyped by PCR. A tail biopsy (0.5-1cm) was digested 
overnight in 700µl lysis buffer (0,1M Tris-HCl (pH 8.5), 5 mM EDTA, 0.02% SDS, 
0.2 M NaCl in distilled water) containing 7µl proteinase K (10 mg/ml proteinase K, 
dissolved in 47% glycerol in MQ-water). After centrifugation (10 min, 15,000 
revolutions per minute (rpm)), the supernatant was mixed with isopropyl alcohol 
(600 µl) to precipitate the genomic DNA. The precipitated DNA was dissolved in 
400 µl Tris-EDTA (10 mM Tris, pH7.5: 1 mM EDTA) by incubating for 1 hour at 
55°C. 1 µl of DNA solution was pipetted into a PCR tube containing 12.5 µl 
GoTaq Green Master Mix (Promega), 1 µl each of the primers (10 µM), and 
adjusted to a total volume of 25 µl with RNase free water. The primers used are 
listed in table 2. PCR was performed using a PTC-200 Peltier thermal cycler with 
the following cycling program: one cycle of 30’’ at 98°C, then 30 cycles of 5’’ at 
98°C, 5’’ at 60°C, and 10’’ at 72°C. Samples were separated on a 2% agarose 
(UltraPure Agarose, Invitrogen) gel, using a gel electrophorysis system (VWR, 
700-0056). 
Table 2. List of primers used for PCR to genotype the mice 
Gene of 
interest 
Primer name Primer sequence Pairs 
with 
Allele Band 
size (bp) 
PHD2 WT MA 1 5’ ACC-TAT-GAT-CTC-AGC-ATT-
TGG-GAG 3’ 
ME 1 WT 340 
GETYPMA 1 5' TCA-GGA-CAG-TGA-AGC-CTA-
GAA-ACT-CT 3' 
ME 1 KO 380 
ME 1 5' AAA-TTC-TAA-TCG-TAG-CTG-
ATG-TGA-GC 3' 
   
PHD2(cKO) PHD2CKO C 5’ CCT-TCC-ATG-TTG-GCT-CAT-
TCC-ATT 3’ 
   
PHD2CKO D 5' TGC-TGA-ATT-GAG-TTG-CAT-    
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ACC-TTG 3' 
Tie2-Cre Cre 850 5’ CGC-CGT-AAA-TCA-ATC-GAT-
GAG-TTG-CTT-C 3’ 
   
Cre 403 5' GAT-GCC-GGT-GAA-CGT-GCA-
AAA-CAG-GCT-C 3' 
   
HIF 700 5' CAA-GCA-TTC-AAT-GTG-GAG-
CTA-TCT 3' 
   
HIF 960 5' TTG-TGT-TGG-GGC-AGT-ACT-
GGA-AAG-ZTG 3' 
   
VE-cadherin 
(PAC)-
CreERT2 
sCre1 5’ GCC-TGC-ATT-ACC-GGT-CGA-
TGC-GA 3’ 
   
asCre2 5' GTG-GCA-GAT-GGC-GCG-GCA-
ACA-CCA-TT 3' 
   
PDGFRα-
CreERT2 
ATG Cre up 5’ CAG-GTC-TCA-GGA-GCT-ATG-
TCC-AAT-TTA-CTG-ACC-GTA 3’ 
   
ATG Cre low 5' GGT-GTT-ATA-ACG-AAT-CCC-
CAG-AA 3' 
   
MMTV-Cre Cre 850 5’ CGC-CGT-AAA-TCA-ATC-GAT-
GAG-TTG-CTT-C 3’ 
   
Cre 403 5' GAT-GCC-GGT-GAA-CGT-GCA-
AAA-CAG-GCT-C 3' 
   
Endo 1 5' CAA-ACC-TGC-TAC-CCG-AAG-GT 
3' 
   
Endo 2 5' CAG-TAT-GCG-GAA-GTT-CTA-GG 
3' 
   
R26i-Cre Cre 850 5’ CGC-CGT-AAA-TCA-ATC-GAT-
GAG-TTG-CTT-C 3’ 
   
Cre 403 5' GAT-GCC-GGT-GAA-CGT-GCA-
AAA-CAG-GCT-C 3' 
   
HIF 700 5' CAA-GCA-TTC-AAT-GTG-GAG-
CTA-TCT 3' 
   
HIF 960 5' TTG-TGT-TGG-GGC-AGT-ACT-
GGA-AAG-ZTG 3' 
   
MMTV-
PyMT 
IMR 15 5' CAA-ATG-TTG-CTT-GTC-TGG-TG 
3' 
   
IMR 16 5' GTC-AGT-CGA-GTG-CAC-AGT-TT 
3' 
   
IMR 384 5' GGA-AGC-AAG-TAC-TTC-ACA-
AGG-G 3' 
   
IMR 385 5' GGA-AAG-TCA-CTA-GGA-GCA-
GGG 3' 
   
mT/mG IMR 7318 5' CTC-TGC-TGC-CTC-CTG-GCT-TCT 
3' 
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IMR 7319 5' CGA-GGC-GGA-TCA-CAA-GCA-
ATA 3' 
   
IMR 7320 5' TCA-ATG-GGC-GGG-GGT-
CGT-T 3' 
   
MMTV-Cre Cre 850 5’ CGC-CGT-AAA-TCA-ATC-GAT-
GAG-TTG-CTT-C 3’ 
   
Cre 403 5' GAT-GCC-GGT-GAA-CGT-GCA-
AAA-CAG-GCT-C 3' 
   
Endo 1 5' CAA-ACC-TGC-TAC-CCG-AAG-GT 
3' 
   
Endo 2 5' CAG-TAT-GCG-GAA-GTT-CTA-GG 
3' 
   
 
2. TUMOR MODELS 
PRIMARY TUMOR GROWTH: Progression from hyperplasia to adenoma and 
ultimately carcinoma was evaluated on H&E stained tumor sections as described 
before (Lin et al., 2003). Tumor growth was monitored by measuring the volume 
of each of the ten individual mammary tumors per MMTV-PYMT mouse once a 
week up to 16 weeks with a caliper using the formula: V = π x [d2 x D] / 6, where 
D is the major tumor axis and d is the minor tumor axis. Per mouse the mean of 
the individual tumor volumes was calculated and used to determine the genotypic 
difference. To analyse the tumor weight and pulmonary metastasis, mice were 
euthanized by cervical dislocation at the end point and the tumors and lungs 
were dissected and analyzed as described below.  
TUMOR CELL PROLIFERATION was detected by immunostaining of MMTV-PyMT 
tumor sections for PHH3. Mosaic pictures were taken, and PHH3+ area was 
quantified and expressed as a % of total tumor area.  
TUMOR CELL INITIATION:  Analysis of MMTV-PyMT tumor initiation was done on 
whole mount carmine stained mammary glands. Inguinal and thoracic mammary 
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glands were dissected from 4 week old PyMTTC-WT and PyMTTC-HE mice. 
Mammary glands were stretched out on a glass slide and fixed with Carnoy’s 
fixative for 2 hours at room temperature. The mammary glands were washed in 
70% ethanol for 15 minutes and then hydrated by gradually changing to distilled 
water. Next they were stained in carmine alum overnight (2% carmine (Sigma-
Aldrich, Bornem, Belgium), 5% potassium aluminum sulfate in distilled water). 
After staining, the mammary glands were gradually dehydrated (15 minutes each 
for 50%, 70%, 90%, 95%, and 100% ethanol), cleared in xylene, and mounted 
with DPX (Prosan). Imaging was performed using a stereomicroscope (Carl 
Zeiss, Munich, Germany). Intraepithelial neoplasias were delineated using 
ImageJ software and the area was determined across both inguinal and thoracic 
mammary glands.  
ANALYSIS OF PULMONARY METASTASIS: Dissected lungs were perfused with 1 ml ink 
solution (15 volume% black ink in sterile water, 2-3 drops of 25% NH3 per 50ml), 
washed with PBS and incubated in destaining solution (34% ethanol, 18% 
formaldehyde, 2.4% acetic acid) to visualize the metastatic nodules. Macroscopic 
metastatic lesions were counted under a dissecting microscope. The metastatic 
index was calculated as the number of metastases divided by total tumor weight. 
 
DETECTION OF CIRCULATING TUMOR CELLS (CTCS): 100 µl blood samples were 
collected from tumor bearing mice at the end stage of the experiment.  Blood 
samples were collected in RNA protect Animal Blood Tubes (Qiagen) and RNA 
was extracted with RNeasy Protect Animal Blood Kit (Qiagen), according to the 
manufacturer’s instructions. The level of CTCs was analyzed by assessing PyMT 
and Cytokeratin 8 transcript levels normalized to Hprt transcript levels.  
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ANALYSIS OF EXTRAVASATION AND COLONIZATION: 2,000,000 MMTV-PyMT tumor 
cells (PyMTTC-WT or PyMTTC-HE) were injected in the tail vein of FVB mice. After 15 
minutes, one, three or 24 hours, the mice were sacrificed and lungs were 
collected to assess tumor cell extravasation and colonization by assessing PyMT 
transcript levels normalized to Hprt transcript levels.  
3. CELL ISOLATION AND CULTURE 
CANCER CELLS AND CAFS FROM PYMT TUMORS: PyMT tumor cells and CAFs were 
isolated from MMTV-PyMT mice of different genotypes according to modified 
protocols of (Schwab et al., 2012) and (Calvo et al., 2013), respectively, cultured 
and used between passages 1 and 5. Briefly, dissected tumors were chopped 
and digested with 2 mg/ml collagenase  (Sigma blend L, Sigma-Aldrich, Bornem, 
Belgium) in RPMI medium containing 5% fetal bovine serum (FBS) (5 ml/g 
tissue) for 1 hour at 37°C. Organoids were pelleted at 1,100 rpm, washed four 
times with digestion buffer and then plated into standard tissue culture flasks in 
plating medium (Ham F-12 medium supplemented with 10% FBS, 100:100 
penicillin/streptomycin (Gibco, Invitrogen), 1.2% glutamine (Gibco, Invitrogen), 1 
µg/ml hydrocortisone (Sigma-Aldrich, Bornem, Belgium), 50 µg/ml gentamicin 
(Gibco, Invitrogen), 5 µg/ml bovine insulin (Sigma-Aldrich, Bornem, Belgium), 10 
ng/ml EGF (Gibco, Invitrogen), and 5 ng/ml cholera toxin (Gibco, Invitrogen)). 
The tumor suspension was plated for 30 minutes; adherent cells were enriched in 
CAFs. The non-adherent cell suspension was transferred to another flask to 
culture cancer cells. After plating for fibroblasts, the CAF enriched culture usually 
still contains some tumor cells. In order to obtain pure populations of CAFs, the 
cells were differentially trypsinized with dispase (Roche, Vilvoorde, Belgium) and 
0.25% trypsin (Gibco, Invitrogen). CAFs were cultured in CAF medium (DMEM F-
12, 10% FBS, 100:100 penicillin/streptomycin, 1.2% glutamine), and cancer cells 
in plating medium.  
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NORMAL LUNG FIBROBLASTS: fibroblasts were freshly isolated from lungs of FVB 
mice, cultured and used between passages 1 and 5. Briefly, dissected lungs 
were chopped and digested in a solution of 2 mg/ml collagenase (Sigma blend L, 
Sigma-Aldrich) in RPMI medium containing 5% fetal bovine serum (FBS) (5 ml/ 
lungs) for 1 hour at 37°C. Organoids were pelleted at 1,100 rpm, washed four 
times with digestion solution and then plated into standard tissue culture flasks in 
CAF medium. The day after isolation, the medium was refreshed. Cells were 
then routinely maintained in 5% CO2 and 95% air (normoxia) at 37°C and the 
medium was replaced every second day.  
TREATMENTS: Mitotic inactivation was achieved by culturing the cells for 24 hours 
in the presence of 2 µg/ml mitomycin C, and was confirmed using a [3H]-
Thymidine proliferation assay (see below). Culture under hypoxia was done in 
5% CO2 and 0.5% O2. Tumor cell conditioned medium was obtained from tumor 
cell cultures seeded at a density of 20 million cells per 10 cm dish in plating 
medium. After one day, confluent cells were washed with DPBS (Gibco, 
Invitrogen) and the medium was changed to 5 ml of full plating medium without 
FBS. Conditioned medium was collected from these dishes 24 hours later. 
4. LENTIVIRAL TRANSDUCTIONS 
Lentiviral transductions were performed as described (De Bock et al., 2013). 
Briefly, a lentiviral vector (pLVx-shRNA2; Clontech) encoding a green fluorescent 
reporter (ZsGreen, for convenience abbreviated as GFP in the text and figures) 
and into which a nonsense scrambled shRNA was cloned (De Bock et al., 2013), 
was used at a multiplicity of infection (MOI) of 10. Cells were transduced 
overnight in the presence of 0.5 μg/ml polybrene (Sigma-Aldrich, Bornem, 
Belgium), and refreshed with regular medium the next day. Transduced cells 
were used in functional assays at least 3 to 4 days post-transduction. 
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5. IN VITRO ASSAYS 
CELLULAR PROLIFERATION was quantified by incubating the cells for 2 hours with 1 
µCi/ml [3H]-thymidine. Thereafter, cells were fixed with 100% ethanol for 15 
minutes at 4°C, precipitated with 10% TCA and lysed with 0.1N NaOH. The 
amount of [3H]-thymidine incorporated into DNA was measured by scintillation 
counting.  
SCRATCH WOUND MIGRATION ASSAY: was performed with MMTV-PyMT cancer cells 
on 24-well plates 18 hours after seeding. A scratch wound was applied on the 
confluent MMTV-PyMT cancer cell monolayer using a 200 µl tip. After applying 
the wound and photography (T0), the cultures were further incubated for 18 
hours, and photographed again (T18hr). Endpoint pictures (T18hr) were taken after 
several wash steps with DPBS (Gibco, Invitrogen) to clear the cellular debris. 
Mean migration distance (gap area at T0 minus gap area at T18hr, normalized by 
the width of the migration front (measured as a straight line, parallel to the 
migration front)) was measured with NIH ImageJ software and is expressed in 
arbitrary units.  
SPHEROID TUMOR CELL INVASION ASSAY: MMTV-PyMT cancer cells (50,000 cells) 
were incubated for 3 days in hanging drops in plating medium (see above) 
containing 20% methylcellulose (Sigma-Aldrich, Bornem, Belgium), to form 
spheroids. Spheroids were then embedded in collagen gel as described (Korff et 
al., 2004) and cultured for 72 hours to induce invasion. Cultures were fixed and 
images were captured with an inverted microscope (Zeiss Axiovert 40CFL). 
Analysis of the entire cancer cell spheroid (as a measure of the collective cancer 
cell invasion) was done using the NIH ImageJ software.  
SPHEROID CAF INVASION ASSAY: CAFs (1,000 cells) were incubated overnight in 
hanging drops in CAF medium (see above) containing 20% methylcellulose 
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(Sigma-Aldrich, Bornem, Belgium), to form spheroids. Spheroids were then 
embedded in collagen gel as described (Korff et al., 2004) and cultured for 18 
hours to induce invasion. Cultures were fixed and images were captured with an 
inverted microscope (Zeiss Axiovert 40CFL). Analysis of the number of sprouts 
and the total sprout length (cumulative length of primary sprouts and branches 
per spheroid) was performed using NIH ImageJ.  
CHIMERIC TC-CAF SPHEROID INVASION ASSAY: Tomato+ PyMTmT/mG tumor cells 
(TCs) (1,000 cells) and GFP+ CAFs (1,000 cells) were co-incubated overnight in 
hanging drops in plating medium (see above) containing 20% methylcellulose 
(Sigma-Aldrich, Bornem, Belgium), to form spheroids. Spheroids were then 
embedded in collagen gel as described (Korff et al., 2004) and cultured for 48 
hours to induce invasion. Cultures were fixed and images were captured with 
Zeiss LSM 780 confocal microscope (Carl Zeiss, Munich, Germany). The number 
of the individual TCs invading into the collagen gel was analyzed.  
CO-CULTURE ASSAYS: A CAF organotypic culture system was set up to analyse the 
effect of CAF-mediated ECM remodelling on TC invasion into a collagen gel. 
Briefly, 250,000 CAFs/ml were embedded in a collagen matrix. After the base 
layer of collagen gel with non-transduced or GFP+ CAFs was solidified at 37°C, 
Tomato+ PyMTmT/mG cancer cell spheroids (50,000 cancer cells/spheroid), 
aggregated 72 hours in advance, were pipetted on top of the base layer, and 
overlayed by a top layer of collagen with non-transduced or GFP+ CAFs. 
Spheroids were cultured for 48 hours to induce invasion. Cultures were fixed and 
images were captured with Zeiss LSM 780 confocal microscope (Carl Zeiss, 
Munich, Germany). Analysis of the invasive tumor area was done using the NIH 
ImageJ software.  
CLONOGENIC GROWTH ASSAY: A base layer of agar was prepared in 12-well plates. 
Agar (high-gel strength, Serva) was dissolved at 0.5% in sterile distilled water 
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(Gibco, Invitrogen) in a microwave oven and was mixed with pre-warmed (56°C) 
Ham’s F12 medium (Gibco, Invitrogen) at a 1:1 ratio. The base layer of agar 
mixture was pipetted into a 12-well plate at 1.5 ml per well, and was left to solidify 
at room temperature. Cancer cells were suspended as a single-cell suspension 
(5,000 cancer cells per 1.5 ml, 1.5 ml per well) and plated on top of the base 
agar. Cancer cell colonies were counted visually under an inverted microscope 
(Motic AE31) after 10 days of incubation at 37°C in normoxia.  
ECM-REMODELLING ASSAY: to assess force-mediated matrix remodelling, CAFs 
were uniformly dispersed in 300 µl of collagen I lattices (in volume%: 38% rat tail 
tendon collagen I (1.25 mg/ml, Biomatrix), 14% NaHCO3 (15,6 mg/ml, Sigma-
Aldrich, Bornem, Belgium), 1% NaOH (1M) and 47% DMEM/F12 (Gibco, 
Invitrogen) containing 250,000 cells/ml CAFs) and seeded in a 24-well plate (300 
µl/well, Corning). Once the gel was solidified, the cells were maintained in CAF 
medium. Gel contraction was monitored daily for 4 days, by taking photographs 
of the gels. To obtain the gel contraction value, the relative diameters of the well 
and the gel were measured using NIH ImageJ software, and the percentage of 
contraction was calculated using the formula (100% - gel area/well area%) 
(Calvo et al., 2013; Tomasek et al., 1992).  
EXTRACELLULLAR MATRIX SYNTHESIS: 350,000 MMTV-PyMT cancer cells or CAFs 
were seeded in 6-well plates in plating or CAF medium, respectively, 
supplemented with 5 mCi/ml [3H]-L-proline (PerkinElmer) and 50 µg/ml ascorbic 
acid which was refreshed every second day. At day 8, cancer cells or CAFs were 
denudated with pre-warmed extraction buffer (20 mM NH4OH, 0.5% Triton X-100 
in PBS). The remaining residues of cells were digested with 10 µg/ml DNase I 
(Roche, Vilvoorde, Belgium) in PBS+ (containing calcium and magnesium). 
Thereafter, the remaining matrix was collected in lysis buffer (4% SDS, 0.1 M 
Tris-HCl, 0.1 M DTT), and equal volumes were counted in liquid scintillation 
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buffer. For imaging purposes, the matrices, after denudation of the cells, were 
washed twice with PBS+ and were stored at 4°C in PBS+ or used immediately for 
immunostaining of collagen I.  
CAF ACTIVATION ASSAY: Lung fibroblasts were seeded into a 6-well culture plate at 
a density of 200,000 cells per well. 24 hours after seeding, the culture medium 
was aspirated and the cells were washed with PBS. Serum-free control or 
MMTV-PyMT cancer cell conditioned medium (see above) supplemented with or 
without 5 µg/ml polyclonal TGF-β-neutralizing antibody (R&D Systems) was 
added to the experimental wells and the cells were further cultured for 8 days. 
The medium was refreshed every third day. On day 8, the cultures were lysed for 
RNA preparation for expression analysis of activation markers, or the cells were 
reseeded for proliferation assessment.  
6. RNA ANALYSIS 
RNA EXTRACTION AND CDNA SYNTHESIS:  RNA was extracted from cells or tissue 
using a premade kit (PureLink RNA Mini Kit, Invitrogen), according to the 
manufacturer’s instructions. One microgram of total RNA was used for reverse 
transcription with the QuantiTect Reverse Transcription Kit (Qiagen).  
EC ISOLATION FOR VALIDATION OF KNOCKDOWN EFFICIENCY:  EC were isolated from 
the lungs of PyMTTie2-WT, PyMTTie2-HE, and tamoxifen treated PyMTCdh5-WT and 
PyMTCdh5-HE mice as described before (Mazzone et al., 2009). Briefly, mice were 
sacrificed by cervical dislocation and lungs were harvested. After a wash in PBS, 
lungs were minced in RPMI medium containing 0.1% collagenase type I and 
incubated for 1 h at 37°C with gentle agitation. The digested tissue was 
centrifuged for 5 min at 1200 rpm, resuspended in RPMI medium containing 5% 
FBS and filtered by a 40 µm-pore size mesh. Filtered cells were incubated with 
magnetic beads previously coated with rat anti-CD31 (BD,Pharmingen), negative 
selection for CD45+  cells  was performed using magnetic beads previously 
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coated with rat anti-CD45 (BD,Pharmingen). CD31+ ECs were selected under 
magnetic filed. Cell purity was assessed by qRT-PCR for Cdh5, Cd31, VegfR2, 
Cd105, Pdgfrβ, Cd45, Vim, Sm22a. CD31+ ECs were used for assessment of 
Egln1 knockdown efficiency by qRT-PCR in PyMTTie2-WT, PyMTTie2-HE, PyMTCdh5-
WT and PyMTCdh5-HE mice. 
QUANTITATIVE REVERSE TRANSCRIPTION PCR: RNA Quantitative reverse 
transcription (qRT)-PCR was performed using TaqMan Fast Universal PCR 
Master Mix (Applied Biosystems) and in-house-designed primers and probes or 
premade primer sets (Applied Biosystems and Integrated DNA Technologies). 
Primer sequences or premade primer set ID numbers are listed in tables 3 and 4. 
Analyses were performed using ABI7500 Fast Real-Time PCR System (Applied 
Biosystems). Gene transcription was calculated as the number of mRNA copies 
relative to the number of mRNA copies of the housekeeping gene hypoxanthine 
guanine phosphoribosyl transferase (Hprt).  
Table 3. List of primers, used for qRT-PCR  
Gene Probe Forward Reverse 
Egln1 ACG-AAA-GCC-ATG-GTT-
GCT-TGT-TAC-CCA 
GCT-GGG-CAA-CTA-
CAG-GAT-AAA-C 
CAT-AGC-CTG-TTC-
GTT-GCC-T 
P
Pymt 
/56-
FAM/AGAATCAGA/ZEN/CCC
TCCCATGGACTCA/3IABkFQ/ 
GAA-CAA-GTA-CCC-
CAG-CTC-ATC 
CAT-TCT-CTG-ACT-
CGC-ATC-TAG-G  
 
Table 4. List of commercially available primers, used for qRT-PCR  
Gene Manufacturer Sequence ID 
Hprt Integrated DNA Technologies Mm.PT.42.12662529 
E-Cadherin Applied Biosystems Mm00486906_m1 
N-Cadherin Applied Biosystems Mm00483213_m1 
Egln1 Integrated DNA Technologies Mm.PT.51.8105240 
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Twist1 Applied Biosystems Mm00442036_m1 
Vimentin Applied Biosystems Mm00449201_m1 
Occludin Applied Biosystems Mm00500907_m1 
Zonula Occludens Protein-1 Applied Biosystems Mm00493699_m1 
Cytokeratin 8 Applied Biosystems Mm00835759_m1 
PDGFRα Applied Biosystems Mm01205760_m1 
Fsp-1 Applied Biosystems Mm00803371_m1 
Lox Applied Biosystems Mm00495386_m1 
Mmp2 Applied Biosystems Mm00439506_m1 
Mmp9 Applied Biosystems Mm00442991_m1 
Vegf-A Applied Biosystems Mm00437306_m1 
Vegf-B Applied Biosystems Mm00442102_m1 
Sele Applied Biosystems Mm00441278_m1 
Vcam Applied Biosystems Mm01320970_m1 
Plgf Applied Biosystems Mm00435613_m1 
            Ang2 Applied Biosystems Mm00545822-m1 
7. PROTEIN ANALYSIS 
IMMUNOBLOT ANALYSIS: Protein extraction and immunoblot analysis were 
performed using a modified Laemmli sample buffer (125 mM Tris-HCl, pH 6.8 
buffer containing 2% SDS and 20% glycerol) (Carmeliet et al., 2001) or using 
RIPA buffer in the presence of protease and phosphatase inhibitors (Roche, 
Vilvoorde, Belgium). Lysates were separated by SDS-PAGE under reducing 
conditions, the protein was transferred to a nitrocellulose or PVDF membrane, 
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and analyzed by immunoblotting. Primary antibodies used were E-cadherin 
(Novus Biologicals), N-cadherin (BD Pharmingen, Erembodegem, Belgium), 
fibronectin (Sigma-Aldrich Bornem, Belgium), α-actin (Cell Signaling Technology, 
Bioké, Leiden, the Netherlands), fibronectin (Sigma-Aldrich Bornem, Belgium), 
lamin A/C (Cell Signaling Technology, Bioké, Leiden, the Netherlands), and β-
actin (Cell Signaling Technology, Bioké, Leiden, the Netherlands). Appropriate 
secondary antibodies were from Dako (Enschede, the Netherlands). Signal was 
detected using the ECL system (Amersham Biosciences, GE Healthcare, 
Diegem, Belgium) according to the manufacturer’s instructions. Quantifications 
were done by densitometry of the bands using the NIH ImageJ software.  
ELISA: Tumor cell conditioned medium was prepared as described above. The 
conditioned medium (5 ml) was concentrated using Centricon tubes (Vivaspin 20, 
Sartorius) and 100 µl was used to quantify TGF-β1 levels. The TGF-β1 level in 
tumor extracts (prepared as described above) or in the concentrated conditioned 
medium was determined using a sandwich ELISA kit (Quantikine ELISA, R&D 
Systems), according to the manufacturers’ instructions.  
8. HISTOLOGY, IMMUNOSTAININGS AND MORPHOMETRIC ANALYSES 
All methods for histology and immunostaining have been performed as described 
by Fischer et al.  (Fischer et al., 2007).  
CELLS AND TISSUE PREPARATION: Cell cultures were fixed in 4% paraformaldehyde 
(PFA) for 10 min at 37°C. Mouse tissue samples were immediately frozen in OCT 
compound (for 7 µm and 40 µm serial sections) or fixed in 4% PFA overnight at 
4°C, dehydrated and embedded in paraffin (for 7 µm serial sections).  
STAININGS: Immunostainings were performed using the following primary 
antibodies: anti-CD105 and anti-PDGFRα (R&D systems, Minneapolis, MN, 
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USA), anti-α-smooth muscle actin-Cy3 (Sigma-Aldrich Bornem, Belgium), anti-
PHH3 (from Cell Signaling Technology, Bioké, Leiden, the Netherlands), anti-
S100a4 (Dako, Heverlee, Belgium), and anti-collagen I (Abcam, Cambridge, 
United Kingdom). Sections were then incubated with the appropriate 
fluorescently conjugated secondary antibodies (Alexa 488 or 546, Molecular 
Probes®, Invitrogen, Life Technologies, Ghent, Belgium) or with peroxidase-
labeled IgGs (Dako, Heverlee, Belgium), followed by amplification with the proper 
tyramide signal amplification systems when needed (Perkin Elmer, Life Sciences, 
Zaventem, Belgium). Nuclei were counterstained with DAPI (Molecular Probes®, 
Invitrogen, Life Technologies, Ghent, Belgium). H&E or Harris Haematoxylin 
(HH) staining and Picro Sirius Red staining of paraffin sections was done using 
standard protocols. Whole mount carmine alum staining of mammary glands was 
done as detailed above.  
MORPHOMETRIC ANALYSES: For morphometric analyses, mosaic pictures of the 
whole tumor or 15-20 random optical fields (20x or 40x magnification) per tumor 
section were taken by a Zeiss Axioplan upright microscope or Leica DMI 6000 B 
inverted microscope (Leica Microsystems, Mannheim, Germany), respectively 
and analyzed using the NIH ImageJ or Leica MM AF powered by MetaMorph ® 
analysis software. Confocal imaging was performed using a Zeiss LSM 510 Meta 
NLO or Zeiss LSM 780 confocal microscope (Carl Zeiss, Munich, Germany). 
Polarized light microscopy (Leica DMRB microscope) was used to visualize the 
birefringence of Picro Sirius Red stained collagen to distinguish between thin and 
cross-linked thick collagen fibres. 
SCANNING ELECTRON MICROSCOPY: Small tumor pieces were fixed overnight in 
2.5% glutaraldehyde in 0.1 M Na-cacodylate buffer, pH 7.2-7.4 at 4 °C. Three 
rinses of 30 min with 0.1 M Na-cacodylate buffer were followed by vibratome 
sectioning (HM 650V, Thermo Scientific Microm, Loughborough, UK) of the 
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tissues (400 µm) embedded in 5% low melting temperature SeaPlaque ® 
agarose (Lonza, Rockland, ME, USA). Sections were postfixed with 2% 
osmiumtetroxide in 0.1 M Na-cacodylate buffer for 2 hrs at room temperature. 
Following dehydration in a graded ethanol series (30-50-70-100%) the organs 
were critical-point dried (BAL-TEC CPD 030, Balzers, Germany). Critical-point 
dried tissues were mounted on stubs with double-sided adhesive carbon tape. 
The stubs were coated with gold (SPI-MODULETM Sputter Coater, SPI Supplies, 
West Chester, PA, USA). Images were obtained with a scanning electron 
microscope (JEOL JSM-6360, Tokyo, Japan) at 10 kV (KU Leuven, Molecular 
Physiology of Plants and Micro-organisms Section). I am thankful to Stefan 
Vinckier from the VIB Vesalius Research Center for assistance in SEM analysis. 
9. STATISTICS 
 Data represent mean ± SEM of representative experiments unless otherwise 
stated. Each experiment was performed at least 3 times, each showing statistical 
significance using the appropriate statistical test. Unless otherwise indicated, 
statistical significance was calculated by standard two-sided t-test with F-testing 
to confirm equality of variance (Prism v6.0b). When the two populations have 
different variance two-sided t-test with Welch’s correction was used (Prism 
v6.0b). When inter-experimental variability was large in in vitro experiments 
performed with isolated cells, mixed model statistics (SAS statistical software 
version 9.3) was used with experiment (i.e. donor mouse) as random factor to 
correct for variation between individual mice. p < 0.05 was considered significant. 
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CHAPTER IV 
RESULTS 
 
PHD2 HAPLODEFICIENCY DOES NOT AFFECT BREAST CANCER PROGRESSION  
To explore the consequences of PHD2 haplodeficiency in tumor and stromal 
cells on breast cancer, PHD2 haplodeficient (PHD2+/-) mice were intercrossed 
with mice expressing the PyMT oncoprotein under control of the MMTV-long 
terminal repeat (LTR) promoter (MMTV-PyMT), a model that spontaneously 
develops metastatic mammary gland tumors and recapitulates many features of 
human ductal breast cancer (Lin et al., 2003). In all experiments, PHD2+/+:MMTV-
PyMT mice (referred to as PyMT+/+) were compared with PHD2+/-:MMTV-PyMT 
(referred to as PyMT+/-) littermates.  
Tumor onset at 4 weeks of age was comparable in PyMT+/+ and PyMT+/- 
mice. In both genotypes, the primary tumors enlarged from 4 to 16 weeks, 
however without differences in growth rate, as analyzed by measuring tumor size 
and end-stage weight (Figure 1A,B). Breast cancers developed at comparable 
(full) penetrance in both genotypes. Morphometric analysis showed no 
differences in the number of tumor nodules and the area of intraepithelial 
neoplastic foci at early stages of tumor progression (4 weeks) (Figure 1C-E). 
Analysis of proliferation, by immunostaining for PHH3, revealed no differences in 
tumor cell proliferation in tumors at different stages of progression and age 
(Figure 1F). Also, [3H]-thymidine incorporation assays showed no difference in 
the proliferation rates of tumor cells isolated from PyMT+/+ and PyMT+/- mice at 
end stage (16 weeks) (Figure 1G).  
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FIGURE 1: EFFECT OF GLOBAL PHD2 HAPLODEFICIENCY ON TUMOR GROWTH AND PROGRESSION 
A, Growth curve of individual tumors in PyMT+/+ and PyMT+/- mice (n = 23-28 ; p = ns). B, Tumor 
weight of tumors in PyMT+/+ and PyMT+/- mice at 4, 7, 11 and 16 weeks of age (n > 6; p = ns). C-
E, Carmine-stained inguinal mammary glands from 4 week old PyMT+/+ (C) and PyMT+/- (D) mice. 
Panel E: quantification of neoplastic area (n = 3-4; p = ns). F, Quantification of the PHH3+ area on 
tumors from 4, 7, 11 and 16 week old PyMT+/+ and PyMT+/- mice (n = 3-4; p = ns). G, Proliferation 
([3H]-thymidine incorporation assay) of cancer cells isolated from 16 week old PyMT+/+ and 
PyMT+/- mice, expressed as relative values to control (n = 6; p = ns). H-J, H&E staining of tumors 
in PyMT mice representing hyperplasia (H), adenoma (I) and carcinoma (J). K, Quantification of 
hyperplastic, adenoma or carcinoma lesion area on tumors from 4, 7, 11 and 16 week old 
PyMT+/+ and PyMT+/- mice (n = 3-7; p = ns). Bar: 5 mm (C,D), 100 µm (H-J). All quantitative data 
are mean ± SEM. 
 
 
Three distinct stages of tumor progression can be identified in PyMT-induced 
mammary gland tumors: hyperplasia, adenoma, and carcinoma (Figure 1H-J). 
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Consistent with previous reports (Lin et al., 2003), PyMT tumors did not develop 
as homogeneous populations of cancer cells within a single stage, but rather 
consisted of a heterogeneous mix of cancer cells at various stages (Figure 1K). 
Thus, tumors at 4 weeks contained not only hyperplastic lesions, but also cancer 
cells at adenoma and carcinoma stages were already present. Tumor 
progression to adenoma, and then carcinoma was also not affected by PHD2 
haplodeficiency as largely similar fractions of hyperplastic, adenoma and 
carcinoma lesions were found in PyMT+/+ and PyMT+/- mice at 4, 7, 11 and 16 
weeks (Figure 1K). At end stage (16 weeks), carcinoma cells prevailed in tumors 
of either genotype (Figure 1K).  
Thus, PHD2 haplodeficiency did not alter PyMT tumor progression and did 
not change the tumor phenotype. 
 
PHD2 HAPLODEFICIENCY REDUCES METASTASIS 
The PyMT transgenic mice exhibit a high frequency of pulmonary metastasis. 
Already at 11 weeks, ~43% of mice (8 of 15 PyMT+/+ mice versus 5 of 15 PyMT+/- 
mice; p = ns; Fischer’s exact test) developed macroscopically visible metastatic 
pulmonary nodules, but on average, only one nodule was detected per mouse. 
However, by 16 weeks, all (22 of 22) PyMT+/+ mice developed numerous large 
pulmonary metastases, while only 74% (17 of 23; * p = 0.0216; Fischer’s exact 
test) of PyMT+/- mice formed pulmonary metastases which were also fewer in 
number (Figure 2A-C). Also the metastatic index, i.e. the number of metastases 
normalized to tumor weight, was reduced in PyMT+/- mice (Figure 2D). We also 
analyzed the extent of micro- and macro-metastasis by measuring the area of 
metastasis (expressed as % of total lung area) on cross sections of lungs from 
PyMT+/+ and PyMT+/- mice at 11 and 16 weeks. This analysis revealed that 
already at 11 weeks PyMT+/- mice showed a trend to reduced metastatic area as 
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compared to PyMT+/+ mice, and that this difference became even more 
pronounced at 16 weeks (Figure 2E).  
FIGURE 2: EFFECT OF GLOBAL PHD2 HAPLODEFICIENCY ON METASTASIS. 
A,B, Pulmonary metastatic nodules (arrowheads) in 16 week old PyMT+/+ and PyMT+/- mice, 
visualized by Indian ink perfusion. C, Pulmonary metastases number in PyMT+/+ and PyMT+/- 
tumor bearing 16 week old mice (n = 22-23; t-test with Welch’s correction). D, Metastatic index 
(number of metastases corrected for tumor weigth) (n = 22-23; t-test with Welch’s correction). E, 
Morphometric quantification of metastatic area on hemotoxylin and eosin (H&E)-stained lungs 
sections from PyMT+/+ and PyMT+/- tumor bearing 11 and 16 week old mice (n = 4 for 11 week old 
mice; n = 28-33 for 16 week old mice; t-test with Welch’s correction). Bar: 5 mm (A,B). All 
quantitative data are mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001. 
 
PHD2 HAPLODEFICIENCY DOES NOT AFFECT LYMPHATIC DISSEMINATION 
As cancer cells can enter the blood directly by intravasating into venous 
capillaries or indirectly via lymphatic vessels, it is important to first evaluate which 
pathway is impaired by PHD2 haplodeficiency as a route to egress from the 
primary site. In breast cancer, lymph nodes are often the first site to harbor 
metastases (Stacker et al., 2002). To assess whether PHD2 haplodeficiency 
affects cancer cell dissemination to lymph nodes, we evaluated the expression of 
cytokeratin 8 as a marker of cancer cells, in axillary and popliteal lymph nodes 
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(Figure 3A) from PyMT+/+ and PyMT+/- mice at end stage. Inguinal lymph nodes 
were not analyzed considering that they are localized in the middle of mammary 
gland tissue. This analysis revealed no differences in metastatic dissemination to 
lymph nodes (Figure 3B-F). Lymphatic vessel development was minimal in PyMT 
tumors, and was also not different in the primary tumors of PyMT+/+ and PyMT+/- 
mice at end stage, as assessed by LYVE-1 immunostaining (Figure 3G-I). We 
then explored whether PHD2 haplodeficiency impairs metastatic dissemination 
through hematogenous routes. 
 
PHD2 HAPLODEFICIENCY REDUCES INTRAVASATION 
Hematogenous metastasis is a complex process consisting of several steps. 
Therefore, we investigated which step of this metastatic process was impaired in 
PyMT+/- mice. As previous reports from the host lab showed that selective EC 
haplodeficiency of PHD2 impaired cancer cell intravasation, we first focused on 
this step. Determination of circulating tumor cells (CTCs) by RT-PCR analysis of 
the mRNA levels of cancer cell-specific markers (PyMT; cytokeratin 8 (Krt8), 
marker of luminal epithelial cells) in the peripheral blood revealed that fewer 
CTCs were present in PyMT+/- mice (Figure 3J,K). Since the number of CTCs is 
not only dependent on cancer cell intravasation, but is also determined by their 
survival in the blood, we analyzed cancer cell viability in non-adherent conditions 
(as is the case in the circulation). However, an in vitro clonogenic assay revealed 
a comparable viability of PyMT+/+ and PyMT+/- cancer cells in these conditions 
(Figure 3L), implying that the reduction in CTCs could be explained by reduced 
intravasation.  
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FIGURE 3: PHD2 HAPLODEFICIENCY EFFECT ON LYMPHATIC AND HEMATOGENOUS CANCER CELL 
DISSEMINATION  
A, Schematic representation of the lymph nodes (LN), in red, in mouse. Mammary gland 
localization is annotated as dotted area. B-F, Representative images of axillary lymph nodes from 
16 week old PyMT+/+ (B,C) and PyMT+/- (D,E) mice stained with H&E or cytokeratin 8 (CK8; a 
marker of cancer cells). Panel F: Histogram showing LN metastasis frequencies in 16 week old 
PyMT+/+ and PyMT+/- mice (n = 12-23 for axillary LN; n = 11-22 for popliteal LN; p = ns; Fisher’s 
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exact test). G-I, Representative images of LYVE-1 staining on tumors from 16 week old PyMT+/+ 
(G) and PyMT+/- (H) mice.  Panel I: quantification of the LYVE-1+ area (n = 5; p = ns). J, RT-PCR 
analysis for Pymt in blood samples as a measure of the number of CTCs in PyMT+/+ and PyMT+/- 
mice (n = 15-17; t-test with Welch’s correction). K, RT-PCR analysis of Krt8 mRNA levels in blood 
samples as a measure of circulating tumor cells in PyMT+/+ and PyMT+/- tumor bearing mice (n = 
10). L, Quantification of the number of colonies of PyMT+/+ and PyMT+/- cancer cells grown in 
non-adherent conditions in normoxia or hypoxia (n = 4-5; p = ns). M, RT-PCR analysis of the 
mRNA levels of genes, involved in the various steps of cancer cell extravasation, including 
adhesion to the endothelium (Sele, Vcam1), permeabilization of the endothelial cell barrier (Vegf-
A, Plgf, Ang2) and proteolytic matrix degradation (Mmp2, Mmp9), in PyMT+/+ and PyMT+/- cancer 
cells (n = 5-6). ND, not detectable. Sele: E-selectin; Vcam1: Vascular adhesion molecule 1; Ang2: 
angiopoietin-2; Mmp: matrix metalloproteinase. N, RT-PCR analysis of Pymt mRNA levels in the 
lungs at the indicated times after intravenous injection of PyMT+/+ and PyMT+/- cancer cells in 
recipient wild type mice, as a measure of cancer cell colonization (n = 10-12). Bar: 200 µm (B-E), 
50 µm (G,H). All quantitative data are mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001. 
 
We next examined whether the reduced metastasis of PyMT+/- tumors could also 
be partly attributable to a difference in cancer cell trapping in pulmonary vessels, 
extravasation or lodging. First, RT-PCR analysis of genes, involved in cancer cell 
extravasation, did not show changes in mRNA levels in PyMT+/- cancer cells that 
could explain the reduced metastasis of PyMT+/- mice (Figure 3M). Second, 
analysis of PyMT transcript levels in the lungs at 15 minutes, and at 1, 3, 6 and 
24 hours after intravenous injection of PyMT+/- or PyMT+/+ cancer cells in wild 
type (WT) recipient mice did not reveal significant differences (Figure 3N). 
Hence, PHD2 haplodeficiency did not affect cancer cell extravasation and 
colonization, but reduced their intravasation.  
 
PHD2 HAPLODEFICIENCY DOES NOT AFFECT CANCER CELL-INTRINSIC INVASION  
We then sought to explore the mechanism underlying the decrease in 
intravasation and metastasis of PyMT+/- tumors. For cancer cells to be able to 
intravasate, they must travel through the tumor matrix and breach the endothelial 
barrier, which requires an invasive behavior (van Zijl et al., 2011). We therefore 
analyzed whether PHD2 haplodeficiency impaired the invasive properties of 
cancer cells. These analyses were performed in both normoxic and hypoxic 
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conditions (48h at 0.5% O2), given the occurrence of hypoxia in the tumor milieu. 
To invade the surrounding stroma, certain cancer cell types can undergo 
epithelial-to-mesenchymal transition (EMT), whereby they lose cell polarity and 
cell-cell adhesion, but acquire more invasive mesenchymal cell characteristics 
(Waldmeier et al., 2012). Hypoxia is one of the main regulators of EMT (Foubert 
et al., 2010; Gort et al., 2008; Yang et al., 2008) and thus a driver of invasive 
phenotype of cancer cells. Since PHD2 is a key regulator of HIF1α and HIF2α, 
we first analyzed HIF1α and HIF2α levels in nuclear and cytoplasmic fractions of 
isolated cancer cells from PyMT+/+ and PyMT+/- mice. Consistent with the 
literature, PHD2 haplodeficiency (Figure 4A) increased HIF1α and HIF2α protein 
levels in both fractions of cancer cell lysates (Figure 4B-G). Similarly, hypoxia 
increased HIF1α and HIF2α protein levels, but PHD2 haplodeficiency did not 
further augment their levels under hypoxic conditions (Figure 4B-G). 
 Although PHD2 haplodeficiency increased pro-invasive HIF1α levels in the 
cancer cells (Figure 4B-D), isolated cancer cells from PyMT+/+ and PyMT+/- mice 
had a typical epithelial cobblestone-like morphology, and did not show clear 
signs of EMT when cultured as a monolayer (Figure 5A,B).  
 Also, analysis of isolated tumor cells did not show any genotypic 
differences in immunoreactive levels of E-cadherin, N-cadherin and fibronectin or 
in the mRNA transcript levels of the junctional molecules N-cadherin (Cdh2), 
Vimentin (Vim) and zonula occludens (ZO-1, Tjp1), Occludin (Ocln), of the pro-
EMT transcription factor Twist1 and of the known pro-invasive factors Mmp2 and 
Mmp9 (Figure 3M; Figure 5C-E). Additionally, cancer cell migration or invasion, 
as analysed by scratch wound assay or 3D spheroids invasion embedded into a 
collagen I matrix, respectively, did not show genotypic differences neither in  
normoxia, nor in hypoxia (Figure 5F-K).   
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FIGURE 4: PHD2 HAPLODEFICIENCY INCREASES HIF1𝛼  AND HIF2𝛼  LEVELS IN CANCER CELLS.  
A, Immunoblotting for PHD2 of total PyMT+/+ and PyMT+/- cancer cell lysates. β-actin was used as 
loading control. Densitometric quantification is indicated (n = 4-6 independent experiments). B-D, 
Immunoblotting for HIF1α of nuclear and cytoplasmic lysates of PyMT+/+ and PyMT+/- cancer cells 
cultured in normoxia (N) or hypoxia (H). β-tubulin or lamin was used as loading control. Panels 
C,D: Densitometric quantification relative to control (PyMT+/+ normoxia) in nuclear (C; n = 5-6; t-
test with Welch’s correction) or cytoplasmic (D; n = 5-6; t-test with Welch’s correction) fractions. 
E-G, Immunoblotting for HIF2α of nuclear and cytoplasmic PyMT+/+ and PyMT+/- cancer cell 
lysates cultured in normoxia (N) or hypoxia (H). β-tubulin or lamin was used as loading control. 
Panels F,G: Densitometric quantification relative to control (PyMT+/+ normoxia) in nuclear (F; n = 
5-6; t-test with Welch’s correction) or cytoplasmic (G; n = 5-6; t-test with Welch’s correction) 
fractions. All quantitative data are mean ± SEM. * p < 0.05, ** p < 0.01, # p = 0.07.  
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FIGURE 5: PHD2 HAPLODEFICIENCY DOES NOT AFFECT CANCER CELL INVASION  
A,B, Representative images of monolayer of cancer cells isolated from PyMT+/+ and PyMT+/- 
tumors at the end stage. C,D, Immunoblotting of EMT protein levels (E-cadherin (C), N-cadherin, 
fibronectin (D)) in PyMT+/+ and PyMT+/- cancer cell lysates. β-tubulin or lamin was used as loading 
control. Densitometric quantification is indicated (n = 4-6 independent experiments; p = ns). E, 
RT-PCR analysis of EMT genes in PyMT+/+ and PyMT+/- cancer cells (n = 3 independent 
experiments; p = ns). F, Scratch wound assay: analysis of PyMT+/+ and PyMT+/- cancer cell 
migration in normoxia or hypoxia (n = 3; p = ns). G-J, Cancer cell spheroid invasion assay: 
analysis of collective invasion of PyMT+/+ (G,I) and PyMT+/- (H,J) cancer cells into a collagen I 
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matrix in normoxia (G,H) or hypoxia (I,J). Note that cancer cells invade collectively as sheets with 
emerging sprouts. Panel K shows the morphometric quantification of the area of the entire 
invasive spheroid (see methods) (n = 3-5 independent experiments; p = ns). Bar: 75 µm (A,B), 
200 µm (G-J). All quantitative data are mean ± SEM.  
 
Despite there being no changes in cancer cell-intrinsic invasive behavior, and 
previous studies that documented only minimal EMT in malignant epithelial cells 
from the MMTV-PyMT tumor model, these cancer cells are still capable of 
disseminating (Trimboli et al., 2008; Waldmeier et al., 2012). We therefore 
investigated additional mechanisms by which PHD2 haplodeficiency might 
reduce intravasation and dissemination. 
 
PHD2 HAPLODEFICIENCY DECREASES INTRATUMORAL HYPOXIA 
Since hypoxia promotes tumor cell invasion and metastasis (De Bock et al., 
2011), we assessed the level of intratumoral hypoxia by staining sections of 
tumors at various stages for the hypoxia marker pimonizadole. At early stages 
(up to 11 weeks), only a minimal level of hypoxia was present in PyMT+/+ tumors 
(Figure 6A). In agreement with reports that breast cancer cells progressively 
outgrow their vascular supply, hypoxia levels substantially increased during the 
last weeks of PyMT+/+ tumor progression, when tumors enlarged exponentially 
(Figure 6A). In PyMT+/- tumors, hypoxia levels tended to be lower at early stages, 
and were significantly reduced by 16 weeks (Figure 6A-C). However, 
immunoblotting revealed that HIF1α protein levels were similar in end-stage 
PyMT+/- and PyMT+/+ tumors (Figure 6D). Likely, the environmental level of 
hypoxia-induced HIF1α protein was balanced by genetic programming in PHD2 
haplodeficient tumor cells (Figure 4B-D). Thus, the reduction in environmental 
hypoxia coincided with the reduction in metastasis, suggesting a possible causal 
link.  
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PHD2 HAPLODEFICIENCY DOES NOT AFFECT VESSEL DENSITY  
Given that endothelial cell haplodefiency of PHD2 improves tumor oxygenation 
by inducing normalization of tumor vessels in xenografts models (Leite de 
Oliveira et al., 2012; Mazzone et al., 2009), we explored whether reduced 
intratumoral hypoxia and impaired intravasation in MMTV-PyMT tumors also is 
related to tumor vessel normalization. We, thus, examined the vascular network 
at different stages to assess whether decreased intratumoral hypoxia in PyMT+/- 
mice is a result of increased vascularization and / or improved functionality.   
In the MMTV-PyMT tumor model blood vessels co-evolve with tumor 
progression to meet the increasing demand for oxygen and nutrients, required for 
tumor growth. Initially, when the tumor is small, diffusion is the major way to 
support its metabolic needs. However, diffusion distance is restricted, e.g. for 
oxygen it is limited to the distance of 20-200 µm (Carmeliet and Jain, 2000; Pries 
and Secomb, 2014). Thus, when tumors have grown beyond the size of 1-2 mm 
in diameter the development of new tumor vasculature is required to support the 
increased metabolic demands (Bergers and Benjamin, 2003). The induction of 
this vasculature is termed the angiogenic switch and can occur at various stages 
of tumor progression, depending on the tumor type and the environment. By 
analyzing vessel number and perfusion at 4, 7, 11 and 16 weeks we were able to 
determine at which stage the onset of the angiogenic switch occurs. We also 
analyzed whether PHD2 haplodeficiency provided a functional advantage from 
the start of tumorigenesis or whether this only occured in the course of tumor 
progression.  
Double immunostaining for CD105 and cytokeratin 8 of tumor sections 
from PyMT+/- and PyMT+/+ mice at 4, 7, 11 and 16 weeks of age were used to 
analyze vessel area as a percent of tumor area (Figure 6E-M). 
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FIGURE 6: PHD2 HAPLODEFICIENCY DECREASES INTRATUMORAL HYPOXIA BUT DOES NOT AFFECT 
VESSEL DENSITY 
A-C, Quantification of PIMO+ hypoxic tumor area (% of total) in tumors from PyMT+/+ and PyMT+/- 
mice at 4, 7, 11 and 16 weeks of age (n = 6-15). Representative micrographs of PIMO staining 
(brown) in end stage PyMT+/+ (B) and PyMT+/- (C) tumors. D, Densitometric quantification of 
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HIF1α immunoblotting in nuclear or cytoplasmic fractions of PyMT+/+ and PyMT+/- tumor lysates at 
16 weeks of tumor progression (n = 4-6). Lamin (for nuclear fraction) or β-tubulin (for cytoplasmic 
fraction) was used as loading control. E-M, Tumors from PyMT+/+ and PyMT+/- mice at 4, 7, 11 
and 16 weeks of age were immunostained for CD105 and cytokeratin 8 (CK8) (F-M) and 
quantified for vessel area expressed as a percent of tumor area (E) (n = 8-11). N, Histogram of 
intercapillary distance, revealing a comparable distribution of vessel intercapillary distance in 
PyMT+/+ and PyMT+/- tumors of 16 week old mice. O, Histogram of vessel size, revealing a 
comparable distribution of vessel size in PyMT+/+ and PyMT+/- tumors of 16 week old mice. Bar: 
50 µm (B,C), 100 µm (F-M). All quantitative data are mean ± SEM. * p < 0.05.  
 
This analysis revealed that the increase in vessel number, relative to tumor area, 
was highest at 7 weeks (Figure 6E), suggesting that the ‘angiogenic switch’ 
preceded the progression to carcinoma stage. However, there were no genotypic 
differences in tumor vessel area and intercapillary distance (Figures 6E-N). Also, 
the distribution of tumor vessels in PyMT+/- and PyMT+/+ tumors from 16 weeks 
old mice according to their size was overlapping in both genotypes, indicating 
that there was no shift from small to large vessels (or vice versa) (Figures 6O). 
As lack of the changes in vessel density could not explain reduced hypoxia, we 
then explored whether PHD2 haplodeficiency improved vessel function. 
 
PHD2 HAPLODEFICIENCY IMPROVES VESSEL FUNCTION AND STRUCTURE 
A hallmark of many cancers is a structurally and functionally abnormal 
vasculature, which reduces tumor perfusion and enhances hypoxia, stimulating 
cancer cell invasion and metastasis (De Bock et al., 2011). To analyze vessel 
functionality, we injected 4, 7, 11 and 16 week old PyMT+/+ and PyMT+/- mice with 
lectin-FITC to label perfused vessels and co-stained the tumor sections for CD31 
to identify all vessels (perfused and non-perfused) so that the percentage of 
perfused vessels could be determined. This analysis revealed that in the control 
tumors already at 4 weeks only 43.5% of the vessels were perfused and vessel 
perfusion gradually decreased with tumor progression to 14.6% at 16 weeks 
(Figure 7A-I). Compared to PyMT+/+ tumors, PHD2 haplodeficiency increased the 
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fraction of perfused lectin-FITC+ CD31+ vessels already from 7 weeks onwards 
(Figure 7A-I). At the early stage (4 weeks), the fraction of perfused lectin-FITC+ 
CD31+ vessels was modestly, but not significantly increased in PyMT+/- tumors 
(Figure 7A,E,I, p = 0.147). 
 As perivascular stromal cells, pericytes and mural cells provide structural 
support to blood vessels and regulate their stability and function, we evaluated 
whether differences in vessel maturation underlined the improved function of 
tumor vessels in PyMT+/- mice. To this end we double-stained tumor sections 
from 16 week old PyMT+/+ and PyMT+/- mice for the mural cell marker α-smooth 
muscle actin (αSMA) and the endothelial marker CD31. Analysis of vessel 
coverage with pericytes (expressed as a percent of total CD31) revealed more 
αSMA+ cell - covered tumor vessels in PyMT+/- tumors (Figure 7J,K).  
A major obstacle to blood-borne transport in tumors is their heterogeneous 
microvascular architecture. Tumors are known to contain many tortuous vessel, 
shunts, vascular loops and widely variable intervascular distance. Local 
heterogeneity in the blood flow and locally increased resistance to blood flow due 
to vessel tortuosity limits the blood-borne transport and thus reduces tumor 
perfusion (Baish et al., 1996; Stylianopoulos and Jain, 2013). Analysis of whole 
mount stainings of thick tumor sections for CD31 revealed that the three-
dimensional architecture of the tumor vessels was comparable in PyMT+/+ and 
PyMT+/- tumors isolated from 16 week old mice (Figure 7L,M). However, similar 
to what was already observed in xenograft tumor models (Mazzone et al., 2009), 
PHD2 haplodeficiency improved endothelial cell lining in 16 weeks PyMT+/- 
tumors as analysed by scanning electron microscopy analysis of the endothelial 
layer (Figure 7N,O). Altogether, PHD2 haplodeficiency in tumor and stromal cells 
promotes normalization of the tumor vasculature in the spontaneously developing 
MMTV-PyMT model.  
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FIGURE 7: PHD2 HAPLODEFICIENCY IMPROVES VESSEL FUNCTION, BUT DOES NOT AFFECT THEIR 
ARCHITECTURE 
A-I, Micrographs of lectin-FITC perfused and CD31-stained vessels in tumors from PyMT+/+ and 
PyMT+/- mice at 4, 7, 11 and 16 weeks of age. Panel I: Quantification of perfusion is indicated 
(CD31+LECTIN+ area, % of total CD31+ area) (n = 5-7; # p=0.07). J,K, Micrographs of αSMA and 
CD31-stained vessels in end stage PyMT+/+ (J) and PyMT+/- (K) tumors. Quantification of vessel 
maturation is indicated (% of αSMA+ covered vessels) (n = 5; # p=0.05). L,M, Confocal images of 
CD31 immunostaining of the vascular network of PyMT+/+ (L) and PyMT+/- (M) tumors. N,O, 
Scanning electron microscopy of PyMT+/+ (N) and PyMT+/- (O) tumors. Arrows indicates gaps in 
endothelial lining. Bar: 50 µm (A-H,J,K), 20 µm (L,M), 5 µm (N,O). All quantitative data are mean 
± SEM. ** p < 0.01. 
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PHD2 HAPLODEFICIENCY IN ECS REDUCES METASTASIS AND INDUCES TUMOR 
VESSEL NORMALIZATION 
Since haplodeficiency of PHD2 in ECs suffices to cause tumor vessel 
normalization (Leite de Oliveira et al., 2012; Mazzone et al., 2009), we also 
intercrossed PHD2+/lox:Tie2-Cre mice with MMTV-PyMT mice (PyMTTie2-HE). RT-
PCR analysis of ECs revealed that Egln1 mRNA expression in PyMTTie2-HE mice 
was reduced by 50% (Figure 8A). While tumor growth was not altered in 
PyMTTie2-HE mice, metastasis and metastatic index were significantly reduced 
(Figure 8B-E). Indeed, EC-specific haplodeficiency of PHD2 phenocopied the 
vascular parameters of PyMT+/- tumors. While vessel number was not altered 
(Figure 8F), vessel maturation was improved (Figure 8G-I) and intratumoral 
hypoxia was reduced (Figure 8J-L). 
Given the limitations of the Tie2-Cre line concerning EC specificity (the 
Tie2 promoter is also active in the hematopoietic lineage), we have also validated 
these results in another line. For this purpose VE-cadherin(PAC)-CreERT2 mice, 
an EC-specific inducible Cre-driver line (Benedito et al., 2012), was intercrossed 
with PHD2+/lox mice and further with MMTV-PyMT mice and was treated with 
tamoxifen for 7 days at the age of 3 weeks (before the onset of tumorigenesis in 
the MMTV-PYMT model). PHD2+/lox:VE-cadherin(PAC)-CreERT2:MMTV-PyMT 
mice are referred to as PyMTCdh5-HE and their control littermates PHD2+/+:VE-
cadherin(PAC)-CreERT2:MMTV-PyMT as PyMTCdh5-WT. RT-PCR revealed 
decreased Egln1 levels in ECs isolated from PyMTCdh5-HE mice (Figure 9A). The 
analyses indicate that also in this line PHD2 haplodeficiency in ECs reduced 
pulmonary metastasis and metastatic index (Figure 9B,C). Analysis of vascular 
parameters revealed that the vessel number was not altered in PyMTCdh5-HE 
tumors, however, we observed an increase in vessel maturation (Figure 9D-G) 
and decreased intratumoral hypoxia (Figure 9H-J).  
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FIGURE 8: TIE2-CRE EC-PHD2 HAPLODEFICIENCY NORMALIZES TUMOR BLOOD VESSELS AND REDUCES 
METASTASIS 
A, RT-PCR analysis of Egln1 mRNA level in lung ECs isolated from PyMTTie2-WT and PyMTTie2-HE 
mice (n = 4-6). B, Growth curve of individual tumors in PyMTTie2-WT and PyMTTie2-HE mice (n = 11-
20 ; p = ns). C, Tumor weight in PyMTTie2-WT and PyMTTie2-HE tumor bearing 16 week old mice (n = 
29-46; p = ns). D, Number of pulmonary metastases in PyMTTie2-WT and PyMTTie2-HE tumor bearing 
16 week old mice (n = 29-46; t-test with Welch’s correction). E, Metastatic index (number of 
metastases corrected for tumor weight) in PyMTTie2-WT and PyMTTie2-HE mice (n = 29-46; t-test with 
Welch’s correction). F, Quantification of vessel area expressed as a percent of tumor area (n = 4-
5). G-I Micrographs of αSMA and CD31-stained vessels in end stage PyMTTie2-WT (G) and 
PyMTTie2-HE (H) tumors. Panel I: quantification of vessel maturation (% of αSMA+ covered vessels) 
(n = 10). J-L, Representative micrographs of PIMO staining (brown) in end stage PyMTTie2-WT (J) 
and PyMTTie2-HE (K) tumors. Quantification of PIMO+ hypoxic tumor area (% of total) in tumors 
from PyMTTie2-WT and PyMTTie2-HE mice at 16 weeks of age is indicated in panel L (n = 6-7). Bar: 
100 µm (G,H), 200 µm (J,K). All quantitative data are mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 
0.01.  
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FIGURE 9: VE-CADHERIN-CRE-DRIVEN EC-PHD2 HAPLODEFICIENCY NORMALIZES TUMOR BLOOD 
VESSELS AND REDUCES METASTASIS 
A, RT-PCR analysis of Egln1 mRNA level in lung ECs isolated from PyMTCdh5-WT and PyMTCdh5-HE 
mice (n = 5-6). B, Number of pulmonary metastases in PyMTCdh5-WT and PyMTCdh5-HE mice (n = 
14-19). C, Metastatic index (number of metastases corrected for tumor weight) in PyMTCdh5-WT 
and PyMTCdh5-HE mice (n = 14-19). D-F Micrographs of αSMA and CD31-stained vessels in end 
stage PyMTCdh5-WT (D) and PyMTCdh5-HE (E) tumors. Quantification of vessel area expressed as a 
percent of tumor area is indicated in the insets (n = 6-8). Panel F: quantification of vessel 
maturation (% of αSMA+ covered vessels) (n = 6-8). G-I, Representative micrographs of PIMO 
staining (brown) in end stage PyMTCdh5-WT (G) and PyMTCdh5-HE (H) tumors. Quantification of 
PIMO+ hypoxic tumor area (% of total) in tumors from PyMTCdh5-WT and PyMTCdh5-HE mice at 16 
weeks of age is indicated in panel I (n = 6-8). Bar: 50 µm (D,E), 200 µm (G,H). All quantitative 
data are mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.01, # p = 0.06.  
 
These results further support the finding that endothelial haplodeficiency of PHD2 
induced tumor vessel normalization and suggest that reduced metastasis in full 
PHD2 haplodeficient mice  (PyMT+/-) is at least partly caused by functional and 
morphological changes of tumor vessels. However, when we compared the 
magnitude of reduction of pulmonary metastasis in endothelial PHD2 
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haplodeficient mice (Figure 8D,E; Figure 9B,C) to that in mice with global PHD2 
haplodeficiency (Figure 2A-D), we observed that pulmonary metastasis in the 
latter was more severely diminished than in EC-specific PHD2 haplodeficient 
mice. This discrepancy in magnitude of metastasis reduction might be explained 
by the contribution of PHD2 haplodeficiency in another cell type to the reduction 
in metastasis in PyMT+/- tumors. We thus explored whether PHD2 
haplodeficiency in additional cell types could influence the metastatic process. 
 
PHD2 HAPLODEFICIENCY DOES NOT AFFECT TAMS  
Tumor-associated macrophages (TAMs), recruited to the tumor, promote tumor 
invasion and metastasis (Goswami et al., 2005; Mantovani et al., 2008). As 
PHD2 haplodeficiency influences TAM infiltration and polarization in the limb 
ischemia model (Takeda et al., 2011), and as such a change in TAMs might 
contribute to the reduced intravasation and metastasis, we analyzed TAM 
infiltration and polarization in the MMTV-PyMT tumors. However, staining for 
F4/80 failed to reveal any genotypic differences in the accumulation of TAMs in 
PyMT+/+ and PyMT+/- tumors (Figure 10A). Additionally, double immunostaining 
for F4/80 and mannose receptor-2 (MRC1) also did not show differences in the 
skewing of macrophages towards M2 polarization (Figure 10B). 
FIGURE 10: PHD2 HAPLODEFICIENCY DOES NOT AFFECT MACROPHAGE  
A, Quantification of F4/80 macrophage infiltration into PyMT+/+ and PyMT+/- tumors at 7, 11 and 
16 week of age, expressed as relative values to control (PyMT+/+ tumor) (n = 3-6; p = ns). B, 
Quantification of MRC1 colocalization with F4/80 to assess macrophage polarization in PyMT+/+ 
and PyMT+/- tumors at 7, 11 and 16 week of age (n = 3-6; p = ns). All quantitative data are mean ± 
SEM. 
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REDUCED ACTIVATION OF CAFS IN PYMT+/- TUMORS  
We then focused our attention on cancer-associated fibroblasts (CAFs), which 
promote tumorigenesis and metastasis (Kalluri and Zeisberg, 2006). Compared 
to PyMT+/+ tumors, PyMT+/- tumors contained substantially fewer activated CAFs 
(Figure 11A-C). Notably, this genotypic difference in CAF activation became 
especially evident beyond 11 weeks, when the genotypic difference in metastasis 
was also evident. Previous studies already showed that CAFs became more 
abundant in PyMT tumors when progressing from adenoma to carcinoma (Calvo 
et al., 2013) (which occurs around 11 weeks of age; Figure 1K), precisely when 
pulmonary macro-metastases first became detectable in the PyMT model (Figure 
2E). This temporal association between the genotypic difference in CAF 
activation and metastasis raised the question whether both processes were also 
functionally linked to each other.  
To further investigate the properties of CAFs, we isolated stromal 
mesenchymal cells from PyMT+/+ and PyMT+/- tumors. Previous studies 
documented that, once normal fibroblasts become activated to CAFs in tumors in 
vivo, they maintain their features in vitro even when cultured for several 
passages, in part because they sustain their activation status through continued 
autocrine production of TGF-β1, SDF-1α and other signals (Kojima et al., 2010). 
Indeed, gene expression profiling revealed that PyMT+/+ CAFs expressed high 
transcript levels of Tgf-β1 and Sdf-1α and their receptors Tgf-βR2 and Cxcr4 in 
culture (Figure 11D).  
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FIGURE 11: PHD2 HAPLODEFICIENCY REDUCES CAF ACTIVATION. 
A-C, Staining of tumor sections from PyMT+/+ (A) and PyMT+/- (B) 16 week old mice for the CAF-
enriched activation marker PDGFRα, counterstained with DAPI. Panel C: quantification of the 
PDGFRα+ area (% of tumor area) in both genotypes (n = 5-6). D, RT-PCR analysis of Sdf-1, Tgf-
β1, Tgf-βR2 and Cxcr4  mRNA levels in CAFs, isolated from PyMT+/+ and PyMT+/- tumors (n = 6-
8). E, Immunoblotting for PHD2 of PyMT+/+ and PyMT+/- CAFs total lysates. Actin was used as 
loading control. Densitometric quantification is shown underneath the lanes (n = 3). F, RT-PCR 
analysis of genes associated with CAF activation (Pdgfrα,  Fsp1) in CAFs isolated from end-stage 
PyMT+/+ and PyMT+/- tumors (n = 3). G-L, Immunostaining of CAFs, isolated from PyMT+/+ (G,J) 
or PyMT-/- (H,K) tumors, for the CAF activation markers PDGFRa (G,H), or αSMA (J,K). 
Quantification of the marker positive area per cell is shown in panels I,L (n = 3-6). M, Proliferation 
(thymidine incorporation) of CAFs isolated from PyMT+/+ and PyMT+/- tumors (n = 3). Bar: 50 µm 
(A,B), 100 µm (G,H,J,K). All quantitative data are mean ± SEM. * p < 0.05, ** p < 0.01, ***p < 
0.001. 
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We took advantage of this “phenotypic memory” to analyze distinct CAF 
behavioral phenotypes in culture. Analysis of PHD2 protein level revealed 50% 
decrease in PyMT+/- CAFs as compared to PyMT+/+ CAFs (Figure 11E). First, 
gene expression profiling and immunostaining studies confirmed that stromal 
cells isolated from PyMT+/- tumors expressed lower levels of markers, enriched in 
activated CAFs, such as FSP1 (fibroblast-specific protein-1, also known as 
S100A4), PDGFRα and αSMA (Figure 11F-L). As the majority of the PyMT+/+ 
stromal cell population expressed these markers (Figure 11G-L), we termed 
them PyMT+/+ CAFs. Second, stromal cells isolated from PyMT+/- tumors (PyMT+/- 
CAFs) exhibited a lower proliferation rate, as measured by [3H]-thymidine 
incorporation into DNA (Figure 11M). Overall, PyMT+/- CAFs were less activated, 
less proliferative, and expressed lower levels of the contractile protein αSMA.  
 
IMPAIRED INVASION OF PYMT+/- CAFS 
We then explored whether CAFs might regulate cancer cell invasion, and 
therefore we first examined their own invasive behavior. More in particular, since 
activated CAFs are highly invasive and assist cancer cell invasion (Calvo et al., 
2013; Kalluri and Zeisberg, 2006), we examined whether PHD2 haplodeficiency 
impaired the invasive ability of CAFs. We embedded CAF spheroids in a collagen 
I gel and monitored their ability to form invasive sprouts (Kalluri and Zeisberg, 
2006; Liu et al., 2011). Notably, compared to cancer cells, CAFs were capable of 
forming more and longer invasive sprouts (Figure 12A,B; compare to Figure 
5G,H), indicating that they were more invasive. However, PyMT+/- CAFs formed 
fewer and shorter sprouts than PyMT+/+ CAFs (Figure 12A-D). In agreement with 
these findings, the expression levels of various matrix metalloproteinases 
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(Mmp2, Mmp9), previously implicated in proteolytic ECM degradation during CAF 
invasion (Lu et al., 2012), were reduced in PyMT+/- CAFs (Figure 12E). Thus, 
PyMT+/- CAFs exhibited profound invasion defects.  
 
INVASION OF WT PYMT TUMOR CELLS IS REDUCED BY PYMT+/- CAFS 
Since CAFs can promote the invasion of tumor cells by direct remodelling of the 
extracellular matrix (ECM) (Duda et al., 2010; Gaggioli et al., 2007; Goetz et al., 
2011), we assessed whether the reduced activation state of PyMT+/- CAFs 
influenced tumor cell invasion in collagen gels. We studied whether CAFs 
influenced the invasion of cancer cells by embedding spheroids consisting of a 
1:1 mixture of cancer cells and CAFs. More in particular, given that PHD2 
haplodeficiency impaired the invasion of CAFs, we assessed whether the 
reduced activation of PyMT+/- CAFs influenced the invasion of WT cancer cells. 
To distinguish cancer cells from CAFs, and to visualize their spatial position 
relative to each other, we stably transduced CAFs, isolated from PyMT+/+ or 
PyMT+/- mice, with a lentiviral vector expressing GFP, and isolated Tomato (red) 
labelled cancer cells from wild type MMTV-PyMT mice that were intercrossed 
with mT/mG mice (abbreviated as PyMTmT/mG). The mT/mG line is a double-
fluorescent Cre reporter mouse that expresses membrane-targeted tandem 
dimer Tomato (mT) prior to Cre-mediated excision and membrane-targeted 
green fluorescent protein GFP (mG) after excision (Muzumdar et al., 2007). For 
our experiments, we did not intercross PyMTmT/mG mice with Cre-expressing mice 
(and thus did not switch on the expression of GFP), but took advantage of the 
constitutive expression of the Tomato reporter by the cancer cells. 
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FIGURE 12: PHD2 HAPLODEFICIENCY REDUCES CAF INVASION. 
A-D, CAF spheroid invasion assay using CAFs isolated from PyMT+/- (A) and PyMT+/- (B) tumors. 
Quantification of invasive sprout number and length is shown in panels C and D, respectively (n > 
14 spheroids). E, RT-PCR analysis of Mmp2 and Mmp9 in CAFs isolated from PyMT+/+ and 
PyMT+/- end stage tumors (n = 3). F-H, Invasion assay using spheroids consisting of a 1:1 mixture 
of Tomato+ PyMTmT/mG tumor cells (TCs, wild type for PHD2; red) and GFP+ CAFs (green), 
isolated either from PyMT+/+ (F) or from PyMT+/- (G) tumors. Quantification of the number of 
individual invading tumor cells is shown in panel H (n > 45 spheroids). Since in this model, tumor 
cells co-invaded together with CAFs (often in the same sprout), we counted the number of 
individual tumor cells that migrated from the spheroid. Bar: 100 µm (A,B,F,G). All quantitative 
data are mean ± SEM. ** p < 0.01, *** p < 0.001.  
 
Analysis of spheroids consisting of a 1:1 mixture of Tomato+ PyMTmT/mG cancer 
cells and GFP+ CAFs, isolated from PyMT+/+ or PyMT+/- tumors, showed that 
fewer cancer cells invaded into the gel when they were co-cultured with PyMT+/- 
CAFs as compared to when they were co-cultured with PyMT+/+ CAFs (Figure 
12F-H). This genotypic difference in invasive behavior of cancer cells, 
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determined by CAFs, could contribute to the genotypic difference observed in 
intravasation and metastasis.  
 
IMPAIRED MATRIX DEPOSITION AND CROSS-LINKING BY PYMT+/- CAFS 
Previous studies documented that CAFs can facilitate cancer cell invasion 
through various effects on the ECM. For instance, CAFs can promote the 
invasion of cancer cells by depositing bundles of cross-linked collagen I, which 
cancer cells use as preferred migration tracks (Calvo et al., 2013; Lu et al., 2012; 
Maller et al., 2013). We first verified that CAFs represented a significant source 
of ECM production in PyMT tumors, to which end we compared the relative 
amount of matrix production by CAFs versus cancer cells. Analysis of [3H]-L-
proline incorporation into the deposited matrix indeed revealed that CAFs 
produced much larger amounts of matrix than PyMT cancer cells (Figure 13A).  
Several lines of evidence indicated that PyMT+/- CAFs produced less 
extracellular matrix than PyMT+/+ CAFs, both in vivo and in vitro. First, Picro 
Sirius Red staining showed that PyMT+/- tumors contained smaller amounts of 
fibrillar collagen (Figure 13B-D). Second, we took advantage of the birefringency 
of cross-linked collagen, which upon polarized light microscopy appears red, 
while non-cross-linked collagen appears green. This analysis showed that 
PyMT+/- tumors contained fewer thick bundles of cross-linked collagen compared 
to PyMT+/+ tumors (Figure 13E-G). Third, analysis of [3H]-L-proline incorporation 
into the matrix deposited by CAFs over a period of eight days showed that CAFs 
isolated from PyMT+/- tumors produced less matrix in vitro (Figure 13H). Fourth, 
the reduced matrix production in culture was not only a result of the decreased 
proliferation rate of PyMT+/- CAFs, since immunostaining of isolated CAFs also 
 111 
showed lower immunoreactive levels of collagen I per cell in PyMT+/- than 
PyMT+/+ CAFs (Figure 13I-K). Thus, CAFs from PyMT+/- tumors produced fewer 
cross-linked collagen fibers, thereby decreasing the amount of available 
migration tracks for cancer cells.  
 
IMPAIRED REMODELING OF THE EXTRACELLULAR MATRIX BY PYMT+/- CAFS  
CAFs can also facilitate cancer cell invasion via another mechanism, i.e. by 
remodelling the extracellular matrix through active contraction (Calvo et al., 
2013), a process that results in matrix stiffening and is known to promote cancer 
cell invasion and metastasis (Calvo et al., 2013; Lu et al., 2012). Since CAFs 
require a contractile cytoskeleton for matrix contraction (Calvo et al., 2013), and 
PyMT+/- CAFs had decreased amounts of immunoreactive αSMA+ actin stress 
fibers (Figure 11J-L), we studied whether the ability of PyMT+/- CAFs to remodel 
the ECM via matrix contraction was impaired. We therefore used the “collagen 
contraction assay”, in which CAFs are uniformly dispersed throughout a collagen 
I gel (Calvo et al., 2013). By contracting the gel, CAFs are able to reduce the size 
of the gel. Notably, this analysis revealed that, compared to PyMT+/+ CAFs, 
PyMT+/- CAFs contracted the collagen gel less, as evidenced by the larger size of 
the gels after incubation (Figure 13L).  
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FIGURE 13: EFFECT OF PHD2 HAPLODEFICIENCY ON ECM PRODUCTION AND REMODELLING BY CAFS 
A, Quantification of ECM deposition by cancer cells or CAFs isolated from PyMT+/+ tumors, 
measured by the [3H]-L-proline incorporation assay (see methods). Data are shown for 2 
independent isolations from different PyMT+/+ mice  (n = 3). DPM, disintegrations per minute. B-
D, Picro Sirius Red staining of PyMT+/+ (B) and PyMT+/- (C) tumor sections. Panel D: 
quantification of Picro Sirius Red+ area (n = 5). E-G, Polarized light microscopy analysis of Picro 
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Sirius Red stained PyMT+/+ (E) and PyMT+/- (F) tumors to visualize thick cross-linked (red) versus 
thin non-cross-linked (green) collagen fibers. Panel G: quantifications of cross-linked and thin 
fibers (n = 5; t-test with Welch’s correction). H, Quantification of matrix synthesis by CAFs 
isolated from PyMT+/+ or PyMT+/- tumors as measured by an in vitro [3H]-L-proline incorporation 
assay (n = 3); DPM, disintegrations per minute. I-K, Immunostaining of CAFs, isolated from 
PyMT+/+ (J) or PyMT+/- (K) tumors, for collagen I. The DAPI nuclear counterstain is shown in blue. 
Quantification of the collagen I-immunoreactive area per cell is shown in panel I (n = 3). L, 
Collagen gel contraction assay using CAFs isolated from PyMT+/+ (blue) or PyMT+/- (purple) 
tumors (n = 4; t-test with Welch’s correction). Inset: representative pictures of contracted gels. To 
determine the contraction index, the area of the gel at the indicated time was subtracted from the 
initial area of the gel at the beginning of the experiment, and this value was expressed as a 
percentage of the initial gel area. M-P, Invasion assay using spheroids of PyMT+/+ tumor cells in 
collagen gels with no CAFs (M), or into which CAFs isolated from PyMT+/+(N) or from PyMT+/- (O) 
tumors were homogeneously dispersed. Panel P: quantification of the area of the entire cancer 
cell spheroids (n > 18 spheroids). Bar: 50 µm (B,C,E,F,J,K), 200 µm (M-O). All quantitative data 
are mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001.  
 
 
To assess whether remodelling of the collagen gel by the CAFs’ contractile 
activity altered the invasion of wild type cancer cells, we embedded cancer cell 
spheroids into a collagen gel, in which CAFs had been uniformly dispersed 
throughout the gel, largely as previously described (Calvo et al., 2013). 
Compared to PyMT+/+ cancer cell spheroids alone, co-embedding dispersed 
PyMT+/+ CAFs in the gel accelerated collective cancer cell invasion by a day, 
indicating that CAFs promoted cancer cell invasion. Notably however, PyMT+/+ 
cancer cells invaded the collagen gel less when they were co-embedded with 
PyMT+/- than PyMT+/+ CAFs (Figure 13M-P). Hence, in conditions where CAFs 
were capable of remodelling the ECM, CAFs from PyMT+/- tumors did not 
stimulate the invasive behavior of the cancer cells to the same extent as PyMT+/+ 
CAFs.  
 
 
 
 
 114 
PYMT+/- CAFS HAVE REDUCED CAPACITY TO PROMOTE METASTASIS IN TUMOR 
GRAFTS AS COMPARED TO PYMT+/+ CAFS  
To assess whether PyMT+/- CAFs also impaired promoting cancer cell invasion 
activities in vivo, we orthotopically transplanted PyMT+/+ tumor cells with or 
without PyMT+/+ or PyMT+/- CAFs as a 1:2 mixture in WT mice. Analysis of 
primary tumor growth confirmed previous findings (Orimo et al., 2005) that co-
transplantation of CAFs increased primary tumor growth, both upon co-
transplantation of either PyMT+/+ or PyMT+/- CAFs (Figure 14A). Also metastatic 
dissemination, at 6 weeks after transplantation, was increased upon co-
transplantation of PyMT+/+ tumor cells and PyMT+/+ CAFs (Figure 14B,C). 
Interestingly, fewer pulmonary metastases could be detected in the group where 
PyMT+/+ tumor cells were co-implanted with PyMT+/- CAFs (Figure 14B,C) than in 
the group where tumor cells were co-implanted with PyMT+/+ CAFs. These 
results further confirm that PyMT+/- CAFs have impaired capacity to mediate 
tumor cell invasion and metastasis.  
FIGURE 14: CAFS FROM PYMT+/- TUMORS HAVE IMPAIRED PRO-METASTATIC CAPACITY. 
A, Growth curve of PyMT tumor xenografts upon PyMT+/+ cancer cell transplantation (alone; 
black), or co-transplanted with PyMT+/+ (blue) or PyMT+/- (purple) CAFs (n = 4-7). B, Number of 
pulmonary metastases evaluated 6 weeks after PyMT+/+ cancer cell transplantation (alone; black), 
or co-transplanted with PyMT+/+ (blue) or PyMT+/- (purple) CAFs (n = 4-7; t-test with Welch’s 
correction). C, Metastatic index (number of metastases corrected for tumor weight) in mice 
injected with PyMT+/+ cancer cells alone (black), or co-transplanted with PyMT+/+ (blue) or PyMT+/- 
(purple) CAFs (n = 4-7; t-test with Welch’s correction). All quantitative data are mean ± SEM. * p 
< 0.05, ** p < 0.01, # p = 0.06.  
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HAPLODEFICIENCY OF PHD2 IN CAFS DOES NOT AFFECT CAF ACTIVATION AND 
PYMT TUMOR METASTASIS 
In order to explore whether PHD2 in CAFs orchestrated metastasis in vivo, we 
intercrossed MMTV-PyMT x PHD2+/lox mice with PDGFRα:CreERT2 mice (Leite de 
Oliveira et al., 2012; Rivers et al., 2008) and treated them at the age of 3 weeks 
with tamoxifen for 7 days to obtain mice with PHD2 haplodeficiency in the 
fibroblasts in vivo (abbreviated as PyMTCAF-HE mice). Analysis of PHD2 protein 
level in CAFs, isolated from these mice, showed that PHD2 levels were reduced 
by 43.1 ± 3.8% (n = 3; p < 0.05). Surprisingly, analysis of PyMTCAF-HE mice 
revealed that neither tumor growth nor pulmonary metastasis were altered when 
compared to PyMTCAF-WT mice (Figure 15A-C).    
Furthermore, analysis of CAF accumulation as determined by 
immunostaining for PDGFRα and analysis of their capacity to deposit an ECM 
(by Picro Sirius red staining) in tumors from PyMTCAF-WT and PyMTCAF-HE mice 
revealed no differences (Figure 15D-I). To further validate these findings we have 
assessed in vitro characteristics of CAFs isolated from PyMTCAF-WT and PyMTCAF-
HE mice. PHD2 haplodeficiency in fibroblasts did not change their capacity to 
proliferate or to remodel collagen gel by contraction (Figure 15J,K). Altogether 
these results showed that selective PHD2 haplodeficiency in fibroblasts did not 
affect the activation of CAFs and tumor cell metastasis. We therefore explored 
other possible mechanisms that could explain the reduced activation of CAFs in 
mice with global PHD2 haplodeficiency (PyMT+/-).  
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FIGURE 15: CAFS FROM PyMTCAF-HE TUMORS HAVE NORMAL PRO-METASTATIC CAPACITY AND 
ACTIVATION CHARACTERISTICS. 
A, Weight of PyMTCAF-WT and PyMTCAF-HE tumors collected at the end-stage (16 week of age) (n = 
16-22; p = ns). B, Number of pulmonary metastases in PyMTCAF-WT and PyMTCAF-HE tumor 
bearing 16 week old mice (n = 16-22; p = ns; t-test with Welch’s correction). C, Metastatic index 
(number of metastases corrected for tumor weight) in PyMTCAF-WT and PyMTCAF-HE tumor bearing 
16 week old mice (n = 16-22; p = ns; t-test with Welch’s correction). D-F, Staining of tumor 
sections from PyMTCAF-WT (D) and PyMTCAF-HE (E) mice for the CAF-enriched activation marker 
PDGFRα, counterstained with DAPI. Panel F: quantification of the PDGFRα+ area (% of tumor 
area) in both genotypes (n = 9-10; p = ns). G-I, Picro Sirius Red staining of PyMTCAF-WT (G) and 
PyMTCAF-HE (H) tumor sections.  Panel I: quantification of Picro Sirius Red+ area (n = 8-9; p = ns). 
J, Proliferation ([3H]-thymidine incorporation) of CAFs isolated from PyMTCAF-WT and PyMTCAF-HE 
tumors (n = 4). K, Collagen gel contraction assay using CAFs isolated from PyMTCAF-WT or 
PyMTCAF-HE tumors (n = 4). Scale bar: 100 µm (D,E,G,H). All quantitative data are mean ± SEM. 
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DECREASED TGF-ß1 SECRETION IN PHD2 HAPLODEFICIENT CANCER CELLS 
The origin of CAFs has not been fully elucidated yet, but the most commonly 
accepted hypothesis is that the majority of CAFs trans-differentiate from resident 
fibroblasts upon stimulation by a plethora of cytokines and growth factors 
secreted by cancer cells, such as TGF-β1, PDGF, FGF2 and SDF1 (Quail and 
Joyce, 2013). Previous studies reported that silencing of PHD2 in a breast 
cancer cell line or epithelial cells reduced the secretion of TGF-β1 (Kalucka et al., 
2013; Wottawa et al., 2012). We therefore investigated whether reduced 
activation of CAFs is related to a reduction in TGF-β1 secretion by PyMT+/- 
cancer cells. ELISA measurements indeed showed that TGF-β1 levels were 
reduced in the supernatant of cultured PyMT+/- tumor cells (TCs) (Figure 16A). 
Interestingly, analysis of 40 other secreted chemokines and cytokines revealed 
no differences in the supernatants of PyMT+/+ and PyMT+/- cancer cells (Figure 
16B-D). We therefore focused on TGF-β1 signalling pathway in our subsequent 
analyses. 
To explore whether decreased secretion of TGF-β1 by PHD2 
haplodeficient TCs would be sufficient to reduce CAF activation and thus impair 
metastasis in vivo, we intercrossed PHD2+/lox mice with MMTV-Cre and MMTV-
PyMT mice, yielding mice with PHD2 haplodeficiency selectively in the TCs 
(abbreviated as PyMTTC-HE). These PyMTTC-HE mice were compared to their wild 
type littermates (abbreviated as PyMTTC-WT). RT-PCR and protein analysis of 
tumor cells, freshly isolated from these tumors, revealed that PHD2 protein level 
and Egln1 mRNA in PyMTTC-HE cancer cells was reduced (Figure 16E,F). This 
effect was selective to cancer cells as Egln1 mRNA levels were the same in 
PyMTTC-WT and PyMTTC-HE CAFs (Figure 16G). 
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FIGURE 16: PHD2 HAPLODEFICIENCY IN CANCER CELLS DECREASES TGF-β1 SECRETION AND 
DECREASED THE NUMBER OF CTCS AND METASTASIS 
A, ELISA analysis of TGF-β1 levels in culture medium conditioned by PyMT+/+ or PyMT+/- cancer 
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cell cultures (n = 3). B-D, Profiling of proteins in supernatant from PyMT+/+ (A) and PyMT+/- (B) 
cancer cells. Quantification of detected proteins is indicated in panel D (n = 3; p = ns; only 
proteins detected in 3 independent experiments have been included in the quantification). E, 
Immunoblotting for PHD2 of PyMTTC-WT and PyMTTC-HE cancer cell total lysates. Actin was used 
as loading control. Densitometric quantification is shown underneath the lanes (n = 3). F,G, RT-
PCR analysis of Egln1 mRNA levels in cancer cells (F) and CAFs (G), isolated from PyMTTC-WT 
and PyMTTC-HE tumors (n > 3). H,I, ELISA analysis of TGF-β1 levels in extracts of PyMTTC-WT or 
PyMTTC-HE tumors (H; n = 5) or in culture medium conditioned by PyMTTC-WT or PyMTTC-HE cancer 
cell cultures (I; n = 3). J, Growth curve of individual tumors in PyMTTC-WT and PyMTTC-HE mice (n = 
5-10; p = ns). K,L, Pulmonary metastatic nodules (arrowheads) in 16 week old PyMTTC-WT (K) and 
PyMTTC-HE (L) mice, visualized by Indian ink perfusion. The number of pulmonary metastases is 
indicated (n = 18-28; t-test with Welch’s correction). M, Metastatic index in PyMTTC-WT and 
PyMTTC-HE tumor bearing mice (n = 18-28; t-test with Welch’s correction. N, RT-PCR analysis for 
Pymt in blood samples as a measure of the number of CTCs in PyMTTC-WT and PyMTTC-HE mice (n 
= 6-8; t-test with Welch’s correction). Bar: 750 µm (K,L). All quantitative data are mean ± SEM. * 
p < 0.05, ** p < 0.01, *** p < 0.001. 
 
Analysis TGF-β1 in tumor cell supernatans as well as in PyMTTC-HE tumor 
extracts confirmed the reduced levels of secreted TGF-β1 (Figure 16H,I). Similar 
to PyMT+/- mice, tumor growth was not affected (Figure 16J), while metastasis 
and circulating tumor cells (CTCs) were decreased in PyMTTC-HE mice (Figure 
16K-N). These results suggest that PHD2 haplodeficiency in TCs could explain 
the reduced activation of CAFs and metastasis in globally haplodeficient PyMT+/- 
mice.  
PHD2 HAPLODEFICIENCY SELECTIVELY IN CANCER CELLS DOES NOT AFFECT 
CANCER CELL INTRINSIC PROPERTIES  
To exclude that this reduction in metastasis was dependent on PHD2-mediated 
tumor cell-intrinsic changes, we analysed the invasive behaviour and EMT-
phenotype of PyMTTC-WT and PyMTTC-HE cancer cells. These tests confirmed that 
no changes in cancer cell migration, tumor spheroids invasion and minimal 
changes in EMT are caused by PHD2 haplodeficiency in tumor cells (Figure 17A-
I), in line with previous findings which documented that in the MMTV-PyMT tumor 
model malignant epithelial cells undergo only minimal EMT, yet are capable of 
disseminating (Trimboli et al., 2008; Waldmeier et al., 2012).   
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FIGURE 17: CANCER CELL PHD2 HAPLODEFICIENCY DOES NOT AFFECT INVASION  
A,B, Immunoblotting and densitometric quantification of EMT protein levels (E-cadherin (A), N-
cadherin (B), Fibronectin (B)) in PyMTTC-WT and PyMTTC-HE cancer cell lysates (n = 3 independent 
experiments; analyzed by mixed model statistics). Actin or lamin was used as loading control. C, 
RT-PCR analysis of EMT genes in PyMTTC-WT and PyMTTC-HE cancer cells (n = 3). D, Scratch 
wound assay: analysis of PyMTTC-WT and PyMTTC-HE cancer cell migration in normoxia or hypoxia 
(n = 4-6; p = ns). E-I, Cancer cell spheroid invasion assay: analysis of collective invasion of 
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PyMTTC-WT and PyMTTC-HE cancer cells into a collagen I matrix in normoxia (E,F) or hypoxia (G,H). 
Note that cancer cells invade collectively as sheets with emerging sprouts. Panel I shows the 
morphometric quantification of the area of the entire invasive spheroid (see methods) (n > 45 
spheroids; p = ns). Bar: 100 µm (E-H). All quantitative data are mean ± SEM. * p < 0.05, ** p < 
0.01. 
 
REDUCED ACTIVATION OF CAFS IN PYMTTC-HE TUMORS 
We then characterized the expression of several markers, known to be enriched 
in activated CAFs: FSP1, PDGFRα, and the contractile protein αSMA in PyMTTC-
WT and PyMTTC-HE tumors in situ, and morphometrically quantified the CAF 
marker-positive area as a percent of the total tumor area. These analyses 
revealed that PyMTTC-HE tumors, as compared to PyMTTC-WT tumors, contained 
substantially fewer activated CAFs (Figure 18A-I). Also, gene expression profiling 
confirmed that CAFs isolated from PyMTTC-HE tumors expressed lower levels of 
these markers, such as FSP1, PDGFRα and αSMA (Acta2) (Figure 18J). 
Moreover, stromal PyMTTC-HE CAFs exhibited a lower proliferation rate, as 
measured by [3H]-thymidine incorporation into DNA (Figure 18K). Similar to 
PyMT+/- tumors, PyMTTC-HE tumors contained smaller amounts of fibrillar collagen 
(Figure 19A-C), which was less crosslinked (Figure 19D-F). Also, CAFs isolated 
from PyMTTC-HE tumors had impaired matrix production (Figure 19G) and 
remodelling capacity in vitro (as assessed by their invasion into collagen I matrix 
(Figure 19H-J), expression of Mmp2 and Mmp9 (Figure 19K), and contractile 
capacity (Figure 19L). Moreover, PyMTTC-HE CAFs did not stimulate the invasive 
behaviour of cancer cells to the same extent as CAFs, primed by PyMTTC-WT 
cancer cells (Figure 19M-O). 
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FIGURE 18: EFFECT OF CANCER CELL PHD2 HAPLODEFICIENCY ON CAF ACTIVATION 
A-C, Double immunostaining of tumor sections from PyMTTC-WT (A) and PyMTTC-HE (B) mice for 
the CAF-enriched activation marker αSMA and the endothelial marker CD105, counterstained 
with DAPI. Panel C: quantification of the αSMA+ area (% of tumor area) in both genotypes (n = 7). 
The staining of the endothelial cells was done to exclude the αSMA+ perivascular smooth muscle 
cells. D-F, Double immunostaining of tumor sections from PyMTTC-WT (D) and PyMTTC-HE (E) mice 
for the CAF-enriched activation markers FSP1 and αSMA, counterstained with DAPI. Panel F: 
quantification of the FSP1+ area (% of tumor area) (n = 7). The double staining for FSP1 and 
αSMA was done to illustrate the heterogeneity of the CAF population in the tumors. G-I, Staining 
of tumor sections from PyMTTC-WT (G) and PyMTTC-HE (H) mice for the CAF-enriched activation 
marker PDGFRα, counterstained with DAPI. Panel I: quantification of the PDGFRα+ area (% of 
tumor area) in both genotypes (n = 7). J, RT-PCR analysis of genes associated with CAF 
activation (Pdgfra, Acta2 (αSMA), Fsp1) in CAFs isolated from end-stage PyMTTC-WT and 
PyMTTC-HE tumors (n = 6-8). K, Proliferation ([3H]-thymidine incorporation) of CAFs isolated from 
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PyMTTC-WT and PyMTTC-HE tumors (n = 3-4). Bar: 50 µm (G,H), 100 µm (A,B,D,E). All quantitative 
data are mean ± SEM and statistical significance in (C,F,I) was analyzed with t-test with Welch’s 
correction. * p < 0.05, ** p < 0.01, *** p < 0.001.  
 
FIGURE 19: EFFECT OF CANCER CELL PHD2 HAPLODEFICIENCY ON ECM PRODUCTION AND LING BY 
CAFS 
A-C, Picro Sirius Red staining of PyMTTC-WT (A) and PyMTTC-HE (B) tumor sections. Panel C: 
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quantification of Picro Sirius Red+ area (n = 7). D-F, Polarized light microscopy analysis of Picro 
Sirius Red stained PyMTTC-WT (D) and PyMTTC-HE (E) tumors to visualize thick cross-linked (red) 
versus thin non-cross-linked (green) collagen fibers. Panel F: quantifications of cross-linked and 
thin fibers (n = 7; t-test with Welch’s correction). G, Quantification of matrix synthesis by CAFs 
isolated from PyMTTC-WT or PyMTTC-HE tumors as measured by an in vitro [3H]-L-proline 
incorporation assay (n = 3); DPM, disintegrations per minute. H-J, CAF spheroid invasion assay 
using CAFs isolated from PyMTTC-WT (H) and PyMTTC-HE (I) tumors. Quantification of invasive 
sprout length is shown in panel J (n > 21 spheroids). K, RT-PCR analysis of Mmp2 and Mmp9 in 
CAFs isolated from PyMTTC-WT and PyMTTC-HE end stage tumors (n = 6-8). L, Collagen gel 
contraction assay using CAFs isolated from PyMTTC-WT or PyMTTC-HE tumors (n = 6; t-test with 
Welch’s correction). Inset: representative pictures of contracted gel. To determine the contraction 
index, the area of the gel at the indicated time was substracted from the initial area of the gel at 
the beginning of the experiment, and this value was expressed as a percentage of the initial gel 
area. M-O, Invasion assay using spheroids of Tomato+ PyMTmT/mG tumor cells (TCs, red) in 
collagen gels into which GFP+ CAFs (green) isolated from PyMTTC-WT (M) or from PyMTTC-HE (N) 
tumors were homogeneously dispersed. Panel O: quantification of the area of the entire cancer 
cell spheroids (n > 18 spheroids). Bar: 50 µm (A,B,D,E), 100 µm (H,I,M,N). All quantitative data 
are mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001.  
 
Overall, PyMTTC-HE CAFs were less activated, less proliferative, and had impaired 
capacity to remodel the ECM and, thus, did not enhance the invasive behaviour 
of cancer cells to the same extent as CAFs, primed by PyMTTC-WT cancer cells.  
Although metastasis in PyMTTC-HE mice was reduced, the reduction was not 
to the same extent as in PyMT+/- mice, suggesting that blockade of PHD2 in both 
ECs and TCs is necessary to restrict metastasis more efficiently. 
 
EDUCATION OF NORMAL FIBROBLASTS BY CANCER CELL-DERIVED TGF-ß1 
To determine whether this decrease in TGF-β1 production by PyMTTC-HE cancer 
cells (Figure 16H,I) contributed to the reduced activation of CAFs, we cultured 
WT normal fibroblasts (NFs) with conditioned media from PyMTTC-WT or PyMTTC-
HE cancer cells. Molecular and functional analysis indicated that NFs acquired the 
activated CAF-phenotype only when cultured in the presence of medium, 
conditioned by PyMTTC-WT but not by PyMTTC-HE cancer cells (Figure 20A-C). 
Furthermore, induction of the CAF phenotype was prevented when TGF-β1 was 
immuno-neutralized (Figure 20A-C), suggesting that indeed TGF-β1 is the 
regulator of CAF activation in the MMTV-PyMT tumor model. 
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FIGURE 20: EFFECT OF CANCER CELL PHD2 HAPLODEFICIENCY ON PARACRINE TGF-β1 CROSS-TALK 
BETWEEN CANCER CELLS AND CAFS 
A,B, RT-PCR analysis of the mRNA levels of the CAF activation markers Pdgfra (A) and Acta 2 
(αSMA; B) in normal fibroblasts cultured in medium conditioned by PYMTTC-WT or PYMTTC-HE 
cancer cells in the presence of a control or neutralizing antibody against TGF-β1 (n = 5-6). C, 
Proliferation ([3H]-thymidine incorporation) of normal fibroblasts cultured in medium conditioned 
by PYMTTC-WT or PYMTTC-HE cancer cells in the presence of a control or neutralizing antibody 
against TGF-β1 (n = 3-6). All quantitative data are mean ± SEM. * p < 0.05, ** p < 0.01, # p = 0.08, 
NS – not significant.  
 
TRANSLATIONAL IMPLICATIONS 
To explore whether inducible global inactivation of PHD2, initiated at the time of 
pre-invasive adenoma, can still prevent progression to metastatic disease, we 
used Rosa26:CreERT2 mice, intercrossed with MMTV-PyMT:PHD2+/lox mice 
(PyMTR26-HE mice). Tamoxifen treatment of PyMTR26-HE mice after onset (7 
weeks, corresponding to 3 weeks after the first tumor nodules appeared; Figure 
21A) of tumor growth failed to affect primary tumor growth but substantially 
reduced pulmonary metastasis (Figure 21B-D). Interestingly, homozygous 
deficiency of PHD2 (PyMTR26-HO; Rosa26:CreERT2:PHD2lox/lox: MMTV-PyMT), not 
only decreased metastasis (Figure 21C,D), but also diminished primary tumor 
growth (Figure 21B). The underlying bases of this reduction of primary tumor 
growth still need to be investigated.  
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 These results warrant further research to explore whether partial PHD2 
inactivation in the neo-adjuvant setting would improve the delivery of 
chemotherapheutics and impair primary tumor growth by improving vessel 
function and decreasing interstitial fluid pressure in this spontaneously 
developing breast cancer model. Moreover, understanding the underlying 
mechanism of reduced primary tumor growth in PyMTR26-HO mice will be pivotal to 
design improved and safe breast cancer regimens of a pharmacological PHD2 
blocker. 
 
FIGURE 21: BLOCKADGE OF PHD2 AT LATER STAGES DIMINISHES PULMONARY METASTASIS  
A, Scheme representing the time-course of tumor initiation, PHD2 exicision and sample 
collection. B-D, Tumor weight of tumors (B), number of pulmonary metastases (C) and metastatic 
index in PyMTR26-WT, PyMTR26-WT and PyMTR26-HO mice at 16 weeks of age (n > 5; t-test with 
Welch’s correction). All quantitative data are mean ± SEM. * p < 0.05, ** p < 0.01.   
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CHAPTER V 
DISCUSSION 
During the last decade, much progress has been made towards improved 
diagnosis and therapy. However, the treatment of metastasis remains an unmet 
medical challenge. The work presented in this thesis identifies the oxygen sensor 
PHD2 as a potential and promising target to reduce metastasis in BC. Using a 
spontaneously developing BC model we show that haplodeficiency of PHD2 in 
both cancer and stromal cells impaired pulmonary metastasis, without affecting 
primary tumor growth. Reduction of metastasis was mediated by two 
independent and distinct mechanisms: (i) tumor vessel normalization and (ii) 
reduced CAF activation as a result of altered paracrine crosstalk from cancer 
cells to stromal CAFs. In turn, primed CAFs reciprocally affected cancer cells by 
modulating their invasive behavior via pleiotropic effects on the extracellular 
matrix.  
THE ROLE OF PHD2 IN CANCER  
Numerous studies characterized the importance of hypoxia signaling in tumor 
biology, but the large majority of them focused on cancer cells (Klotzsche-von 
Ameln et al., 2011; Semenza, 2012; Su et al., 2012; Wottawa et al., 2012). 
Moreover, the role of PHD2, the key regulator of HIF1α, in tumorigenesis and 
metastasis remains largely unresolved. Previous studies described the role of 
PHD2 in regulating the behavior of cancer cells. However, divergent (even 
opposite) phenotypic effects have been reported. Indeed, silencing of PHD2 in 
cancer cells does either not affect, increases or reduces primary tumor growth 
(Bordoli et al., 2010; Chan et al., 2009; Klotzsche-von Ameln et al., 2011; Su et 
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al., 2012; Wottawa et al., 2012). These discordant results may be due to the 
different types of tumor models and experimental approaches used. Moreover, to 
date, only a single study evaluated the role of PHD2 in cancer cells on 
metastasis, and identified a role for PHD2 in the late steps of metastasis (Naba 
et al., 2014).  
Moreover, the role of PHD2 in stromal cells adds an additional level of 
complexity. Selective PHD2 haplodeficiency in ECs reduced metastasis without 
affecting tumor growth, by normalizing the abnormal tumor vessels and reducing 
tumor cell intravasation (Mazzone et al., 2009), and deficiency of PHD2 in 
myeloid and T-cells decreased primary tumor growth (Mamlouk et al., 2014). 
These studies suggest that PHD2 could be an anti-BC drug target in stromal 
cells. However, it remained unclear what to expect when PHD2 is targeted in all 
cells of the tumor, both cancer cells and stroma, in a clinically more relevant 
spontaneously developing tumor model. Would primary tumor growth be 
increased, reduced or unchanged? What would be the effect of PHD2 blockade 
on metastasis?  
 By crossing PHD2 haplodeficient mice into the spontaneously developing 
breast cancer model MMTV-PyMT, closely resembling human luminal BC, we 
could evaluate the role of PHD2 in both cancer cells and the stroma. No effect of 
PHD2 haplodeficiency in cancer and stromal cells was observed on primary 
tumor growth in this study, but pulmonary metastasis and circulating tumor cells 
were significantly reduced. Moreover, further in vitro and in vivo phenotyping 
confirmed that there was no effect of PHD2 haplodeficiency on tumor proliferation 
and progression. These results support the concept of the oxygen sensor PHD2 
being a potential drug target for decreasing metastatic disease and prolonging 
the survival of BC patients.  
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PHD2 HAPLODEFICIENCY IN CANCER AND STROMAL CELLS IMPROVES VESSEL 
STRUCTURE AND FUNCTION 
Previous studies highlighted different possible effects on tumor angiogenesis 
(Bordoli et al., 2010; Klotzsche-von Ameln et al., 2011; Leite de Oliveira et al., 
2012; Mazzone et al., 2009) or vasculogenesis (Chan et al., 2009) upon targeting 
of PHD2 in either ECs or in cancer cells. Development of the vasculature is 
necessary for tumor growth. When deprived of oxygen and nutrient supply, 
cancer cells stimulate the development of vessels by upregulating angiogenic 
factors such as VEGF, and this response is under control of PHD2 (Bordoli et al., 
2010; Lee et al., 2008). However, this production of pro-angiogenic factors is 
often excessive in the tumor microenvironment. As a result, these growth signals 
turn into abnormalization factors, tilting the process of neovascularization 
towards unproductive angiogenesis, and leading to the formation of vessels with 
abnormal features (Carmeliet and Jain, 2011b). This may initiate a vicious self-
sustaining cycle, in which tumor vessel abnormalities will impair tumor perfusion 
and increase intratumoral hypoxia, increasing abnormalization factors even more 
and amplifying vascular disorganization even more.  
Coordinated responses of ECs and cancer cells to hypoxia regulate 
angiogenesis. Indeed, targeting one of these cell compartments in tumors 
induces a direct response on the other. Silencing PHD2 in cancer cells led to 
increased angiogenesis (Bordoli et al., 2010; Klotzsche-von Ameln et al., 2011) 
or vasculogenesis (Chan et al., 2009). On the other hand, haplodeficiency of 
PHD2 in ECs rendered them pre-adapted to hypoxia and favored the endothelial 
cell normalization responses. This lowered intratumoral hypoxia and thus 
decreased the invasive phenotype of cancer cells (Leite de Oliveira et al., 2012; 
Mazzone et al., 2009). Our analyses show that targeting PHD2 in both cancer 
and stromal cells did not affect vessel density. This seems surprising at first, 
given that PHD2 haplodeficiency in cancer cells increased HIF1α and HIF2α 
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levels in nuclear and cytoplasmic fractions, and thus would results in higher 
VEGF level. Previous studies indicated that PHD2 haplodeficient ECs are more 
quiescent, and their mitogenic and migratory responses to VEGF are impaired 
(Mazzone et al., 2009). Hence, they suggest that PHD2 haplodeficiency in ECs 
prevents excessive angiogenesis and maintains the same number of vessels as 
in WT conditions. 
 Further analysis confirmed that PHD2 haplodeficiency in ECs in the 
MMTV-PyMT spontaneous tumor model induced endothelial normalization in 
mice lacking PHD2 in cancer and stromal cells. Not only did vessels from PyMT+/- 
tumors have better EC lining and pericyte coverage, but their function was also 
improved. Consequently, intratumoral hypoxia was decreased in PyMT+/- tumors.  
These results suggest that despite the increased pro-tumorigenic HIF1α 
levels in cancer cells, ECs, haplodeficient for PHD2, were able to retain their pro-
quiescent phenotype and favor tumor vessel normalization. Importantly, analysis 
of metastatic dissemination in mice lacking one allele of PHD2 selectively in ECs 
revealed that the magnitude of reduction of metastasis was smaller in these 
PyMTTie2-HE and PyMTCdh5-HE mice than in PyMT+/- mice. This raised the question 
whether another cell population was also limiting the metastatic process in 
PyMT+/- mice. 
PHD2-DEPENDENT REGULATION OF CANCER CELL INVASION BY CAFS 
Malignant breast epithelial cells can invade tissues in different ways. When they 
undergo EMT and become mesenchymal in nature, they acquire invasive 
properties and are capable of breaching matrix-dense tissue barriers (Friedl and 
Wolf, 2003; Waldmeier et al., 2012). Alternatively, when they do not undergo 
EMT but remain epithelial in nature, they are still able to invade tissues via 
collective migration, especially when assisted by invasive CAFs (Calvo et al., 
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2013; Friedl and Wolf, 2003). In line with previous reports (Trimboli et al., 2008; 
Waldmeier et al., 2012), we observed only minimal signs of EMT in this breast 
cancer model. Wild type cancer cells alone (i.e., without co-invading CAFs) 
invaded the collagen gel only minimally. PHD2 did not control these cancer cell-
intrinsic invasive processes. In contrast, our data show that CAFs stimulated the 
invasion of cancer cells when they were co-cultured with cancer cells, a process 
that was under the control of PHD2 in the cancer cells.  
CAFs can modulate cancer cell invasion via several complementary 
mechanisms. First, these stromal cells can alter cancer cell invasion by 
depositing bundles of cross-linked collagen, known migration “highways” for 
invading cancer cells (Lu et al., 2012). Our findings not only indicate that CAFs 
were a prominent source of matrix production in PyMT tumors, but also reveal 
that PyMT+/- and PyMTTC-HE CAFs deposited smaller amounts of thick bundles of 
cross-linked collagen. A second mechanism whereby CAFs might regulate 
cancer cell invasion is by remodeling the ECM via force-mediated contraction 
(Calvo et al., 2013). This process is part of a “mechano-reciprocal” response of 
CAFs to the heightened tensile forces in the tumor environment, which increases 
the contractility of these stromal cells (Lu et al., 2012). Contraction of the matrix 
induces physical movement and alignment of collagen fibers, which results in 
enhanced cross-linking of collagen fibers and increased matrix stiffness (Calvo et 
al., 2013). The importance of such matrix remodeling is highlighted by the fact 
that matrix stiffness promotes cancer cell invasion and dissemination 
(Provenzano et al., 2006). Noteworthy, since remodeling of the matrix by CAFs 
enhances the activation of the CAFs themselves, a self-sustaining feed-forward 
loop of CAF activation and matrix remodeling is initiated that progressively 
aggravates malignancy (Lu et al., 2012). Our findings indicate that PyMT+/- and 
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PyMTTC-HE tumors not only contained fewer activated CAFs, but also that CAFs, 
primed by PHD2 haplodeficient cancer cells, expressed lower levels of the 
contractile protein αSMA, and effectively contracted the collagen gel less. Also, 
the amount of cross-linked collagen fibers was reduced in PyMTTC-HE tumors.  
A third mechanism relies on the remodeling of the tumor matrix by 
proteolysis. By proteolytically remodeling the ECM, CAFs can (i) physically free 
up space for invading cancer cells (ii) liberate matrix-bound migratory signals, or 
(iii) alter biochemical / structural properties of matrix components, all stimulating 
cancer cell migration (Cirri and Chiarugi, 2011). Our expression analysis showed 
that CAFs, primed by PHD2 haplodeficient cancer cells, produced less matrix-
degrading metalloproteinases, providing circumstantial evidence for this 
mechanism.  
Together, these mechanisms may provide a mechanistic explanation of 
how CAFs, primed by PHD2 haplodeficient cancer cells, did not enhance the 
invasive behavior of cancer cells to the same extent as CAFs, primed by wild 
type cancer cells. Since such invasive activity helps cancer cells to travel through 
the tumor matrix and breach the endothelial barrier during intravasation (van Zijl 
et al., 2011), these mechanisms can explain why metastasis was lower in 
PyMTTC-HE and PyMT+/- than PyMTTC-WT and PyMT+/+ tumors. 
The results from PyMTTC-HE mice provided evidence of an additional 
mechanism through which PHD2 haplodeficiency in cancer and stromal cells 
reduces metastasis.  
CAF ACTIVATION IS NOT DEPENDENT ON PHD2 LEVELS IN FIBROBLASTS 
CAFs are an important stromal cell population, contributing up to 90% of the 
tumor mass in some tumors (Karagiannis et al., 2012). However, only a few 
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papers documented an involvement of hypoxia signaling in CAF behavior 
(Chiavarina et al., 2010; Gilkes et al., 2013; Kim et al., 2012). Not surprisingly, 
HIF1α in fibroblasts functions as a tumor promoter (Chiavarina et al., 2010). It is 
also a critical regulator of ECM remodeling by fibroblasts (Gilkes et al., 2013) and 
critical component of tumor vasculature (Kim et al., 2012). In line with these 
findings, transplantation of fibroblasts, silenced for PHD2 by 87.5%, in close 
proximity of a wound accelerated the wound healing process, by increasing 
fibroblast proliferation and angiogenesis at the wound site (Zhang et al., 2013). 
As PHD2 haplodeficiency in fibroblasts would result in increased HIF signaling, it 
might promote pro-tumorigenic effects, rather than contribute to a reduction in 
metastasis. Interestingly, haplodeficiency of PHD2 in fibroblasts did not affect 
tumor progression and metastatic dissemination, as compared to mice having 
wild type fibroblasts. Their characteristics were also unchanged in vitro, 
suggesting that PHD2 haplodeficiency in fibroblasts does not affect their intrinsic 
properties and thus does not contribute to the reduction of pulmonary metastasis 
in global PHD2 haplodeficient mice.  
PHD2-DEPENDENT REGULATION OF TGF-β1 CROSSTALK 
Silencing of PHD2 in a breast cancer cell line and in keratinocytes reduces TGF-
β1 secretion (Kalucka et al., 2013; Wottawa et al., 2012). In agreement with 
these findings, PHD2 haplodeficiency in PyMT cancer cells also lowered the 
release of TGF-β1 from these malignant cells. Since TGF-β1 is an established 
inducer of the differentiation of normal fibroblasts to activated CAFs (Calon et al., 
2014; Evans et al., 2003), the reduced release of TGF-β1 by PyMT+/- cancer cells 
could thus explain the reduced activation of PyMT+/- CAFs. Additionally, mRNA 
levels of Sdf-1α and Tgf-β1 were lower in PyMT+/- than PyMT+/+ CAFs. Since 
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these cytokines are released by activated CAFs as autocrine signals to maintain 
an activated state (Kojima et al., 2010), their reduced expression could further 
contribute to the decreased activation of PyMT+/- CAFs. Together, these data 
suggest a model where PHD2 haplodeficient cancer cells initially reduce the 
activation of CAFs releasing less paracrine TGF-β1 to the CAFs. Secondly, these 
hypo-activated CAFs in turn maintain their reduced activation status by 
expressing lower levels of the autocrine activation signals SDF-1α and TGF-β1, 
resulting in a self-sustaining loop. 
 TGF-β1 is the most potent factor inducing myofibroblast differentiation 
(Desmouliere et al., 1993; Ronnov-Jessen and Petersen, 1993) and one of the 
strongest cytokines regulating pro-fibrotic reactions (Branton and Kopp, 1999). It 
is also known that TGF-β signaling regulates cell-intrinsic responses in epithelial 
cells, normal fibroblasts and their transformed counterparts. The importance of 
TGF-β signaling in non-transformed epithelial cells has been well characterized. 
In healthy tissue, TGF-β1 inhibits epithelial cell proliferation, but stimulates the 
proliferation of fibroblasts (Giannouli and Kletsas, 2006; Strutz et al., 2001). 
However, cancer cells become insensitive to the growth arresting activity of TGF-
β1 (Bierie and Moses, 2006; Siegel and Massague, 2003). In the same context, 
transdifferentiation of fibroblasts to myofibroblasts upon TGF-β1 stimulation has 
been associated with carcinoma progression by increased myofibroblast-derived 
production of HGF (De Wever et al., 2004; Lewis et al., 2004). However, when 
TGF-β signaling was lost in FSP-1 expressing fibroblasts (by conditional deletion 
of exon 2 from Tgf-βR2 in the FSP1-expressing fibroblast population), carcinoma 
initiation, progression and metastasis were enhanced by the release of the 
tumor-promoting paracrine signals TGF-α, Mst-1 and HGF (Bhowmick et al., 
2004; Cheng et al., 2005). Additionally, heterozygous deletion of Tgf-βR2 in 
 135 
FSP1+ fibroblasts does not significantly affect tumor growth, but increases 
pulmonary metastasis (Fang et al., 2011). This highlights the differential role of 
TGF-β signaling in non-transformed fibroblasts, where TGF-β can suppress HGF 
expression. However, once fibroblasts are transdifferentiated into myofibroblast, 
they can promote HGF signaling. Moreover, TGF-β derived from CAFs can 
regulate tumor progression by increasing the expression of CXCR-4 on cancer 
cells and thereby enhancing their response to SDF-1, abundantly produced by 
CAFs (Ao et al., 2007). Our results show that cancer cell-secreted TGF-β1 
regulated the transdifferentiation of myofibroblast in PyMT+/+ and PyMTTC-WT 
tumors. This activation of CAFs was impaired in PyMT+/- and PyMTTC-HE mice. As 
a consequence, PyMT+/- and PyMTTC-HE CAFs had diminished, but not completely 
ablated, Tgf-β1 and Sdf-1 mRNA levels, but Tgf-βR2 mRNA levels were not 
changed. These results suggest that PyMT+/- and PyMTTC-HE CAFs are still able 
to respond to surrounding TGF-β ligands and thus this might prevent the 
production of tumor-promoting paracrine signals. Additionally, conditional 
deletion of PHD2 in fibroblasts did not alter tumor growth and metastasis, 
suggesting that TGF-β signaling might not have been impaired in this cell type. 
 Overall, these diverse and opposing biological functions of TGF-β 
signaling in cancer at different stages of tumor development and progression 
make it a challenging target for cancer therapy. Potentially, partial blockade of 
TGF-β signaling, by upstream targeting at cell-specific site, might be a strategy to 
inhibit the pro-tumorigenic axis of this pathway. 
POSSIBLE TRANSLATIONAL IMPLICATIONS 
Finally, our genetic data might have translational implications, as they identify 
PHD2 as pro-metastatic factor. We have not only observed that PHD2 
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haplodeficiency normalizes tumor blood vessels, but also that it impaired CAF 
activation. 
From a conceptual perspective, it is puzzling that inactivation of PHD2 by 
hypoxia in the tumor microenvironment suppresses the pro-metastatic activity of 
CAFs, given the vast literature that hypoxia promotes metastasis (De Bock et al., 
2011; Semenza, 2012). The precise pathophysiological purpose of this 
phenomenon remains to be elucidated. Regardless however, from a therapeutic 
perspective, blocking this CAF-dependent pro-metastatic activity of PHD2 might 
offer novel opportunities to suppress cancer cell dissemination. In fact, the results 
of this study highlight the importance of CAFs in promoting metastasis, and 
illustrate that even in the absence of prominent alterations in the intrinsic invasive 
behavior of cancer cells (migration, EMT, etc), a change in CAF behavior suffices 
to impair metastasis. Moreover, we provide genetic evidence that global PHD2 
haplodeficiency from the start of tumorigenesis is not only well tolerated, but also 
reduces metastatic disease. Intrestingly, PHD2 blockadge seems sufficient to 
reduce metastasis when initiated at the later stages, when invasive adenoma is 
already present. This implies that administration of a pharmacological PHD2 
blocker, which would inhibit PHD2 in both cancer and stromal cells, might be 
therapeutically considered to prevent / minimize metastatic disease. 
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CHAPTER VI 
  CONCLUSION AND FUTURE PROSPECTS 
 
This work provides evidence that blocking PHD2 in cancer and stromal cells of 
the spontaneously developing BC model, MMTV-PyMT, did not affect primary 
tumor growth but resulted in a substantial reduction of pulmonary metastasis. We 
revealed that reduced metastasis was related to both tumor vessel normalization 
and impaired paracrine cross-talk between cancer cells and fibroblasts. TGF-β1 
secretion was reduced in PHD2 haplodeficient cancer cells, which subsequently 
led to reduced fibroblast transdifferentiation into CAFs. While cancer cells 
activate fibroblasts in the tumor stroma, CAFs modulate the local 
microenvironment (by remodelling and contracting the ECM) for cancer cells to 
enable their invasion and dissemination to distant organs. The diminished CAF 
activation in PyMT+/- and PyMTTC-HE tumors reduced CAF-mediated cancer cell 
invasion.  
 These results suggest that blocking PHD2 in cancer cells could be beneficial 
to restrain metastatic dissemination in BC patients, and could thus be considered 
as a potential target for novel anti-metastatic drugs. We do not exclude the 
possibility that blocking PHD2 might impair metastasis via additional 
complemantary mechanisms. For instance, effects on the pre-metastatic niche 
and outgrowth from micro- to macro-metastasis, as it has been recently reported 
(Naba et al., 2014), should be further evaluated in a spontaneously arising tumor 
model.   
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